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EXECUTIVE SUMMARY 
The Human Genome Analysis Programme (HGAP) is part of the Second Framework 
Programme of Community activities in research and technological development. This 
programme was set up under the heading "Health"of the "Quality of Life" section for: 
using and improving new bioltechneogies in the study of the human genome 
for a better understanding of the mechanism of genetic functions as well as the 
prevention and treatment of human diseases; 
developing an integrated approach to the ethical, social and legal aspects of 
possible applications of the results obtained. 
As part of its regular evaluation exercise, the Commission appointed in December 
1992 a panel of independent experts to carry out the evaluation of the HGAP. The 
authority for the Evaluation Panel is laid down in Article 4 (3) of the Council Decision 
adopting this programme (O J . N° L196 of 29.6.1990,p.8). The same article specifies 
that the evaluation should be carried out having regard to the scientific and technical 
achievements of the programme, the quality and practical relevance of its results, the 
effectiveness of its management, its ethical, social and legal aspects, and its impact 
and benefits on national research programmes. 
In carrying out this evaluation the Panel visited four centres involved in the 
programme and interviewed over thirty people : Commission and national officials, 
participants in the HGAP and users. 
The total funds committed to this programme were 15.6 MECU. The distribution of 
funds was as follows : Genetic Maps 21 %, Physical Maps 27.6 %, Data Handling and 
Databases 15%, Advanced Genetic Technologies 18%, Training Activities 12 %, 
Administration 6.4%. 
HGAP involved approximately 100 EC institutes. 
CONCLUSIONS 
The panel finds that the HGAP has largely become a success and is an important driving 
force in the field of European human genome research. Genome research is, for the moment, 
advancing at an extremely rapid pace. In recent years the progress has been particularly 
striking in Europe, with the success of enterprises such as yeast whole-chromosome 
sequencing, whole genome physical maps and refined genetic maps. It is clear that HGAP 
has played an important role to establish a more balanced relationship with the US. It is, 
however, also clear that strong programs such as the one supported by AFM in France have 
been an important driving force. The HGAP was approved with a two year budget of 15.6 
MECU. The amount of money devoted to genome research by the EC is very small 
compared to the budgets of the genome programs in the U.S. and Japan. The HGAP has 
therefore only supplemented ongoing national efforts and the weight of EC funding on 
individual programs greatly depends on the strength of the national programs. The EC has 
given very minor support to large French groups (less than 10%), while it has been quite 
important for Great Britain, Germany, Italy and other European countries. The EC support 
would range from <5% to 50% of the total funding of each project. For the transnational 
projects, this kind of support can, in most cases, only have a modest impact and the potential 
for less well advanced countries to benefit from the transnational programs is limited. 
The establishment of the resource centres, and training programs is of great help to organised 
scientific laboratories as well as less advanced ones or less established groups. This is a very 
important aspect of the HGAP and in general in today's science, since organisation and 
availability of resources are major issues. In this respect the HGAP has been very useful 
to the European genome research community, and this aspect should be stressed in the design 
of the future programs. 
The cDNA program in the current HGAP has not developed as fast as was hoped although 
quite a number of partial cDNA sequences have been generated. There will clearly be a great 
need for large collections of high quality cDNA libraries in the future. 
The ultimate goal of the global human genome project is the sequencing of the whole human 
genome. Large sequencing programs are presently not included in the HGAP. This situation 
should be rectified in a future HGAP. 
The transnational projects have been of importance for promotion of European collaborations. 
They have also provided means for small laboratories, particularly in less developed countries 
to gain access to sophisticated technologies. 
The fellowship program is a very essential component of the HGAP. It appears to have been 
implemented in a satisfactory way. 
It was recognized that the activities undertaken within the ESLA program had justification. 
However, the evaluation panel debated whether the program should be financed to the same 
extent as done in the past simply because there are limited resources and many pressing 
questions to be investigated. 
The already completed ESLA program can be regarded as a promising pilot study. The panel 
woulld like to emphasize that Europe offers unique possibilities for these kinds of studies due 
to the diversity in the health care and social programs that operate in the different countries. 
The workshop support has in the past been taken from the administration budget. Although 
CAN-HUG and the ESLA working group provided input into the program it seems to some 
extent to have been adminstrated in an ad hoc manner. 
RECOMMENDATIONS 
1. It is the opinion of the panel that a third HGAP should be launched. Modifications 
in the project plan are, however, necessary due to the remarkable progress that has 
been made during the last year. It seems very likely that a high resolution genetic 
map and also a complete YAC- based physical map of the human genome will be 
completed within another year. 
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It is necessary to make a new strategic plan for the HGAP. This strategic plan should 
also consider the possibility of approaching sequencing of the entire genome by a 
"shot gun approach". Such an effect would require a drastic increase in funding. 
A key feature of HGAP are the resource centers and it is essential to ascertain their 
continued existence. Making the results of whole genome physical mapping readily 
available to the community will be an extensive but necessary task; it must be tackled 
by informatic means including an accessible, complete and user-friendly database, but 
also at the level of the distribution of YAC- and cosmid clones, a very labour-
intensive task. Making these reagents readily accessible to all European scientists, for 
instance by wide distribution of "polytene filters" containing ordered YACs for all 
human chromosomes would be an essential step. In general a wider range of ordered 
libraries is required, to serve the most diverse needs of genome research, once the 
first physical map will be completed. 
In the future ordered collections of full length cDNAs will be required from all 
different tissues of the body. Resource centers providing ordered cDNA libraries as 
a service to the scientific community should be given high priority in a future HGAP. 
Allocation of resources to megascale cDNA sequencing projects should be considered. 
The concept of cDNA sequencing to obtain a complete catalogue of the human genes 
was after all a European idea. 
Mega-scale genomic sequencing which was not a component of the original HGAP 
needs to be considered in a future HGAP. It will be necessary to carry out some pilot 
projects involving megabase-sequencing to assess the future possibilities to approch 
sequencing of whole human chromosomes. Also, the possibility of sequencing the 
entire genome by a "shot gun approach" needs careful consideration. It is suggested 
that an ad hoc group is assembled to look into this problem. If the EC intends to 
participate in such a project it will have to greatly expand the program budget to faster 
reach the ultimate goal of the global genome program, the complete nucleotide 
sequence of the human genome. 
EUROGEM, on the other hand, will soon have completed its mission once the high 
resolution genetic map has been finished. 
Bioinformatics is a field that is likely to develop very rapidly in the near future. The 
design of user-friendly software for analysis of massive amounts of data will 
undoubtedly be an important aspect of a future HGAP. In view of the very 
widespread criticism directed to GDB, it becomes useful to envision alternative 
databases or at least different database access system: in this respect, the progress of 
the Heidelber IGD (Integrated Genome Database) appears promising and the 
distribution model advocated by this group, using a locally running ACeDB system 
fed with data from the other genome databases, appears particularly promising. 
Communication between biologists and computer scientists remains imperfect: they 
still belong largely to two quite different cultures. Both fields have been evolving 
very quickly in recent years, and few individuals possess competence in both fields. 
An increase in their numbers, through attractive fellowships and positions, is probably 
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the only way of easing this difficulty. 
Moreover attention, and some funding, should be devoted to improving interfaces 
between the "genome world" and the general biology community, including not only 
medical genetics but also, for example, groups performing functional research in the 
mouse system so that structure and function are brought closer together. 
9. The transnational projects should be continued although they must be selected with 
great care. In supporting research and formulating suggestions on how to distribute 
research funds, it will be cogent to remember that collaborations, which are 
undoubtedly very important, cannot be organized by anyone, but must and will 
develop spontaneously. In that respect, it cannot be wise to stipulate collaborations 
between scientists from certain areas in Europe or even make the assignment of funds 
dependent on such collaborations. Such ideas are counterproductive. It would be 
preferable to rather start a special program of a limited extent for the support of 
deserving scientists in the bio-medical field working in those countries of Europe 
which are presently still weaker in melecular biology but are capable of catching up 
rapidly. 
10. The training program appears largely to have been a success and a continuation of the 
program is recommended. It may, however, be necessary to find new means to 
spread information about the program since the number of applications was much 
smaller than anticipated. It should also be kept in mind that some modifications of the 
program might be very beneficial for young scientist working in the field of human 
genome analysis. There is one problem, which all European countries seem to share, 
i.e., the support and independence of young investigators who have proven themselves 
in their own or in other countries as first rate scientists. There is a very considerable 
lure by laboratories in the Unite States with its very flexible administrative structure 
at most universities and, above all, with an impressive number of top research centers 
at many U.S. universities. It will be increasingly attractive for young Europeans to 
seek to associate themselves with laboratories at such centers for longer or shorter 
periods of time, but usually during their years most productive for original research. 
Biomedical research, nowadays, can best be perfomed at centers of a critical size. It 
is necessary to recognize that it is one of the important tasks for science funding and 
organization in Europe to create a counterbalance to these very powerful centers for 
basic biomedical research in the U.S. A suggestion along these lines is to create 
positions for young independent researchers in the biomedical research areas which 
would allow highly qualified young scientists to pursue research of their own choice 
at one of the European universities, but uninhibited by their often very "traditional" 
administrative structures. In addition to positions, funds for consumable supplies, 
equipment and research personel should be attached to these positions. It is proposed 
that such structures would help very considerably in attracting or re-attracting many 
of the most productive young researchers from abroad to European countries. 
11. ESLA programs are essential components of genome prorgrams. The panel 
recommends, although not unanimously, that the ESLA Program is continued and that 
long range support is provided. It is important that the program is announced as 
extensively as possible and that the contractors receive the proper information about 
the expected output of the program. An urgent component in future ESLA programs 
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will be to provide means for the participating groups to cooperate, interact and 
exchange ideas and results. 
Special efforts should also be made to include economics of technical change, science 
policy and science studies in the program. The geographical inbalance is another 
problem that needs attention. 
12. Support to workshops and meetings is clearly an essential component of HGAP and 
continuation of the program is recommended. However, some administrative changes 
are recommended. It is, for instance suggested that a scientific advisory board is 
established to advice on the policy of the program and to screen applications. Efforts 
should be made to obtain a better balance with regard to topics among the workshops 
that are supported. The support via HUGO to single chromosme workshops is 
essential and should be continued. In general, support should be given to chromosome 
workshops taking place in Europe as a contribution to the organization. Support 
should also be given as travel grants to European participants in workshops taking 
place outside of Europe. It seems also worthwile to support workshops which bring 
together scientists working within the HGAP on similar topics (as has been done to 
same extent in the past), for instance those working in EUROGEM or with cDNA 
libraires. This would obviously stimulate contacts between groups in different 
European countries. 
13. Another welcome addition to the program would be education of practising physicians 
all over Europe. With the rapid progress in Medical Genetics our practising 
colleagues are already in a difficult position vis-a-vis their patients who will ask 
pressing questions. Specialized training programs might al least provide a partial 






1. Programme! vedrørende analyse af det humane genom (HGAP) hører under det andet 
rammeprogram for EF's aktioner inden for forskning og teknologisk udvikling. 
Programmet blev oprettet under punktet "Sundhed" i rubrikken "Livskvalitet" med henblik 
pâ: 
Udnyttelse og forbedring af den nye bioteknologi til studiet af det humane genom med 
henblik pa en bedre forstâelse af mekanismerne i genernes funktion samt forebyggelse 
og behandling af sygdomme.; 
udvikling af en integreret vurdering af de etiske, sociale og juridiske aspekter ved de 
mulige anvendelser af de resultater, der opnas. 
2. Som et led i Kommissionens almindelige evalueringsaktiviteter blev der i december 1992 
udpeget en gruppe uafhaengige eksperter, som skulle foretage evalueringen af resultaterne. 
Bemyndigelsen af evalueringsgruppen er fastlagt i artikel 4, stk. 3, i Radets beslutning om 
vedtagelse af programmet (EFT nr. L 196 af 29. juni 1990, s. 8). I samme artikel 
bestemmes det, at evalueringen skal gennemføres under hensyntagen til de opnâede 
videnskabelige og tekniske resultater, deres kvalitet og praktiske relevans, de etiske, 
sociale og juridiske aspekter og programmets betydning for nationale 
forskningsprogrammer. 
I forbindelse med evalueringen besøgte gruppen fire centre, der er involveret i 
programmet, og interviewede mere end 30 personer. Der var tale om tjenestemaend i 
Kommissionen og fra medlemsstaterne, deltagere i programmet og brugere. 
3. Der er i alt afsat 15.6 mio. ECU til programmet. Dette bel0b er fordelt med 21% til 
genetisk kortlaegning, 27,6% til fysisk kortlaegning, 15% til databehandling og databaser, 
18% til avanceret genteknologi, 12% til uddannelse og 6,4% til forvaltning. 
Ca. 100 institutter i EF var involveret i programmet. 
KONKLUSIONER 
Evalueringsgruppen mener, at programmet i det store og hele er en succes, og at det fungerer som 
en vigtig drivkraft for forskningen i det humane genom. Genomforskningen g0r for tiden meget 
hurtige fremskridt. I de seneste ar har fremskridtene isaer vaeret bemaerkelsesvaerdige i Europa, 
hvor man har haft held med sekvensering af hele gærkromosomer, fysisk kortlaegning af hele 
genomer og nøjagtige genkort. Programmet har klart spillet et vigtig rolle for opnaelsen af et mere 
ligevaegtigt forhold mellem Europa og USA. Det stär imidlertid ogsa klart, at vægtige programmer 
som det, der stottes af AFM i Frankrig, har vaeret en vigtig drivkraft. HGAP-programmet blev 
vedtaget for en periode pa to ir med et budget pa 16.6 mio. ECU. I forhold til USA og Japan 
anvender EF meget sma beløb pa genforskning. Programmet har derfor kun vaeret et supplement 
til de aktiviteter, der gennemfares pa nationalt plan, og EF-finansieringens vaegt i de enkelte 
programmer afhaenger i stort omfang af de nationale programmers styrke. EF har kun i meget 
begraenset omfang støttet stærre franske grupper (mindre end 10%), hvorimod st0tten til det 
Forenede Kongerige, Tyskland, Italien og andre europaeiske lande har vaeret ganske betydelig. EF 
kan bidrage med 5% til 50% af hvert projekts samlede udgifter. Med hensyn til de transnational 
XI 
projekter vil denne type støtte i de fleste tilfaelde kun have en beskeden betydning, og mindre 
udviklede lande har kun begraensede muligheder for at fa gavn af de transnational programmer. 
Oprettelsen af ressourcecentre og uddannelsesprogrammer er en stor hjaelp for bade velfungerende 
videnskabelige laboratorier og for mindre udviklede eller mindre veletablerede grupper. Dette 
omrade er et vigtigt aspekt ved programmet og ved moderne videnskab i almindelighed, eftersom 
organisering og radighed over ressourcer er af stor betydning. Programmet har i den henseende 
vaeret meget nyttigt for den europaeiske genomforskning, og denne omstaendighed bet der laegges 
vaegt pa ved tilrettelaeggelsen af nye programmer. 
cDNA-programmet under HGAP har ikke gjort sa hurtige fremskridt, som man havde habet, 
selvom der er udviklet delvise cDNA-sekvenser. Der vil bestemt vaere et stort behov for store 
cDNA-biblioteker af høj kvalitet fremover. 
Det endelige mal for det verdensomspaendende projekt vedrørende det humane genom er 
sekvensering af hele det humane genom. HGAP omfatter ikke i øjeblikket st0rre sekvenserings-
programmer. Dette bør der rades bod pa i fremtidige programmer. 
De transnationale projekter har haft betydning for det europaeiske samarbejde pa omradet. De har 
ogsa gjort det muligt for sma laboratorier, isaer i mindre udviklede lande, at fa adgang til 
avanceret teknologi. 
Fellowship-programmet er en meget vigtig del af HGAP, og dets gennemførelse har tilsyneladende 
vaeret tilfredsstillende. 
Det anerkendes, at aktiviteterne under ESLA-programmet (etiske, sociale og juridiske aspekter), 
var berettigede. Eftersom ressourcene er begraensede, og der er mange omrader, der snarest skal 
unders0ges, har evalueringsgruppen dog diskuteret, om der fortsat skal ydes støtte til ESLA-
programmet i samme omfang. Det allerede gennemførte ESLA-program kan betragtes som en 
lovende pilotunders0gelse. Evalueringsgruppen vil gerne understrege, at der i Europa er 
enestaende gode muligheder for at gennemfere denne type undersøgelser pa grund af den 
mangfoldighed af social- og sundhedsordninger, der gaelder i de forskellige lande. 
St0tten til workshop-arbejdet er hidtil taget fra administrationsbudgettet. Selv om CAN-HUG og 
ESLA arbejdsgruppen har medvirket i programmet, har ledelsen af det tilsyneladende i et vist 
omfang vaeret ad hoc-praeget. 
HENSTILLINGER 
1. Evalueringsgruppen mener, at der bør ivaerksaettes et tredje program vedrørende analyse af 
det humane genom. Pa grund af det seneste ars bemaerkelsesvaerdige fremskridt er det 
imidlertid n0dvendigt at indføre aendringer i programmet. I løbet af endnu et ar vil man 
højst sandsynligt kunne faerdigg0re et detaljeret genkort og et fuldstaendigt, YAC-baseret 
fysisk kort af det humane genom. 
2. Det er n0dvendigt at fastlaegge en ny strategisk plan for programmet. I forbindelse hermed 
kunne man overveje muligheden for at anvende haglgevaerkloning ved sekvenseringen af 
hele genomet. Dette kraever, at støtten 0ges vaesentligt. 
3. Et af programmets nøgleelementer er ressourcecentrene, og det er yderst vigtigt, at deres 
fortsatte eksistens sikres. En stor, men nødvendig opgave er at gøre resultaterne af hele 
den fysiske genomkortlaegning let tilgaengelige. Dette skal g0res ved hjaelp af edb-
hjaelpemidler, herunder en aben, fuldstaendig og brugervenlig database, men ogsa gennem 
XII 
distribution af YAC - og cosmidkloner - en meget arbejdskrævende opgave. Det vil vaere 
et stort skridt i den rigtige retning at gare disse tilgaengelige for alle europaeiske forskere, 
f.eks. ved en omfattende distribution af "polyten filtre", der indeholder ordnede YAC'er 
for alle menneskelige kromosomer. Der er generelt brug for et starre antal ordnede 
biblioteker for at kunne dække genomforskningens forskellige behov, nar det farste fysiske 
kort er faerdigt. 
Der vil i fremtiden vaere behov for ordnede samlinger af cDNA'er i fuld laengde fra alle de 
forskellige dele af kroppens vaev. Ressourcecentre, der kan stille ordnede cDNA-
biblioteker til radighed for forskersamfundet, bar derfor prioriteres hajt i det naeste 
program. 
Det bar overvejes at yde statte til megaprojekter for sekvensering af cDNA. Ideen om 
sekvensering af cDNA for at fa et fuldstaendigt katalog over de menneskelige gener opstod 
trods alt i Europa. 
I det naeste program for analyse af det humane genom bar man inddrage storstilet 
genomsekvensering, der ikke indgik i det farste program. Det vil blive nadvendigt at 
gennemfare nogle pilotprojekter, hvori der indgar megabase-sekvensering for at vurdere 
mulighederne for en fremtidig sekvensering af fuldstaendige humane kromosomer. 
Muligheden for at sekvensere hele genomet ved hjaelp af haglgevaerkloning bar ogsa naje 
overvejes. Det foreslas, at der dannes en ad hoc-gruppe, som skal undersage dette 
problem. Hvis EF agter at deltage i et sadant projekt, skal programmets budget ages 
vaesentligt, for at man hurtigere kan na det endelige mil for det verdensomspaendende 
genomprogram - en fuldstaendig nukleotidsekvensering af det humane genom. 
EUROGEM vil pa sin side have fuldfart sin opgave, sa snart det detaljerede genkort er 
faerdigt. 
Bioinformatik er et omrade, der sikkert vil underga en meget hurtig udvikling i den 
naermeste fremtid. Udviklingen af brugervenligt software til analyse af store maengder data 
vil uden tvivl udgare en vigtig del af det naeste HGAP. I betragtning af den meget 
udbredte kritik af GDB er det en god ide" at overveje mulighederne for andre databaser 
eller om ikke andet forskellige systemer for adgang til databaser. Heidelber IGD 
(Integrated Genome Database) ser i den forbindelse lovende ud, og der er isaer store 
forventninger til denne gruppes distributionsmetode, der indebaerer brug af et lokalt 
ACeDB-system med data fra de andre genomdatabaser. Kommunikationen mellem biologer 
og dataloger er endnu ikke tilfredsstillende. De to grupper tilharer stadig i haj grad to 
forskellige kulturer. Der er inden for begge omrader foregaet en meget hurtig udvikling i 
de senere ar, og kun fa har kompetence inden for begge fag.Dette problem kan 
sandsynligvis kun lases ved at age antallet af sadanne tvaerfaglige eksperter ved at tilbyde 
attraktive udvekslingsordninger og stillinger. 
Der bar desuden ofres opmærksomhed og midler pa at forbedre kontakten mellem den 
genteknologiske forskerverden og de almenbiologiske forskere, herunder ikke blot inden 
for laegevidenskabelig genetik, men ogsa grupper, der udfører funktionel forskning i 
musesystemet sa der kan skabes en taettere forbindelse mellem struktur og funktion. 
De transnationale projekter bar fortsaettes, men de skal udvaelges med stor omhu. I 
forbindelse med statte til forskning og forslag til, hvordan midlerne skal fordeles, bar det 
erindres, at samarbejde, der uden tvivl er meget vigtigt, ikke kan planlaegges. Samarbejde 
skal og vil derimod opsta spontant. Det er derfor ikke hensigtsmaessigt at kraeve 
samarbejde mellem forskere fra bestemte egne i Europa eller lade tildelingen af midler 
vaere betinget af dette samarbejde. En sadan fremgangsmade virker mod hensigten. En 
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bedre løsning er at ivaerksætte et saerligt program af begraenset omfang for at støtte 
kvalificerede forskere inden for biomedicin, der arbejder i de europaeiske lande, som 
endnu har en svag stilling inden for molekylaerbiologi, men som er i stand til hurtigt at 
rade bod pa dette. 
10. Uddannelsesprogrammet har i det store og hele vaeret en succes, og det bar derfor 
fortsættes. Dog er det måske nødvendigt at finde nye mader at formidle oplysninger om 
programme! pa, eftersom der blev indgivet langt faerre ansøgninger end forventet. Det bar 
ogsa tages i betragtning, at visse aendringer i programmet kunne være til stor gavn for 
unge forskere, der arbejder med analyse af det humane genom. Alle europaeiske lande har 
tilsyneladende et problem til faelles, nemlig hvordan man sikrer underhold og 
uafhaengighed for unge forskere, der i deres eget eller andre lande har vist, at de er 
videnskabsmænd af højeste klasse. For disse forskere har laboratorier i USA, der har en 
meget fleksibel administrativ struktur, og frem for alt de imponerende mange fremragende 
forskningscentre ved de amerikanske universiteter stor tiltraekningskraft. Det vil blive 
stadigt mere attraktivt for unge europæere at blive tilknyttet laboratorier i disse centre for 
kortere eller længere tid, men typisk i de ar, hvor de er mest produktive inden for 
grundforskning. Biomedicinsk forskning kan kun udføres pa centre, der har en vis 
størrelse. Man må gøre sig klart, at en af de vigtigste opgaver i forbindelse med støtte og 
organisering af forskningen i Europa er at skabe et modstykke til disse meget magtfulde 
centre for biomedicinsk grundforskning i USA. Et skridt i denne retning kunne vaere at 
oprette stillinger for unge, uafhængige forskere inden for biomedicinsk forskning, der ville 
gore det muligt for unge, højt kvalificerede videnskabsmaend at beskaeftige sig med den 
forskning, de ønsker, ved et af de europaeiske universiteter, uden at de bliver begraenset af 
de ofte meget "traditionelle" administrative strukturer, der hersker her. I forbindelse med 
disse stillinger bør der ogsa gives midler til materialer, udstyr og forskningspersonale. Det 
forventes, at de naevnte foranstaltninger i vaesentligt omfang vil kunne medvirke til at 
tiltraekke eller lokke mange af de mest produktive unge forskere tilbage til de europaeiske 
lande. 
11. ESLA-programmer er en yderst vigtig del af genomprogrammer. Evalueringsgruppen 
foreslar - omend ikke samstemmende - at ESLA-programmet fortsaettes, og at det støttes 
pa lang sigt. Det er vigtigt, at kendskabet til programmet udbredes sa meget som muligt, 
og at kontrahenterne bliver ordentligt informeret om det forventede resultat af 
programmet. Det er absolut nødvendigt, at nye ESLA-programmer giver de deltagende 
grupper mulighed for at samarbejde, pavirke hinanden og udveksle ideer og resultater. 
Der bør ogsa ydes en saerlig indsats for, at de økonomiske aspekter ved den tekniske 
udvikling, forskningspolitikken og de videnskabelige undersøgelser inddrages i 
programmet. Et andet problem, der bar tages op, er den geografiske uligevaegt. 
12. St0tte til workshops og mader er helt klart en vigtig side af HGAP, og det anbefales, at 
programmet fortsaettes. Der bar dog foretages nogle administrative aendringer. Det 
foreslas, at der f.eks. oprettes et videnskabeligt konsulentrad, der skal radgive om 
programmet og sortere ansøgningerne. Der bar ydes en indsats for at skabe en bedre 
emnemæssig balance mellem de workshops, der modtager støtte. Den støtte, der via 
HUGO gives til workshops for enkelt-kromosomer, er af stor betydning og bar fortsaettes. 
Der bar i almindelighed ydes støtte til kromosomworkshops i Europa som et bidrag til 
HUGO. Der bat ligeledes gives rejsestipendier til europaeiske deltagere i workshops, der 
afholdes uden for Europa. Det vil nok ogsa kunne betale sig at støtte workshops, hvor 
forskere, der arbejder med beslaegtede omrader, kan modes (som man tidligere i et vist 
omfang har gjort). Der kan f.eks. vaere tale om forskere, der arbejder i EUROGEM eller 
med cDNA-biblioteker. Dette vil klart kunne forbedre kontakten mellem grupper i 
forskellige europaeiske lande. 
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13. Videreuddannelse af praktiserende læger over hele Europa ville vaere en anden velkommen 
udvidelse af programmed For mange praktiserende laeger kan genetik vække traumatiske 
minder om deres lægeeksaminer. Med de hurtige fremskridt inden for laegevidenskabelig 
genetik star vore praktiserende kollegaer allerede i en vanskelig situation over for deres 
patienter, der stiller indgaende sperøsmal. Specialiserede uddannelsesprogrammer kunne i 






1. Das Programm Analyse des menschlichen Genoms (Genomprogramm) ist Teil 
des zweiten Rahmenprogrammes der Gemeinschaft für Forschung und 
techno Iogische Entwicklung. Dieses Programm wurde unter dem Abschnitt 
"Gesundheit" des Kapitels "Lebensqualitat" mit folgendem Ziele 
ausgearbeitet: 
Nutzung und Verbesserung neuer Biotechnologien zur Untersuchung 
des menschlichen Genoms im Hinblick auf ein besseres Verstandnis 
des Mechanismus der Genfunktionen sowie die VerhUtung und 
Behandlung menschllcher Krankheiten 
Erarbeitung einer integrierten Konzeption, die die thischen, 
sozialen und rechtlichen Aspekte im Zusammenhang mit möglichen 
Anwendungen der erzielten Ergebnisse berücksichtigt. 
2. Im Rahmen ihrer regelmasigen Bewertungstatigkeiten beauftragte die 
Kommission im Dezember 1992 einen Ausschub unabhangiger 
Sachverstandiger mit der Bewertung des Genomprogrammes. Die 
Zustandigkeit des Bewertungsausschusses wurde nach Artikel 4 Absatz 3 
der Entscheidung des Rates zur Annahme dieses Programmes (ABI. Nr. L 
196 vom 29.6.1990, S. 8) festgelegt. In diesem Artikel heiBt es 
ferner, daB die Bewertung unter BerUcksichtigung der 
wissenschaftIichen und technischen Ergebnisse des Programmes, der 
Qualität und praktischen Bedeutung dieser Ergebnisse, der Wirksamkeit 
seiner Abwicklung, seiner ethischen, sozialen und rechtIichen Aspekte 
sowie seiner Auswirkungen auf die einzelstaatIichen 
Forschungsprogramme und ihres Nutzens für diese zu erfolgen hat. Im 
Laufe der Bewertung besuchte der AusschuB vier am Programm beteiligte 
Stellen und befragte über dreibig Personen, darunter Beamte der 
Kommission sowie der Mitgliedstaaten, am Programm zur Analyse des 
menschlichen Genoms Beteiligte und Anwender. 
3. FUr dieses Programm wurden insgesamt 15.6 Mio. ECU bereitgesteiIt. 
Dieser Betrag wurde wie folgt aufgeteilt: Genkarten 21 X, 
physikalische Karten 27,6 X, Datenbehandlung und Datenbasen 15 X, 
fortgeschrittende Gentechnologien 18 X, Ausbildung 12 X, 
VerwaItungsausgaben 6,4 X. 
Am Genomprogramm beteiligten sich rund 100 EG-lnstitute. 
SCHLUSSFOLGERUNGEN 
Der AusschuB hält das Genomprogramm fUr einen Erfolg und fUr ein 
bedeutendes Anspornmoment auf dem Gebiet der Erforschung des menschlichen 
Genoms. In der Genomforschung werden zur Zeit rasche Fortschritte erzielt. 
In den letzten Jahren war der Fortschritt in Europa besonders deutlich; 
Erfolge wurden unter anderem auf dem Gebiet der Sequenzierung von ganzen 
Hefechromosomen, ganzer physikalischer Genomkarten und verbesserter 
genetischer Karten erzielt. Das Genomprogramm hat eindeutig bei der 
Wiederhersteilung des Gleichgewichts in den Beziehungen du den Vereinigten 
Staaten eine wichtige Rolle gespielt. Sicherlich haben jedoch auch wichtige 
Programme wie AFM in Frankreich als bedeutendes Antriebsmoment gewirkt. Das 
Genomprogramm wurde mit einem Zweijahresetat von 15.6 Mio. ECU 
verabschiedet. In der EG wird im Vergleich zu den Vereinigten Staaten und 
Japan fUr Genomforschung sehr wenig Geld aufgewendet. Das Genomprogramm 
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diente somit nur der Stützung bereits angelaufener einzelstaatIicher 
Tatigkeiten, und der Einfluß der EG-Mittel auf die einzelnen Programme hängt 
weitgehend von der Qua Iitat der einzelstaatIichen Programme ab. Die EG hat 
die franzdsischen Gruppen in geringerem Ma3e (weniger ais 10 %) unterstützt, 
we it mehr dagegen die britischen, deutschen, italienischen und diejenigen 
anderer europaischer Lander. Die EG-Hilfe belief sich auf 5 - 50 % der 
Gesamtausgaben der einzelnen Projekte. Auf Internationale Projekte wirkt 
sich diese Unterstützung in den meisten Fallen nur in bescheidenem MaSe aus, 
und die weniger fortgeschrittenen Lander k5nnen aus den internationalen 
Programmen nur beschrankten Nutzen Ziehen. 
Die Errichtung von "resource centres" und die Ausarbeitung von 
AusbiIdungsprogrammen ist zur Unterstutzung gut organisierter 
wissenschaftIicher Laboratorien Oder auch weniger fortgeschrittener Oder 
weniger bekannter Stellen sehr nützlich. Dies ist ein bedeutender Aspekt des 
Genomprogramms und der heutigen Wissenschaft allgemein, da Organisation und 
Mittel wesentliche Faktoren darstellen. In dieser Hinsicht war das 
Genomprogramm fur die in Europa auf diesem Gebiet tatigen 
Wissenschaftskreise sehr nützlich, und dieser Aspekt ist bei der 
Ausarbeitung kunftiger Programme hervorzuheben. 
Mit dem cDNA-Programm wurden im Rahmen des Genomprogrammes nicht so rasche 
Fortschritte erzielt wie erwartet, obwohl eine ganze Anzahl cDNA-Sequenzen 
erarbeitet worden sind. Fur die Zukunft ist eindeutig ein hoher Bedarf an 
umfassenden Sammlungen von cDNA-Bibliotheken von hoher Qua Iitat zu erwarten. 
Das Endziel des umfassenden menschIichen Genomprojekts besteht in der 
Sequenzierung des gesamten menschIichen Genoms. Das Genomprogramm umfaBt zur 
Zeit keine umfassenden Sequenzierungsprogramme. Dies ist in einem küinftigen 
Genomprogramm zu andern. 
Die überstaatIichen Projekte haben die Zusammenarbeit in Europa gefördert. 
Sie stellten auch kleinen Laboratorien Mittel zur VerfUgung, insbesondere in 
weniger entwickelten Landern, urn diesen den Zugang zu hochentwickelten 
Technologien zu ermogIichen. 
Das Stipendienprogramm ist ein sehr wichtiger Teil des Genomprogramms. Es 
scheint bisher befriedigend durchgeführt worden zu sein. 
Die Tatigkeiten im Rahmen des ESLA-Programmes wurden für gerechtfertigt 
erachtet. Der BewertungsausschuS erörterte Jedoch die Frage, ob das Programm 
im gieichen Maß3e wie bisher zu finanzieren sei, weil die verfügbaren Mittel 
beschrankt sind und zahlreiche dringende Fragen zu erörtern sind. Das 
bereits abgeschlossene ESLA-Programm kann als vieIversprechende Pilotstudie 
betrachtet werden. Der AusschuS unterstreicht, daS Europa wegen der 
vielseitigen Programme der einzelnen Staaten auf dem Gebiet des Gesundheits-
und Sozialwesens einzigartige M5glichkeiten fUr solche Studien bietet. 
Die Workshops wurden bisher aus Verwaltungsmitteln unterstUtzt. Trotz der 
Beiträge von CAN-HUG und der ESLA-Arbeitsgruppe scheint das Programm in 
einem gewissen MaBe ad hoc verwaltet worden zu sein. 
EMPFEHLUNGEN 
Der Ausschuß ist der Ansicht, daS ein drittes Genomprogramm in die Wege 
geleitet werden sollte. Angesichts der im vergangenen Jahr erzielten, 
beachtlichen Fortschritte sind jedoch Änderungen des Projektplanes 
erforderIich. Mit großer WahrscheiIichkeit dUrfte binnen einem weiteren Jahr 
eine hochauflosende Genkarte sowie eine volIständige physikalische Karte 
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(auf YAC-Grundlage) des menschlichen Genoms ferteiggestelIt werden. 
2. Ein neuer strategischer Plan für das Genomprogramm ist festzulegen. 
Darin sollte auch die Möglichkeit eines "shot gun"-Ansatzes für die 
Sequenzierung des gesamten menschlichen Genoms in Erwagung gezogen 
werden. Dies würde eine betrachtIiche Erhöhung des Mitteleinsatzes 
bedingen. 
3. Die "ressource centres" bilden einen entscheidenden Aspekt des 
Genomprogramms, ihr Fortbestehen muB unbedingt gewährieistet sein. 
Eine umfangreiche, jedoch notwendige Aufgabe besteht darin, die 
Ergebnisse der physicalischen Genkartierung Jederzeit 
gemeinschaftsweit verfügbar zu machen. Sie sollte mit Hilfe der 
Informatik einschließIich einer zugänglichen, vollständigen und 
anwenderfreundlIchen Datenbasis gelöst werden, Jedoch auch die 
Verteilung von YAC- und Cosmid-Klonen umfassen, was viel Arbeit 
verursacht. Ein wesentlicher Schritt würde darin bestehen, diese 
Reagentien den europaischen Wissenschaftlern Jederzeit zur Verfügung 
zu halten, z.B. durch eine ausgedehnte Verteilung von PolytenfiI tern, 
die geordnete YACs fur alle menschlichen Chromosomen enthalten. 
Allgemein ist ein größerer Bereich von geordneten Bibliotheken 
erforderIich, urn den diversifiziertesten Bedarf an Genomforschung 
: nach Erstellung der ersten physikalischen Karte zu decken. 
4. In Zukunft werden geordnete Sammlungen von (einem Gen entsprechenden) 
vollstandig sequenzierten cDNAs von alien Gewebetypen des Korpers 
erforderlich sein. Den "resource-centres", die geordnete cDNA-
Bibliotheken als Dienstleistung an die wissenschaftIiche Gemeinschaft 
Iiefern, solite in einem kunftigen Programmen eine hohe Priorität 
eingeraumt werden. 
5. Die Bereitstellung von Mitteln fUr cDNA-Sequenzierung in sehr großem 
MaBstab ist in Betracht zu Ziehen. Die Erstellung eines volIstandigen 
Katalogs menschlicher Gene durch die cDNA-Sequenzierung war 
bekanntlich eine europaische Idee; 
6. Die Genomsequenzierung in sehr groBem MaBstab, die im urspünglichen 
Genomprogramm nicht vorgesehen war, sollte in einem kunftigen 
Programm berücksichtigt werden. Einige Pilotprojekte mit "Megabasis"-
Sequenzierung zur Bewertung der kunftigen Möglichkeiten der 
Sequenzierung ganzer menschlicher Chromosomen werden durchgeführt 
werden müssen. Ernsthaft in Betracht zu Ziehen ist ferner die 
Möglichkeit der Sequenzierung des gesamten Genoms nach dem "shotgun"-
Verfahren. Es wird vorgeschlagen, zur Prüfung dieser Frage einen Ad-
hoc-Ausschuß einzusetzen. Beabsichtigt die EG, sich an einem soIchen 
Projekt zu beteiligen, so muß sie ihre Programmittel beträchtIich 
aufstocken, um das Endziel des umfassenden Genomprogrammes - die 
vol I standige NukIeotidsequenz des menschlichen Genoms - rascher zu 
erreichen. 
7. Der Auftrag von EUROGEM wird nach Erarbeitung der hochafIösenden 
Genkarte rasch beendet sein . 
8. Das Gebiet der BioinformatIk dUrfte sich in nachster Zeit stark 
fortentwickeln. Die Entwicklung einer anwenderfreundlichen Software 
zur Analyse der groBen Masse an Daten ist sicherlich ein wichtiger 
Aspekt eines zukUnftigen Genomprogramms. Wegen der häufigen Kritik an 
GDB soliten nunmehr alternative Datenbasen oder zumindest ein anderer 
Zugang zu den Datenbasen ins Auge gefaBt werden; in dieser Hinsicht 
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ist auf die mit der Heidelberger IGD (Integrierte Genom-Dantenbank) 
erzielten Fortschritte hinzuweisen. Besonders erfolgversprechend 
erscheint das von dieser Gruppe empfohlene VerteilungsmodelI - ein 
auf Srtlicher Ebene betriebenes ACeDB-System, in das auch Daten aus 
anderen Genom-Datenbasen eingespeist werden. Die Kommunikation 
zwischen Biologen und Datenverarbeitungswissenschaftlern ist 
weiterhin mange I haft - beide gehttren weiterhin einem verschiedenen 
Kulturkreis an. Beide Gebiete haben sich in den letzten Jahren rasch 
fortentwickelt, und Leute mit Fachkenntnissen auf beiden Gebieten 
sind selten. Der einzige Weg zur Minderung dieses Problems besteht 
vermutlich darin, die Zahl solcher Fachleute durch attraktive 
Stipend!en und Stellungen zu erhohen. 
Ferner ist der Verbesserung der Kontakte zwischen GenomspezialIsten 
und den übrigen Biologen einschließIich nicht nur der medizinischen 
Genetik, sondern z. B. auch der Gruppen, die funktionelle 
Untersuchungen an Mäusen durchführen, vermehrte Aufmerksamkeit zu 
schenken, und diesbezügiiche BemUhungen sind finanziell zu 
unterstützen, urn eine Annaherung von Struktur und Funktion zu 
ermöglichen. 
9. Die mehrstaatIichen Projekte sind fortzusetzen, wenn sie auch sehr 
sorgsam auszuwahlen sind. Bei der Unterstützung von 
Forschungstatigkeiten und der Abgabe von Empfehlungen ist unbedingt 
daran zu erinnern, daB Zusammenarbeitstatigkeiten ungeachtet ihrer 
groBen Bedeutung nicht von irgendjemandem in die Wege geleitet werden 
können, sondern sich spontan ergeben mussen und es auch werden. Es 
Ist somit nicht sinnvoll, Zusammenarbeitsvorhaben zwischen 
Wissenschaftlern bestimmter Gebiete in Europa vorzuschlagen Oder 
sogar Mittel dafür bereitzustelten, dies ware geradezu 
kontraproduktiv. Vorzuziehen ware ein Sonderprogramm beschrSnkten 
Ausmasses zur UnterstUtzung von Wissenschaftlern mit Verdiensten auf 
dem Gebiet der Biomedizin in europäischen Landern, in denen die 
Molekularbiologie zur Zeit weniger fortgeschritten ist, die den 
Abstand Jedoch rasch aufholen konnten. 
10. Das AusbiIdungsprogramm scheint weitgehend erfolgreich gewesen zu 
sein; seine Fortsetzung wird empfohlen. Vielleichrt sol I ten jedoch 
neue Mittel zur Verbreitung der Informationen Uber das Programm 
gefunden werden, da die Zahl der Anwendungen we it niedriger war a Is 
erwartet. Nicht zu vergessen ist ferner, daB bestimmte Änderungen des 
Programmes fUr auf dem Gebiet der Analyse des menschlichen Genoms 
tatige Junge Wissenschaftler sehr nützlich sein konnten. Ein Problem 
scheint in alien europäischen Ländern aufzutreten, d. h. die 
UnterstUtzung und Unabhängigkeit junger Forscher, die sich im In-
oder Ausland als hervorragend erwiesen haben. Die sehr flexible 
Struktur der Laboratorien an den meisten amerikanischen Hochschulen 
und vor a Ilern die beachtliche Zahl von Spitzenforschungszentren an 
vielen dieser Hochschulen Uben eine starke Anziehungskraft aus. Eine 
Iangere Oder kUrzere Assoziierung mit Laboratorien solcher Stellen 
wird fUr junge Europaer zunehmend vorteilhafter, in der Regel gerade 
in den produktivsten Jahren ihrer Forschertatigkeit. Die 
biomedizinische Forschung last sich zur Zeit am besten in 
Forschungsstellen von kritischer GröBe durchfUhren. Es muB anerkannt 
werden, daB eine der ersten Aufgaben der Finanzierung und 
Organisation der Wissenschaft in Europa darin bestehen muB, ein 
Gegengewicht zu diesen sehr attraktiven biomedizinischen 
Forschungsstellen in den USA zu schaffen. in diesem Zusammenhang wird 
u. a. angeregt, Stellen fUr unabhangige junge Forscher auf 
biomedizinischen Gebieten zu schaffen, wodurch hochqualifizierte 
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Jung© Wissenschaftler selbstgewählte Forschungen an elner 
europäischen Hochschule fortfUhren könnten, ohne durch die oftmals 
sehr "traditionellen" Verwaltungsstrukturen gehemmt zu sein. AuSerdem 
sol I ten Mlttel zur Deckung der Materialverbrauchskosten, Geräte und 
Forschungspersonal für diese Posten zur VerfUgung gestellt werden. Es 
wird die Meinung vertreten, da8 solche Strukturen viele der 
produktivsten Jungen Forschungskrafte aus dem Ausland nach Europa 
anziehen Oder zurückholen konnten. 
11. ESLA-Programme sind wesentliche Elemente der Genomprogramme. Der 
AusschuS empfielt - wenn auch nicht einstimmig - das ESLA-Programm 
fortzusetzen und langfristig zu unterstützen. Das Programm muß 
moglichst eingehend angekUndigt werden, und die Vertragnehmer 
müssen die erforderIichen Informationen über die erwarteten 
Programmergebnisse erhaiten. Wichtig fUr künftige ESLA-Programme sind 
die Zurverfügungstellung von Mitteln fUr eine Zusammenarbeit, 
gegenseitige Beeinflussung und einen Austausch von Ideen und 
Ergebnissen an die beteiligten Gruppen. 
Besondere Anstrengungen sind ferner notwendig, urn die 
wirtschaftIichen Aspekte der technischen Veranderung, der 
Wissenschaftspolitik und wissenschaftIicher Untersuchungen in das 
Programm aufzunehmen. 
12. Die Unterstützung von Arbeitstreffen und Sitzungen ist eindeutig ein 
wesentlicher Faktor des Genomprogramms; die Fortsetzung des 
Programmes wird empfohlen. Einige administrative Änderungen werden 
Jedoch vorgeschlagen. So wird angeregt, zur Beratung in 
programmpolitischen Fragen und zur Auswahl der Anträge eine 
wissenschaft!iche Gruppe einzusetzen. Die UnterstUtzung von Workshops 
Uber einzelne Chromosomen durch HUGO ist wesentlich und sollte 
fortgesetzt werden. Allgemein sind Workshops Uber Chromosomen in 
Europa a Is Beitrag zur Organisation zu unterstUtzen. Ferner sind 
Europäische Teilnehmer an Arbeitstreffen außerhalb Europas durch 
ReisevergUtungen zu unterstUtzen. Sodann sol I ten Workshops von 
Wissenschaftlern unterstUtzt werden, die sich im Rahmen des 
Genomprogrammes mit ähnlichen Themen befassen (wie dies bisher in 
einem gewissen Maße bereits der Fall war), z. B. EUROGEM oder cDNA-
Bibliotheken. Dies ware der Kontaktaufnahme zwischen den in 
verschiedenen europaischen Landern auf diesem Gebiet tatigen Gruppen 
sicher förderIich. 
13. Eine weitere begrUBenswerte Erweiterung des Programmnes ware die 
Fortbildung praktizierender Ärzte in ganz Europa. FUr viele 
praktische Ärzte ist die Genetik vielleicht eine traumatisierende 
Erinnerung an die Zeit ihres Studienabschlusses an der medizinischen 
Fakultät. Angesichts des raschen Fortschrittes auf dem Gebiet der 
medizinischen Genetik geraten die praktizierenden Ärzte oftmals in 
Schwierigkeiten, wenn ihnen ihre Patienten heikle Fragen stellen. 
Spezialisierte FortbiIdungsprogramme könnten das Problem zumindest 
teilweise Iösen. 
XXI 
. \-i-..<aa Z: - i' i rsr : .2 >r; •..;-. ;-. .-,": = ;:,;. '. ■';.;. • - , ..- ■ i ^ c 9!/. 
'.-■.■•• , ^ v r ^ : i s : ' : t ; : . •-;. ■ ?:-. ■ ■;*«<■;.■; -
, 1 ^ f n - j ^ M t S ^ V i . u 'S'-?frt ■■•? t r - . ^ H ,< ■■C-if „'ad •§;«■:•/i.}V:-> "rav - ; , i '«!$> 
'■■■ ■ fjjb >*re u , . ; '.tampon. •;sf1;a'v on lis ^^.r.^;--^ sic-fi* t na fc r t c^ i i 
•'■■3l> , t.-'li.?"ofc^*?*-i ■" !i«f::3£'fV:oc.." Uib *'J J-\-:v; '"■ 5 S ^ n .? te^rviJ ;' ,; 
-sJ'l ?-o# brti.s ft .; !■:?:;■->3Vf- t.j •; i ' j W fkvii'h ri-2r.-!tjp*sr-'w:,vj ^ ? ' otr . ?-«'■ iec?i'" 







1. To IlQOYoamxa AvdX,vaT|5 xov Av0cxan;ivov rovioicbjAaxoc; (IIAAr) oaioxeXei nioog xov 
5evxeoov jcQOYodmiaxog-JtXatOLcn) xcov SoaaxriQioxTixtov XTJC; Koivdxrytac; axov xojiea xr\q 
egewag xai xe/yokoyocqc, avdrcxvJjric;. To Jtooyganjjux avxd xaxaoxiaxT|xe p-e jj&crn xo 
xecpdXaio "Yyeta" xou xjxnuaxog XTIS IIoidxTixac; Zanfe, jie axoitd: 
XT| xGTlatlxo;Ilco^TlOTl N**1 peXxtcoari vdcov xexvoXoyu&v OXTI |ieXexr| xou avGodmivov 
yoviStcofxaxog, Y101 T ^ xaXvieOTi xaxav6tiaT| xov (ATixavtajiov xcov Y^et'-wftv 
XzvcouQYixbv xaGcog xai YK* TTJV Jto6X.Tj\|ni xat 6eoaJteia xcov avBQComvcov aaSeveicbv, 
- » xriv avdnxu^ri HiaS oXoxXTiocondvrig JIOOOCYYICTTIC; oxij 5eovxoXoYixf|, xoivcovixfi xai 
VOJAIXTI Jtruxri xcov evSexdjievcov ecpaQHOYCbv arcd xa anoxeXianaxa Jtov 
EJtixuYXdvovxai. 
2. Q5 M^Q°5 xov EQYOU""15 xaxxixfig aJjioXdyricrns,r\ EJCIXOOTCTJ 6i6gtaexov AexeijJJgio 1992, paa 
o^dSa ave^dpxnxcov e(uteiooYvco(ixovcov Y«I va JipofJovv crniv a|ioX6yrioii xou IIAAr. Ta 
xaGfjxovxa n\c, 0[id5ac; A^ioXoYnorig ogi^ovxai oxo do9oo 4 (3) XTJC; outdcpaaric; xov 
Zv[45ovX.iov yixx XTI 6eonKrn avxov xov Jioc>YOdjA|xaxog (EE agi9. L 196 xx\c, 29r\c, Iovviov 
1990, oeX. 8). To COLO doBoo ogi^ei 6x1 r\ a^ ioXoYTiaTi Jtgeitei va emxevx6ei acpov Xt|cp6ovv 
tor6\Jrn xa ejtiaxT)|j.ovixd xai xexvixd ejuxevyHaxa xou JtooYQaiiixaxog, ti Jtoidxrixa xat x\ 
jtQaxxixfi OT]|xaaia xcov ajEOxeXeafidxcov xov, r\ oaroxeXeanaxixornxa xrjg 6iaxetQLafJ5 xov, TI 
6eovxoXoYixf|, xoivcovixfi xai VOJAIXTI Jtxvxfi, xaOcbg xai TJ ejiiooaari xai xa ocpeX.T| xov oxa 
e9vixd egewrixixd jtooYQ^M-Jia'ca-
Tia XT|V TCQa.y\ixnonoii\aT{\ xr\c, aJjtoXoyriO'nS, *l O|xo8a erciaxecp9r|xe xeaaega xevxga Jtov 
avmjiexexowaxo JigoyQajJifiaxai e^exaoe Jtegioadxeoaarcd xgidvxa dio^a: ai;icofAaxovxovs 
XT15 EJUXOOJCTJC; xai xcov eBvixcbv agxcbv, av{ifiex6xovxe<;axo IIAAr xai XQflotec;. 
3. OicnrvoXix^5Jiioxcbaei5nov6iexd9TiaavYiaxo3io6Yoap4iaavx6,av^Qxovxavae 15,6 MECU. 
H xaxavofi.fi xcov jtiaxcoaecov eixe cog c^ fjc;: yeyeivxol x&Qteg 21%, cpvaixoi x&Qiec, 27,6%, 
ejie£egYaaia5e6ojjievcovxai xgdne^eg Seoofiivcov 15%, 3iQOT|Y(J^ VT|YevextxfixexvoXoYwx 18%, 
6oaaxriQi6xT|xe5 xaxdQxiarig 12%, 5ioixTiOT| 6,4%. 
Zxo HAAr av[A(Aexeixav3ieQuiov 100 ioov(iaxa aito xov xtooo xcov Koivoxf|xcov. 
EYMnEPAEMATA 
H ojjidoa Gecoget 6x1 xo IIAAr arifieicoae \txrf6Xr\ ejuxvxia xai ancoxeXel jiia ar|[Aavxixf| xivtyxfigta 
SvvajxTi oxov xofiia xrjg evooma'ixfig egeuvac; Y " 1 ^ O avQodxnivo YOviSicojJia. Ilgog xo 3tao6v, T| 
eoevva Yia xa YOvi6icbjJiaxa Jiooxcogei HE evav vmegPoXixd xaxv ov0[io. Kaxd xa xeXevxaia xQ6via, 
TJ 11960605 f|xav iSiaixega evrvjicoaiaxfi OXT|V Evoawrri, xai ar|H£icb9Tpce eaiixuxia ae xoneig, 6jccog 
axov Jcgoo6ioQia(A6 XT15 vovxXeoxioixTJg aXX.T|Xovxiag OXOXXTIQCOV XCOV xQ<UMX)fia>fJia'ta,v 
c;vjiOfiT]xvxcov, ae cpvaixovg X'&Qits OXOXXTIQCOV Yovi6ico|juixcov xaBcbg xai oe XenxoHegeic; Yevexixovg 
Xdoxeg. Etvai aacpeg, 6x1 xo HAAr exei 5ia6ooqjwixioei crrmavxix6 06X0 axrjv xaBieQcoari ^ w 
iaoQoojiT|nevcov oxeaecov \xz X15 H J I A . Etvai 6|xcog e^iaov aacpeg 6x17iooyod|xpxxxa djtax; exetva 
JIOV ^xow vjioaxTiQixSei an6 XT|V AFM OXTJ TaXXia anoxeXovv jua cninavxtxf| xivTjxf|gux 6uvanT|. To 
HAAr eyxeieiTxe \t£ JiopibtoXoYiofAdovo excbv, xtjg idfyux; xcov'15,6 MECU. To icood nov 5ie9eaav 
01EK OXT|V egewa yta xa YOvi6icbnaxa e£vai JioXv [uxo6 oe axeori jie xa xov6vX«x xrjg epewag Y"1 
xa YOviSicbjJiaxa axig H.EL-A. xai axriv Iancovia. Tia xov Xoyo avxd, xo HAAr axcXxbg aviwiXfigcoae 
xgexovaecj eOvixeg JiocoxoPovXieg, xai xo v\jx>g XT|CJ xoivoxixfig xG^JW^oddxrioTig nenovco(xevcov 
JiooYoamxdxcove|agxdxai oe HCYdXo PaG^o 0016 XT|V UJXV xcov eSvixcbv JipoyGaRwixcov. Oi EK exow 
ujroaxTiQi^eieXdxiaxa \i&/6XEC,yaXkv>dc, o\v6&ec, (ae Jioaoaxd(uxodxepoand 10%), evcbT| xntooxfigigri 
XXIII 
lytav aoxexd otijiavTtJtii YW* ™1 MeYdXn Bgexavia, XTJV IxaXia xai dXXeg Evocaraxtxec; X ^ e ? . H 
xoivoxtxii xeilM*tT06o'clx1l evlox«JTi xv|jiatvexai and < 5% ecoc; 50% TTIS OWOAAXIJC; XOT^a*o66xT|OT|5 
xd0e ecvyou. I \ a xa 8iaxoaxixd igya, auxog o XQOJCOS xQt\\ljaxo^y"\ar\^ V^OQtL va exei xig 
jtegiaadxeQec; qpoges (uxof) Jiovo eniQOoij, TO 6e ev8exd|ievo dyzkoc, and xa ouxxoaxixd 
JCQOYQdfi|iaxaY«<oi x t 5 XiYdxepo JiooriYfievegxtfrQ6? eivai rceQiOQionivo. 
H eYxaxdoxacni xevxpoov yevexwcbv jcdgcov xai t) ooYdvaxni JiooYOaiifJiaxcov xaxdoxunic; arcoxeXel 
fAeydXTi parjGeia yux xa ogvavco^va emoxr)|jumxd eovaoriiQia aXXd xai ywi XAYOTCOO JioorjYueva fj 
yta XiY6xeooxaxa!;ico(ievec; 0|idSec;. IIooxeixaiYia \ua noXv OT]|JUXVXIXT) Jtxuxii TOW IIAAr xai Yevtxd 
Trig OUYXOOVH5 ejtiaxriniig, aizibr\ r\ OQYdvcoan xai T| 8td0ear) TOJV udocov ajtoxeXovv fktoixd Qt\utxa. 
2xo ari|ieio avxd, xo ILAAr rjxav JIOXV xQtjomo YW* TTJV XOIVOXIXTI egeuva oil xcov YOvtSuofidxcuv, 
xai T) jrrux'n ctwxii ngfaiei va xovioxei xaxd xov axeSuxond xo>v iieXXovxixcbv rtoOYQaftudxarv. 
To JiodYpa(i.|Aa cDNA oxo vcptoxdjAevo IIAAr Sev avajtxvxBrpte xoao YOfryooa oao avanevoxav, 
(xoXov6xt jrooexin|xiv liegixeg vovxXeoxiSixes aXXtiXouxteg cDNA. Eivat aacpes, dxi oxo |i£XXov 6a 
xwcdp^et TCOXV \i£y6Xr\ avavxTi yia crn(iavxixeg xodite^eg ouXXoyn? wJniXfic; rcoioxrixag cDNA. 
O xeXixoc; axoxog 6Xou xov JigoYodjAjJuxxos yta xo av0Qcbmvo YOvi6tco|Jia, etvai r\ aveuoeoti xrig 
vovxA«oxi8ixfis aXXriXouxwxs OXOXXTJQOV xou avGocbmvov YOviStcbpuxxog. MeYdXa3tQOYod(i|juixa JIOV 
aaxoXouvxai jxe XTJV vovxXeoxiSixfj aAXtiXovxia 6ev ov{uteQiXa(i0dvovtai oxo icaodv IIAAr. H 
xaxdaxaari a\rvf{ EJii0dXXexai va &toQ0co8ei oe iieAlovxtxd IIAAr. 
Ta 8iaxoaxixd ecvya eixav \ieyaht\ or\\ixxoia Yta Trjv jroocb6t)OTi rug evoaBKiixiJs awepvaaCas. 
IlaQeCxav ejtiotis xa piioa oe juxod eovaaxriQia, lotaixeoa oe XiYdxeoo aveJcxvYiAeveg x ^ ^ , Y101 
jtQOopaori oe lOTeQavYXDOvegxexvoXoYiec;. 
To JXQOYoafifAa ima8i8axxoQixcbv ojrovSc&v arcoxeXei jua JtoXv orinavxixii irruxii xou IIAAr. 
Oaivexai 6xi xaxd xo JoaQelSdv eqxxg(x6oTnxexaxd TQOJCO t»tavoatonixt>t6. 
AvaYvcoQiornxe6xt oi8paoxriQi6xtixes3Kn) aveX,TJ<p9t|oavoxa nXataiaxoiJ JtooYodfjqxaxo^ESLATixav 
5txau)XoYT|(iive5. Evxovxotg, r\ o^doa a^ioXoYiiong e^exaoe xaxd JIOOO xo vtyoc, xrig X0Tl}Aaxoo6xT|0T]5 
xov stooYodfAjiaxog jxQeJtet va eivai xo i8to dncog xa i xaxd xo JcageX96v, aizi&r\ oi JIOOOI eivat 
jceQtooio(iivoi xai nQkrczi va 51606x^1601^ 3ioXXd eneiYOvxa 6epxxxa. To iion oXoxXtiocopivo 
jiQOYoajjijia ESLA BecoQ^Brpce cog (ita evGagpuvxixii 3xo6xvjni \t£kbtv\. H 0|id5a auBv\x£i va 
TOTOYQa(X|Aiaei6xi TI Evgaxrcti rcooaqpeQei fiOvaStxeg 6\rvax6rnxe5 yux fieXexes avxou xov eiooug, XOYCO 
xcov vcpiaxafxevcov oatoxXioecov oxov xojjiia xr\c, VYCIOVO|XIXTI5 JteQi0aX,ijni5 xai xcov xotvcovixcbv 
JcgoYQaixjidxaiv jjiexa^u xcov 6ia(p6QCov xcooc&v. 
H xQimttTOOoxixii evCaxvorj xcov owavxfiaecov Jioaxxtxfis eQYaaia^ Y t vOTav wna xo JiaoeXfiov and 
xov jtQO\bioXx)Yionx3xri5 8101x110115. MoXov6xixo CAN-HUG xai i\ o\uaba eQYaoiagESLA eiafJYOYav 
oxoixeia oxo JCQdYQajxjAa, cpaivexai 6x1 ae OQIOJAEVO &O.Q\XJ6 imriQ^e jiia ad hoc 5iaxeiQior|. 
£YETA£EI£ 
1. Kaxd XTjv djroijni XT15 ojidoag 6a noejtei va xe6eC ae ecpaofAOYti eva XQIXO IIAAr. Evtovxoig, 
eivai ajtapaCxTixes OQio(xeveg xgoirxMioirioeig oxo 0x^810 xou TcooYQdfifiaxog, XOYCO TUS 
e^aiQexixiig nooooou Jtou exei otmeicoOeixaxd xa xeXevxaia xodvia. Oaivexai noXO rnSavo, 
6x1 nioa oe eva exog 6a exei oXoxXiiQCoOel evag jxoXv axQi^iig Yevextxo5 X^oxiig xaBcog xai 
evag Jt^QTig cpuoix65 X^TTIS XOV av6gdwiivcnj YOvi8ico|iaxo5, Paoia|iivoc; oxa YAC (xexvuxd 
XQConoocbuaxa t;vno(ivxiixcov). 
XXIV 
Etvai anaoatxrixo va xaxaoxio8et vfo oxoaxnYixo oxi&hoyia xo IIAAr. To axoaxriYtxo avx6 ox&io 
jtQenei ealari5 va Xau0dvei txrcoijni XT| owaxoxnxa JtpooeYYwniS xng vovxXeoxioixijc; aXXnXovxtag 
oXoxXijpov xov YOvidic&naTog, uioto xng xvxatas xXcovaxrng (1x660805 shot gun). Mia xexoux 
evig^ewxanaixet TO)X,^ OTj^ avrmTi aO^oi) Tt|5 xe^^ToS6TT)OTi5. 
Ta xevxoa Yevexixcov Jtoocov aJtoxeXovv eva 0T)|iavxix6 oxoixeio xau IIAAr xai etvai anaoatxrixo 
va 6iaocpaXia6et T| awexiis vJiaQ§»i xovg. H d^eot] 8ux8eaiu6xrixa yux xovg eQewnxes xcov 
ajcoxeXeoiidxcov xnc; cpvaoais xttCtOYG&WTlS oXoxXfipov xau Yovioicouaxog, eivai eva |i£YdXo aXXd 
anaoalrnxo £070. To 6070 avx6 jioercei va vXajioiTi6et (ie pioa JCOV JtoodQxovxai an6 xtiv 
IIXnoocpoQixii, axJUJceQiXajiPavojifevcov Jtooaixcov, oXoxXnQCouevcov xai cpiXixcbv JCQOS xov xp^o^n 
xoarcet;cov 5e6ou£vcov, aXXd xai ae ercuieoo Slavonic; xcov xXcovcov YAK xaScbc; xai xcov xoo^ioiaxcbv 
xXcovcov, dayo JCOV arcaixei evxaan tgyaoiaq. To va xaxaoxovv xa avxiooaaxTiQia aired Jtooaixd 
oe dXovg xovg evocojeaiovg ejooxtinoveg, Jt.X- (teoco rng evgetag dtavo^rig "jtoXvxevixcov epiXxexov" 
JCOV jceoiexow SiaxexaYuiva YAC yui 6Xa xa av8Qa»uva XQ<»|Jiatoa<&M<ita, 6a |jun:ooovae va 
anoxeXeoei eva ovoiaoxixo $r\\ia. Tevixd, cutaixetxai eva evQvxeoo cpdaua diaxexaYHevcov 
0i0Xic>6nxcov Y101 v a e^vmiQexiiaovv xic; JtXeov 8iacpOQexix£g avdyxec; oxriv Soewa xov 
Yovioicbpaxos, arco XTJ axiY|n\ JCOV 8a exei oXoxXncxo8ei o JCQCoxog cpvaixdg xaQT'lS-
Xxo uiXXov, 8a aJcaixnSovv 5iaxexaY|ieveg OVXXOYSS oXoxXfjoov XOV urjxovg xau cDNA, arcd oXovg 
xovg 5iacpOQexixovg UTXOVS xov aconaxos. 0 a jcgexcei va 6o8et (AeYdXri JcooxeoauVnixa, ae eva 
lieXXovxixo IIAAr, oxa xeVcoa Yevexixcov JCOOOOV JCOV 6a Jiaoexow 8iaxexaY(ieveg Pi0Xio8fjxes 
cDNA, ox, urcnQeota JCQOC; XT|V emoxiiuovixTJ xoivoxnxa. 
0 a jcoercei va Xi|cp6ei tuioijni r\ 6id0ecrn JCOCXOV oe eQYa JCOV acpogovv xov |AeYdXng xXifiaxas 
3iooooiOQiO|i6 xng vovxXeoxiotxfjg aXXnXovxiag xov cDNA. 'AXXcooxe, o Jcooo5ioQi0uog xng 
vovxXeoxiotJcng aXXnXovxtag xov cDNA \xz OXOJCO va xaxaoxio8et 3tX.tiQT|g xaxdXoYog XCDV 
avGoamivcov YOVI6IO>V tjxav evoana'txii toea. 
O Jiooo8iOQtaji6sxTi5 vovxXeoxiSixiig aXXtiXovxiag ae jieYa-xXLuaxa, 3tov 8ev ODtoxeXovae x\vt\\ia 
xov agxtxov HAAr, Jtofercet va Xr)<p6ei vreo\|n| oxo neXXovxix6 IIAAr. Eivai aJtaoalxrixo va 
exxeXeo^ovvoQUJfJi£vajco6xvJtaeQYa n»v 6a avujteQiXaupdvow3topo6tOQia|iaxTi5 vovxXeoxt8wtfig 
aXXT)Xovxlag ae excineoo \tzya-$6m\s, yia va exxijniSovv 01 neXXovux6c; Swaxdxnxeg JiooaevYioTig 
oniv aXXtiXovxia xcov OXOMXTIQCDV av0gamivcov xQConaxoaco|iaxa>v. Ejtiarig, jtQfeirei va X.ticp8ei noXv 
jioooexxixd vjtoxpT) n 6wax6xrixa jroooftioQionot) xr\c, aXXTiXovxtag oXoxXi]oov xov 
xoo))iaxoo<b|jaxog (ie xvxala HXCOVCOOTI. nooxeivexai ti ovoxaaxi ojidoag ad hoc yw. va e^exdoei xo 
jtQopXtina avx6. Edv r\ EK nooxldexai va ov|juiexdoxei ae dva xexoto tgyo, 8a Jig&tei va av^qaei 
oe iieYdXo Pa6uo xov JiooiincoXayLOHO xov JipoYQdmiaxog, (bare va ejtixevx8ei pie xaxvxeoo gv8(io 
o xeXixog axoxog oXoxXfjoov xov nooYQdfjuxaxog Y"1 T a YOv^^Maxa, STIXOOTJ, T\ avevQeoi] xr\c, 
J1X.TIQOV5 aXXTiXovxiag xcov vovxXeoxi5tcov xov av6Qdwuvov Yovidwbjjiaxog. 
An;6 XTJV dXXti JtXevod, xo EUROGEM 6a exei ovvxona oXoxXTigaxrei xriv ajcoaxoXii xau, ano XTI 
axiYM-fj JCOV 8a exei oXoHX.Tjoco8et o axQiPfig yeveiiwbc, xdorng. 
H PiojiXt]Ooq)OQiHi) etvai evag xouiag JIOV evoexexai va avajxxvx6ei \xz noXv xaxv QV8(JU3 oxo evYvg 
(icXXov. O oxe5iao|x6g XoYianiHtov, qpiXtxcbv npog xovg XQW1^, Y101 TTIV avdXvati xeodaxiov 
aoiduov 6e5o(ievcov 6a axcoxeXeoei avauxpipoXa jxCa oi^iavxtxfi TCXVXTJ xov (xeXXovxixov HAAr. 
Kaxomv xng JtoXv evxovrjg xQixuajg 3U)v aoxi)dT|xe 31005 ""iv xodjiet^a oeoofiivcov Yta xo av8oajJiivo 
Yovi6tco[ia (GDB), eivai xG^aifio va JcpopXecpOovv evaXXaxxixig xodjcet^ eg 6eoo(iivcov r\ xovXdxioxov 
iva 6uupooexix6 owrnna 31060^001)9 0x15 xodne^eg 8e8ouiva>v: oxo ar\\xzix) avx6, i\ Jto6o8og xov 
nc>OYOd|Juiaxo5 XT|5 Xa'CSeXPeayrig IGD (Integrated Genome Database - OXoxXrioo)|jievTj TodJcel;a 
Aeoouivcov YUI xa row5icbfiaxa) cpalvexai evdaQovvxixTJ, evto xo Jtpdxvjco 6iavo|xfi5 n&u Jcpoxetvexai 
ajc6 xnv ouaoa avxii, ti onola xot)Oi4A07COiei eva xomxo avoriijjia ACeDB, Jtov xoocpoooxeixai \tz 
oxoixeia OJC6 dXXeg xodjtec^g 8e8ouivcov, cpaivexai toiaixeoa ev8aQQwxixo. 
IlaoajAevei eXXuriig n enixoivcavia uexa^v PioXaycov xai ejciaxT||x6vcov xrig JcXTioocpoQixrig: aviptow 
0x6(10, oe u£YdXo Pa8fio, oe Svo evttkdn; diacpOQexixovg xoixeig. Ta xeXevxaia xQOvia xai 01 ovo 
xouei^ e^eXix6iixav JIOXV Y9nYopa,xat XiYa dxoj«x. exow vvcboeig xai axovc; 8vo avxov^ xoneig. 
XXV 
H atj^ ricrn tou OQIB\UXV xcov ejtioxTjixcWcov avxc&v, Lieoco eXxuoxixcbv jisxaSi&xxxoQtxcovujccnoo^icov 
xai 9eaecov, eivai evSexojxevcog o fiovaoixog XQOJiog YWX "va ^eJteoaoGei 11 5-uaxoAXa avxt|. 
EjtutXiov, 6a JtQenei va So9ei mooaoxtu xa9cbg xai xQ I^AOtoooxfioeig, YWX v a 0eX.xico8ouv xa OT)(ieia 
ejtacprjg \izza%6 xov "xoanou xot> Yovt&uo|xa.xog" x a i tow xo|jia xrig Y E V ^ 5 pW)AoYiag, 
oufUte^LXajiPavonivtigdxt novo xrjg Yevextxijg taxcnxfig, aXXd xat YWX JtaQd6etYH«,T0,v OJAOOCOV jtov 
6ie£aYOw egewa YWX xig XeixovQYieg oxo OVOXTHWX xcov Jiovuxcbv, cboxe ot 5o|ieg xai TJ XeixovoYia 
va arxJxextaxcruvJieQioa6xeoo. 
9. EjtipdXXexai va auvexwj9ouvxa Siaxpaxixd ecr/a, JtQ&tei 6(icog va emXeYOvxai (xe (XCYOXTI Jtooaoxii. 
Ze 6,xi acpopd XTJV evCaxvatj xrjg egeuvag xai xri biaxvmoar\ jiooxdaecov oxexixd ne xov XQOJCO 
xaxavojAfig xcov jiiaxcbaecov nou Jtoooou;ovxai YWX XTJV egewa, eivai ajcaoaixrixo va vJtev0u{i.ia9ei 
6x1 ot aweQYaoieg, Jiou eivai avajxcpipoXa nakv annjavxixeg, 5ev \JJIOQEI va OQYavcbvovxai OJIO 
xaveva, aXXd aiQfatei va avaanruaaovxai xai 6a avanxvoaovxai au96Q|xnxa. 2xo anneio avx6, 6ev 
eivai oxomfAO va xa9oQi£ovxai 01 auveQYaaieg ftexa^u enioniMOvcov and ogianeveg Jtegioxeg triS 
Evoawtrig,fj ax6(Aa va xaxave|xovxai01 Jtwjxcoaeig avdXoYa fie xig auveQYaaieg auxeg. Texoieg loeeg 
eivai avxutaoaYCOYixeg. ©<* rjxav jtooxinoxeoova xeGei ae eqxxQnovT| eva e^eioixeu^evo jq^oaiifia 
JiegiOQiO(xevou euooug YWX XTJV eviaxvaTj aljidXoYCOv ejuaxrijiovcov axov xofiea xijg pio-uxxoixfig, o t 
ojtoioi eQY&£ovxai 0x15 x<i>Qex; ""15 EvQdwttjg JCOV JtaooixriaCow Jtoog xo itaoov neYaXvxeoeg 
aouvanieg OXTI [xogiaxiii PIOXOYWX OXML eivai txaveg va av[i3ikr\Q<boovv YQTJYOoa xa xevd. 
10. To Jto6YOa|x|ia xaxdpxicnig qxxivexai 6x1 cuioxeXeae \t£y6Xr\ emxvxia xai YWX TOV XOYO aux6 
rcpoxeivexai TJ auvexwrii xou. Ev§exexai evxouxotg va arcooeix9ei a7taoaixT|XT| TI aveugeaii vecov 
xpdjtcov YWX XTI 8idooar| JtXriQOcpoQWov crxjexwd. \iz xo jrp6YQan|Aa, acpau o aQi0|Aog xcov aixrjaecov 
a\)[A(Aexoxii5 TJxav |nxQ6xeopc; and 6,xi eixe JtoopXecpOei. 0 a Jiginti eaicrrig va XricpSei imotjni, 6x1 
ogioiieveg xQOJtojtoifiaeig oxo aodYQajiiJiaGa fjxav JCOXU xo^ai^eg Y"! XOVC, vtovc, emaxTi|iOveg nov 
eQYd^ovxai oxov xo^ia xrig avaXttarig xou av8ocancivOTJ YOviStcbjuxxog. Yjrdoxei eva xcgopX-Tina, xo 
OJCOIO cpatvexai va eivai xoiv6 ae 6X 5^ xig EvQama'inLc, x<^ QE5, to JtQ6fihr\\w. br\kjabi\ TT\$ 
vKOOvi\Q[^i\<; xai xr\q ave^aQxtiaiag xcov vfecov eQeamrccov jtov exoirv ajto6ei^ei oxti Xtooa xoug, i[ ae 
dXXeg x ^ e s . oxi eivai 5iaxexf)ijjiivoi ejiiaxiijjoves. Ta eQYaaxfiQiaxcov H.II.A aaiatEkjovv ati(ijavxix6 
OTifAeio £A§Tig, XOYCO xr\g iSiaixeoa eue^ixxiig dioixrixixrig 6 0 ^ 5 xcov ^eQiaaoxeocovTOxveaiaxrijiicov 
xai, xugicog, XOYCO XOV evxrxrtcoaiaxoij agi6|xou xoompaicov eoeuvnxixcov xivxpojv JCOV XCIXOV^YOVV 
ae JtokkA naveitiaxrifAia xcov H J I ^ . 0 a eivai oXodva JCIO eXx\xrtixo yui xoug v£ov<; Evoorcaiovg 
va eitiSicoxouv va aweQYdi;ovxat \nz egYaortiQia xexoicov xfevxocov yva naxQOJtQoeeaneg fi 
Ppaxurco68eaiAec;xQov''tt&; reeQioooug aXkA xvoicog xaxd XT| Sidoxeia xcov KIO JiaoaYCOYixcbv xovg 
XQovcov 6oov acpOQd XTJ 5ie^aY0>rn n:QcoxoYevoijg egewag. STJ^eoa, tj egeuva oxov xonia xrjg Pio-
laxQixiig pjioQei va 5ie^ax0et M* TOV KaXvxepo 6waxd XO6JXO ae ndkv \jxy61a xevxoa. Eivat 
avaYxaio va avaYvcoQiaOei, 6x1 eva artd xa JIIO arj^iavxixd xaGrptovxa, ae 6,xi acpood xn 
XQTj|iaxo66xT]aTixai XTJV OQYdvcoariXTig eJcurriinTig OXTIV EvpaxnTj, eivai TI 6iiniox)QYWiev6c; avxipapov 
ae auxd xa jiokv tax^Qd xevxoa Paaixrig PionaxQixiig egeuvag xcov H.EL.A. IlgoxeCvexai oxo arineio 
auxo, T] STiiiiouQYW1 Geoecov YWX veoug, ave^ <iQXT|xov5 eQeuvnxeg axa areSia exeiva xrig Pio-iaxgixfig 
eQeuvag, xov emxQejtouv ae e^auiexixd ei8ixeu|xevoug veovg erciaxn^veg va 5ie§aY<iY0w egeirva 
XT|5 ejtiXoYfjg xovg ae eva aaid xa euQCOJiaibtd 3tave3ttaxfi(iia, aJteXev6eQC0[ievoi ajt6 xig auxv<i JtoXu 
"jtaoaSoaiaxeg" 8ioixr|Xixeg xouc; So^ig. ZXTJ OTi^ iovQYia Geaecov, 9a nqtrcei va rtooaxeeeiti 6id9eaTi 
juaxcbaecov Yia XTJV JtQ0[iTi9eia avaXxoatncov vXixcbv xai e^o^Xia^ioij xa9cbg xai YWX XTIV c^o6a>.T|T|ni 
eQeuvTixixou jiQoacojcixoij. YjtoXx>Yu;exai 6x1 xexoieg oojxeg 9a pon9fiaouv xcdkv arijAavxixd OXT|V 
3iQoaeXeixjTi r\ ejiavanooaeXeuari noXkdrv coi6 xovg nio JcaoaYCOY'-xcrijg veovg eQeimixeg oucd xo 
e^aycegix6 crcig evocojcaixeg xcooeg. 
11. Ta jiooYodjAixaxa ESLA areoxeXouv Paaixeg awiaxcbaeg xcov 3tpoYpamidxcov YWX xa YOvi8icb(jiaxa. 
H on&Sa jipoxetvei, av xai 6x1 onocpcova, XTJ ouvexwjri xov'jtopYQdji+iaxog ESLA xai XT|V nxxooxii 
(iaxoojcQ69eajiT|g eviaxvarig. Eivai ar|juxvxix6 va Yivei xo JtobYQanna oao xo 6wax6v eupuxeoa 
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YVGXTKJ, xai 01 avaooxoi va X&Pow xtg xax&XXriXeg ftXrioocpoQiEg yia *o ava|icv6nevo anoxeXeoiid 
xou "Eva OT)(javruc6 oxoixeioxcov ^eXXovcutc^no^oaiifukcovESLA Ga acpooa xtjv naQcr/r\ fieacov 
axis aumiex^xouoeso(juS6e5 jxe oxond xt| awe0vaota,XT|v aXX,T|X«il6paaii xai xi)v avxaXXavTi ioe<&v 
xai aicoxeXeanaxarv. 
0 a KQtxei ejiCorig va xaxa0Xi?9ovv t^ialxeQegaooojcdBeiegYia va ov(uceQiXTi(p9ovvoxo JiQOYoajA(xa 
Tl oixovo|uxfj xcov xexvixcfav aXXaytiv xaOax; xai n JCOXITIXT) xai 01 iteXexec; yva TTIV emaxfjiit). H 
eXXeujni Y«0Ypaq)ixTi5 loogopjuag arcoxeXei eva aXXo Jio6pX,T)na axo orcoto Jigfciei va 6o9et 
nooaoxTJ. 
12. H evioxvoii xo>v owavxiiaeajv Jigaxxixfjg eovaoiag xai xoov auvedQiaaecov anoxeXel aacpcbg jiia 
fkxoixfj awiaxo&aa xov IIAAr xai nooxeivexai rj OW^IOTJ XOV JtpoYP&jAjjKUog avxov. Evxouxoig, 
awiaxtbvxai ogiO|ieveg 5ioixi)xixeg aXXay^g. Ilooxetvexai yva naoaoeiYna t\ ovoxaori niag 
aiumijiovixiig ov(j0ovXevxixi]g ejiixoojcng |ie oxono va Yvconoooxet YW* ""iv xcoXixixi] xov 
jrQOYOd(A|Aaxoc;xai va e|exa£ei xig aixiioeig. IlQ&iei va xaxapVnBovv nooorcdBeieg YU* va enixevx8et 
xaXvxeQT) lOOQOOJiia ae 6,xi aqpopd xa 6e|xaxa |xexa^0 xcov owavxr|oetov noaxxixfjg GQyaxj'vac, JCOV 
XQTlnaxoooxovvxai. H xPTlM t^oSoxixtj evtaxvori, (leoco xou OQYavionov HUGO, owavxfiaecov 
jtoaxxixiig egYoaias |xe avxixel|xevo eva xd8e cpooa x(KO(*oacotiaexei OVOUXOXIXTI awiaata xai jtgfatei 
va awexia8ei. Tevixa, JiQfercei va 5o8ovv eviaxvaeig axig awavxrjaeig Jioaxxixris eQyaxjiac, jie 
avxixeijAcvo xa %Q(o\iaToa(ayuaxa JCOV 5iOQYavd)vovxai oxnv EVQCOJCTI, cog oweiacpoQd axov 
jiapoutavco OQyavio\x6.0a jco&iei ejtiarig va doBovv eviaxvaeig, fie xri ixop/pfj x&Xv\|rrig xa>v 5ajravc&v 
xa|ioiov, ae evoa»taiovg egewtixeg Jtov ovmiexexow ae awavxfioeig Jtoaxxtxfig eQYaaiag exx6g 
Evpdwtrig. A£i£ei ejuang va eviaxvBovv 01 awavxrjaeig rcoaxxixfjg ep^aatag 01 orcoteg 
avvKevxpdJvow eJiioxfi|AOveg Jtov eovdtovxai oxa JtXataia xov IIAAr ae av&XoYa 6e|xaxa (ojccog 
eYive cog eva 0a8n6 xaxd xo JtapeX86v), Yia JKxo&SeiYita'covg eJCiaxTJfjioveg exetvovg JCOV egYd^ovxai 
axo EUROGEM r\ fie 0i0Xio6fjxeg cDNA. Eivai nooqxiveg 6x1 \u xov XQOJCO aux6 Ga JIQOCO6TI9OVV 
01 ejca<pec; jiexa^ij O|xo6arv ae 6ia<poQexixdg euoaxaaixeg x^ >Qe9-
13. Mia 6Xh\ ewtp6o8exxri jroooOnxti axo nQOYQaftfia eivai t\ xaxaQxiar) xXivixt&v taxodrv ae 6XTI XTIV 
EvoduiT]. Tta atoXXovg xXivixoug laxooug, 11 Yevextxtj oaioxeXeC Cacog pXa xoavfiaxixtj eniteiQCa xt\c, 
ejtoxTig Jiov edivav e^exdoeig oxtiv Iaxgixq 2x°M- Me tiiv xaxeia JIQOOOO axtiv Yevexixri laxQixr), 
01 xXivixoi cruvddeXxpoi n«5 pgiaxovxai T|8TI ae 6VOXOX.TI 0eoTi evavxi xcov aa6evtbv xovg JXOV 6a xoug 
6exotrv jtieaxixeg eoooxrjaeig. Ta e^ei5ixeu|iivanooYod|J4iaxaxaxdQXiaT|g (jutooouv xouXdxioxov va 
ajtoxeXeaow nia {legaci) \xxn\ axo JIQ6PXT)(JUX. 
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El Program a de Analisis del Genoma Humano (HGAP) forma parte del Segundo 
Program a marco de Acciones Comunitarias de Investigacion y Desarrollo Tecnol6gico, 
y se incluye en el apartado "Salud" del capitulo "Calidad de Vida". El program a tiene por 
objetivo: 
utilizar y perfeccionar nuevas biotecnologias para el estudio del genoma humano, 
a fin de comprender mejor los mecanismos de las funciones geneticas y prevenir 
y tratar las enfermedades hum anas; 
elaborar un enfoque integrado de los aspectos eticos, sociales y juridicos que 
planteen las posibles aplicaciones de los resultados obtenidos. 
En el marco de sus tareas de supervision periodica y en virtud del apartado 3 del articulo 
4 de la Decision del Consejo por la que se adopta el HGAP (D.O. n° L196 de 29.06.1990, 
p.8), la Comision designo en diciembre de 1992 un grupo de expertos independientes para 
que evaluaran dicho programa. En ese mismo articulo se especifica que la evaluacion ha 
de llevarse a cabo teniendo en cuenta los logros cientificos y tecnicos del program a, la 
calidad y la importancia practica de los resultados, la eficacia de la gestion, los aspectos 
6ticos sociales y juridicos, y las aportaciones y repercusiones en los program as nacionales 
de investigacion. 
Durante la evaluacion el grupo de expertos visito cuatro centros que participaban en el 
programa y consultaron a mas de trenta personas (funcionarios nacionales y comunitarios, 
participantes en el HGAP y usuarios). 
El importe total asignado al programa ascendio a 15,6 millones de ecus, distribuidos de 
la siguiente manera: mapas geneticos 21%, cartografia fisica 27,6%, tratamiento de datos 
y bases de datos 15%, tecnologias geneticas avanzadas 18%, formacion 12% y gestion 
6,4%. 
En el HGAP intervinieron aproximadamente 100 centros comunitarios. 
CONCLUSIONS 
El grupo de trabajo piensa que el HGAP ha conseguido un gran exito y es una importante fuerza 
motriz en el panorama de la investigacion europea sobre genoma humano. Actualmente, la 
investigacion sobre el genoma esta avanzando a un ritmo extremadamente rapido. El progreso ha 
sido especialmente espectacular en Europa durante los ultimos afios, con el exito de empresas 
como la secuenciacion de un cromosoma completo de levadura, mapas fisicos de genomas 
completos y mapas geneticos perfeccionados. Esta claro que el HGAP ha desempenado un papel 
importante en el establecimiento de relaciones mas equilibradas con los Estados Unidos. No 
obstante, tambien esta claro que ciertos program as, como el apoyado por la AFM en Francia han 
sido tambien un elemento importante. El HGAP fue aprobado con un presupuesto bianual de 15,6 
millones de ecus. El importe dedicado a la investigacion del genoma en la CE es muy pequeno 
comparado con los presupuestos de los program as sobre genoma de los Estados Unidos y de 
Japon. Por tanto, el HGAP se ha limitado a complementar actividades nacionales existentes, y la 
importancia de la financiacion comunitaria de los distintos programas depende en gran medida 
del peso de los programas nacionales. La CE ha concedido apoyo muy escaso a grandes grupos 
franceses (menos del 10%), mientras que ha sido importante en el caso de Gran Bretana, 
Alemania, Italia y otros paises europeos. El apoyo comunitario varia entre <5% al 50% del coste 
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total de cada proyecto. En el caso de proyectos transnacionales, este tipo de apoyo, en la mayoria 
de los casos, solo supone una modesta influencia, y la posibilidad de que los paises menos 
avanzados se beneficien de los program as transnacionales es limitado. 
El establecimiento de los centres de recursos y los program as de formacidn son de gran ayuda 
para los laboratorios cientificos organizados, asi como para los grupos menos avanzados o menos 
establecidos. Este es un aspecto muy importante del HGAP y de la ciencia actual en general, ya 
que la organizacion y la disponibilidad de los recursos son temas fundamentales. A este respecto, 
el HGAP ha sido muy util a la Comunidad europea de investigacion sobre el genoma, aspecto que 
debe acentuarse cuando se elaboren futuros program as. 
El program a sobre ADNc del HGAP actual no se ha desarrollado con la rapidez que se esperaba, 
aunque se han producido bastantes secuencias parciales de ADNc. Esta claro que, en el futuro, 
se dejara sentir la necesidad de disponer de grandes colecciones de bibliotecas de ADNc de 
elevada calidad. 
El objetivo final del proyecto global sobre el genoma hum an o es la secuenciacion de todo genoma 
humano. Actualmente no se incluyen en el HGAP grandes program as de secuenciacion. Esta 
situacion debera corregirse en un futuro HGAP. 
Los proyectos transnacionales han sido importantes para fomentar la colaboracion europea y 
tambien han proporcionado medios a los pequenos laboratorios, especialmente en paises menos 
desarrollados, para acceder a tecnologias complejas. 
EI program a de asociacion es un componente fundamental del HGAP y parece que se ha Ilevado 
a cabo de forma satisfactoria. 
Se admite que las actividades emprendidas dentro del program a ESLA estaban justificadas. No 
obstante, el grupo de evaluacion debatio si el program a deberia financiarse con la misma amplitud 
que en el pasado, dado el caracter limitado de los recursos y la amplitud de la gam a de cuestiones 
urgentes que deben investigate. 
El program a ESLA ya completado puede considerarse como estudio piloto prometedor. El grupo 
de trabajo desea Ilamar la atencion sobre el hecho de que Europa ofrece posibilidades unicas para 
este tipo de estudios, debido a la diversidad de los sistemas sociales y de atencion sanitaria que 
funcionan en los distintos países. 
El apoyo economico a los seminarios se ha tornado en el pasado del presupuesto de gestion. 
Aunque el grupo de trabajo de ESLA y CAN-HUG han colaborado con el program a, parece que 
se ha administrado de manera ad hoc. 
RECOMENDACIONES 
1. El grupo de evaluacion considera que debe organizarse un tercer HGAP. No obstante, es 
necesario introducir modificaciones en el plan del proyecto debido al importante progreso 
que se ha observado durante el ultimo ano. Parece muy probable que en el plazo de otro 
ano se complete un mapa genetico de alta resolucion y tambien un mapa fisico completo 
del genoma humano basado en el CAL (Cromosoma artificial de levadura). 
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2. Es necesario elaborar una nueva estrategia de HGAP. Esta estrategia debe considerar 
tambien la posibilidad de enfocar la secuenciacion del genoma completo) mediante un 
"enfoque de tiro de escopeta". Esto exigiria un aumento importantisimo de la 
financiacion. 
3. Un rasgo clave del HGAP lo constituyen los centros de recursos y es fundamental 
asegurar la continuaci6n de su existencia. La tarea de poner los resultados de toda la 
cartografia fisica del genoma rapidamente a disposition de la Comunidad sera vasta pero 
necesaria; debe apoyarse en medios inform aticos, con inclusion de una base de datos 
accesible, completa y de facil uso, pero tambien a nivel de la distribucion de clones de 
cosmidos y de CAL, tarea que exige la dedication de mucho trabajo. Constituiria un paso 
fundamental el poner estos reactivos rapidamente al alcance de todos los cientificos 
europeos, por ejemplo mediante la amplia distribucion de "filtros de politeno" con CAL 
ordenados para todos los cromosomas humanos. En general, se requiere una gama mas 
amplia de bibliotecas ordenadas para satisfacer las mas diversas necesidades de la 
investigation sobre el genoma, una vez se haya completado el primer mapa fisico. 
4. En el futuro, se necesitaran colecciones ordenadas de ADNc de longitud completa 
procedentes de todos los tejidos del organismo. Los centros de recursos que proporcionen 
bibliotecas ordenadas de ADNc como servicio a la comunidad cientifica deberan tratarse 
con prioridad en un futuro HGAP. 
5. Debe considerarse la asignacion de recursos a proyectos de secuenciacion de ADNc a 
gran escala. Despues de todo, la idea de secuenciar el ADNc para obtener un catalogo 
completo de los genes humanos es de origen europeo. 
6. En un futuro HGAP debe considerarse la inclusion de la secuenciacion genomica a gran 
escala, que no formaba parte del HGAP original. Sera necesario realizar algunos 
proyectos piloto con secuenciacion de megabases para evaluar las posibilidades futuras 
de tratar la secuenciacion de cromosomas humanos completos. Asimismo debe 
considerarse cuidadosamente la posibilidad de secuenciar el genoma completo mediante 
un "enfoque de perdigonada". Se sugiere la creation de un grupo especifico para tratar 
este problema. Si la CE tiene intention de participar en un proyecto de este tipo, tendra 
que ampliar en gran medida el presupuesto del program a para conseguir mas rapidamente 
el objetivo final del program a sobre el genoma global, la secuencia nucleotidica completa 
del genoma humano. 
7. Por otra parte, EUROGEM habra completado su mision una vez term in ado el mapa 
genetico de alta resolution. 
8. La bioinformatica es un campo que probablemente se desarrollara muy rapidamente en 
el futuro proximo. El diseño de program as de uso facil para el analisis de grandes 
cantidades de datos constituira indudablemente un aspecto importante de un futuro 
HGAP. A la vista de las criticas generates de que es objeto GDB, parece util prever bases 
alternativas de datos o, al menos, un sistema diferente de acceso a las bases de datos: a 
este respecto, parece prometedor el avance de la IGD (Integrated Genome Database) de 
Heidelberg y el modelo de distribucion preconizado por este grupo, con un sistema 
ACeDB que funciona localmente y se alimenta con datos procedentes de otras bases de 
datos sobre genoma, parece particularmente prometedor. Sigue dejando que desear la 
comunicacion entre biologos y cientificos de la inform atica: siguen perteneciendo en gran 
medida a dos culturas bastante diferentes. Los dos sectores han evolucionado muy 
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rapidamente en los ultimos aSos, y pocas personas son competentes simultaneamente en 
los dos. 
Probablemente, la unica forma de eliminar esta dificultad es aumentar el numero de estas 
personas mediante puestos y becas atractivas. 
Por otra parte, debe dedicarse atencion, y cierta financiacion, a la mejora de la interface 
entre el "mundo del genoma" y la comunidad de biologia general, con inclusidn no sdlo 
de la genetica medica sino tambien, por ejemplo, de grupos que realicen investigación 
funcional en el sistema del raton, de forma que puedan aproximarse estructura y funcidn. 
9. Deben continuarse los proyectos transnacionales, aunque tengan que seleccionarse muy 
cuidadosamente. Al prestar apoyo a la investigacion y formular sugerencias sobre como 
distribuir los fondos de investigacion, deberá recordarse que las colaboraciones, que son 
indudablemente muy importantes, no pueden ser organizadas por nadie, sino que deben 
desarrollarse espontaneamente. A este respecto, no es pradente estipular la colaboracion 
entre cientificos procedentes de determinadas zonas de Europa o incluso condicionar la 
atribucion de fondos a dichas colaboraciones. Tales ideas son contraproductivas. Sena 
preferible iniciar un program a especial de extension limitada para apoyar a los cientificos 
que lo merezcan en el campo biomedico que trabajen en los paises de Europa que siguen 
presentando un bajo nivel en biología molecular pero son capaces de elevarlo 
rapidamente. 
10. El program a de formacion ha sido en gran medida todo un exito, por lo que se 
recomienda continuarlo. No obstante, puede ser necesario encontrar nuevos medios de 
difusion de informacion sobre el program a, ya que el numero de solicitudes fue muy 
inferior al previsto. Debe tenerse en cuenta tambien que la modificacion de ciertos 
aspectos del programa podria ser muy beneficiosa para jovenes cientificos que trabajen 
en el campo del analisis del genoma humano. Existe un problema que parecen compartir 
todos los paises europeos, que es el del apoyo y la independencia de jóvenes 
investigadores que se han revelado como cientificos de primer orden en su propio pais 
o en otro distinto. Existe una atraccion muy importante por parte de los laboratorios de 
los Estados Unidos, con su flexibilisima estructura administrativa de la mayoria de las 
universidades y, sobre todo, con un numero impresionante de centros de investigacion de 
maximo nivel en muchas universidades. Cada vez sera mas atractivo para los jóvenes 
europeos intentar asociarse con los laboratories de tales centres durante mas o menos 
tiempo, pero generalmente durante sus anos mas productivos para la investigacion 
original. Actualmente, la investigacion biomedica se realiza de forma optima en los 
centres que han alcanzado un tamano critico. Es necesario reconocer que una de las 
importantes tareas de la organizacion y financiacion de la ciencia en Europa es crear un 
contrapeso frente a estos poderosos centres de investigacion biomedica fundamental de 
los Estados unidos. Desde aqui se sugiere la creacion de puestos para jovenes 
investigadores independientes en las areas de investigacion biomedica que permitirian a 
jovenes cientificos de elevada cualificacion proseguir las investigaciones que ellos 
mismos eligieran en algunas de las universidades europeas, pero al margen de sus, 
frecuentemente muy "tradicionales", estructuras administrativas. Ademas, a estos puestos 
deberian asignarse fondos para adquirir material fungible, equipo y personal de 
investigacion. Se supone que tales estructuras ayudarian muy considerablemente a los 
paises europeos a retener o volver a atraer a muchos de los jovenes investigadores mas 
productivos, que de otra forma saldrian de Europa. 
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11. Los program as ESLA son componentes basicos de los program as sobre el genoma. El 
grupo de trabajo recomienda, aunque sin unanimidad, que se continue con el program a 
ESLA y que se le proporcione apoyo de largo alcance. Es importante que el programa 
se anuncie lo más ampliamente posible y que los contratistas reciban inform aci6n 
adecuada sobre los resultados que se csperan del programa. Un componente urgente de 
los futures program as ESLA consistira en proporcionar medios para que los grupos 
participantes cooperen, interactuen e intercambien ideas y resultados. 
Tambien debe procurarse incluir la economia del cambio tecnico, la politica cientifica y 
los estudios de la ciencia en el programa. Otro aspecto que exige atencion es el 
desequilibrio geografico. 
12. El apoyo a seminarios y reuniones constituye claramente un componente fundamental del 
HGAP, por lo que se recomienda continuar con este programa. No obstante, se 
recomiendan ciertos cambios administrativos. Por ejemplo, se sugiere la creaci6n de un 
grupo consultivo cientifico, encargado de emitir dictamenes sobre la politica del programa 
y de seleccionar las solicitudes. Debe intentarse obtener un mejor equilibrio respecto a 
los temas tratados en los seminarios objeto del apoyo. El apoyo a traves de HUGO a 
seminarios sobre cromosomas sencillos es fundamental y debe continuar. En general, debe 
prestarse apoyo a los seminarios sobre cromosomas que se celebren en Europa como 
contribucion a la organizacion. Tambien debe darse apoyo en forma de bolsas de viaje 
a europeos que participen en seminarios celebrados fuera de Europa. Tambien parece 
conveniente apoyar seminarios en que se reunen cientificos que trabajan dentro del HGAP 
sobre temas similares (como se ha hecho en el pasado en cierta medida), por ejemplo los 
que trabajen con bibliotecas de ADNc o EUROGEM. Evidentemente, asi se fomentarian 
los contactos entre grupos de distintos paises europeos. 
13. Tambien seria una adicion positiva la inclusion en el programa de la educacion de 
medicos en ejercicio en toda Europa Para muchos medicos en ejercicio, la genetica puede 
ser un recuerdo traumatico de la epoca en que se examinaban en la facultad de medicina. 
Con el rapido progreso de la genetica médica, nuestros colegas en ejercicio ya encuentran 
dificultades cuando sus pacientes les plantean preguntas urgentes. El problem a podria 
resolverse, al menos parcialmente, median te program as especializados de formacion. 
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RESUME 
Le programme "Analyse du genome humain" appartient au deuxieme programme cadre 
pour des actions communautaires de recherche et de dEveloppement technologique. II a 
EtE fixé au paragraphe "SantE" du chapitre "QualitE de la vie", avec les object ifs suivants: 
utiliser et amEliorer les nouvelles biotechnologies pour 1 'Etude du genome humain 
en vue d'une meilleure comprehension des mécanismes des fonctions gEnEtiques, 
ainsi que de la prevention et du traitement de maladies humaines; 
Elaborer une approche intégrée des aspects Ethiques, sociaux et juridiques des 
applications possibles des rEsultats obtenus. 
Dans le cadre de ses responsabilitEs en matiere devaluation, la Commission a nommé en 
decembre 1992 un groupe d'experts independants charges d'Evaluer le programme 
"Genome humain". Le mandat de ce groupe est fixE a l'article 4 paragraphe 3 de la 
decision du Conseil arrêtant le programme en question (JO L 196 du 29.6.1990, p. 8). 
Le même article precise que revaluation doit prendre en compte les resultats scientifiques 
et techniques du programme, leur quality et leur valeur pratique, l'efficacitE de la gestion 
du programme, ses aspects Ethiques, sociaux et juridiques ainsi que son incidence sur les 
programmes nationaux de recherche et les avantages que ceux-ci en ont tires. 
Au cours de son Evaluation, le groupe d'experts a visits quatre centres participant au 
programme et a rencontre* plus de trente personnes - fonctionnaires de la Commission et 
fonctionnaires nationaux, participants et utilisateurs. 
La somme des fonds allouEs au programme s'Elevait a 15,6 millions d'Ecus, rEpartis 
comme suit: cartes gEnEtiques 21%, cartographie physique 27,6%, traitement des donnees 
et bases de donnees 15%, technologies gEnEtiques avancEes 18%, formation 12%, 
administration 6,4%. 
Une centaine d'instituts de la CommunautE ont participE au programme. 
CONCLUSIONS 
Le groupe d'experts estime que le programme "Genome humain" est une reussite et qu'il joue 
un role moteur dans la recherche europEenne sur le genome humain. Les recherches actuelles 
dans ce domaine progressent avec une extreme rapidity. Au cours de ces dernieres annees les 
progres ont EtE particulierement sensibles en Europe, marques par le succès d'entreprises telles 
que le sEquençage du chromosome de levure entier, la cartographie physique de genomes entiers 
et des cartes gEnEtiques affinees. II est évident que le programme a jouE un rdle important dans 
l'Etablissement de relations plus EquilibrEes avec les Etats-Unis. Cependant, il est tout aussi 
Evident que des programmes de grande ampleur comme celui que subventionne l'AFM en France 
ont stimuli la recherche. Le programme "GEnome humain" a EtE adoptE avec un budget de 15,6 
millions d'ecus sur deux ans. Les sommes allouEes par la CommunautE europeenne a la recherche 
sur le genome sont tres modestes comparEes aux budgets des programmes amEricains et japonais 
dans ce domaine. Le programme "GEnome humain" n'a done fait que completer les actions 
nationales en cours et le poids des subventions communautaires dans les diffErents programmes 
depend largement de l'ampleur des programmes nationaux. La contribution communautaire 
accordée a des groupes francais importants est mineure (moins de 10%), alors qu'elle est 
substantielle au Royaume-Uni, en Allemagne, en Italie et dans d'autres pays europEens. L'aide 
communautaire varie de moins de 5% a 50% du budget total de chaque projet. En ce qui 
concerne les projets transnationaux, ce type d'aide ne peut avoir, dans la plupart des cas, qu'une 
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incidence modeste, et les possibility pour les pays mo ins avances de benéficier de ces 
programmes sont limitees. 
La mise en place de centres d'approvisionnement et de programmes de formation est très utile 
aux laboratoires scientifiques bien organises aussi bien qu'aux laboratoires moins avances ou aux 
groupes moins structures. II s'agit la d'un élément important du programme, et des activites 
scientifiques actuelles en general, car l'organisation et la disponibilité des ressources sont des 
questions essentielles. Sur ce point, le programme a été precieux pour les chercheurs europeens 
dans le domaine du genome, et cet element doit fitre souligné dans 1'elaboration de programmes 
futurs. 
Le programme sur l'ADN c dans le programme "Genome humain" actuel n'a pas 6t6 developpe" 
aussi rapidement qu'on l'esperait, bien qu'un grand nombre de sequences partielles d'ADN c aient 
été établies. II est clair qu'a l'avenir un grand nombre de bibliotheques d'ADN c de haute qualite" 
seront nécessaires. 
L'objectif du projet "Genome humain" dans son ensemble est le sequencage du génome humain 
entier. Le programme ne contient pas actuellement de programmes de sequençage de grande 
ampleur. Cela devrait fitre le cas dans le futur. 
Les projets transnationaux ont sensiblement contribué a la promotion de la collaboration au niveau 
europeen. Ils ont aussi permis à de petits laboratoires, notamment dans des pays moins 
développés, d'accéder a des technologies avancees. 
Le programme de bourses d'Etudes est une composante essentielle du programme "Genome 
humain". Il semble avoir été realisé de maniere satisfaisante dans le passe. 
Les experts reconnaissent que les activity ESLA sont justifiées. Cependant, ils se demandent si 
ces elles doivent benéficier du même financement que par le passé, tout simplement parce que 
les ressources sont limitees et que de nombreuses questions doivent fitre étudiées d'urgence. 
Les activites ESLA deja terminées peuvent être considerees comme une étude pilote prometteuse. 
Le groupe d'experts desire faire remarquer que l'Europe, par la diversity des programmes 
appliques dans les différents pays en matiere de soins de santé" et de protection sociale, offre des 
possibility uniques pour ce type d'etudes. 
Les séminaires ont été, dans le passé, finances par le budget administratif. Bien que le CAN 
Analyse genome humain et le groupe de travail ESLA aient contribué" a l'organisation du 
programme, il semble que celui-ci a été administré" assez convenablement. 
RECOMMANDATIONS 
1. Le groupe d'experts estime qu'il convient de lancer un troisieme programme "Genome 
humain". Le plan du projet doit cependant fitre modified compte tenu des progrès 
remarquables realises au cours de la dernière année. II est tres probable qu'une carte 
génétique a haute resolution ainsi qu'une carte physique complete du génome humain sur 
la base du chromosome artificiel de levure pourront toe établies en un an. 
2. II convient d'élaborer un nouveau plan strategique pour le programme. Ce plan doit aussi 
. envisager la possibility d'aborder le sequencage du genome entier selon une "approche 
en aveugle". Cette approche necessiterait un financement beaucoup plus important. 
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3. L 'existence de centres d'approvisionnement est une caractèristique essentielle du 
programme. Mettre a la disposition des chercheurs les resultats de la cartographie 
physique du gènome entier sera une tåche de longue haleine mais necessaire; elle doit 
être entreprise avec des moyens informatiques, notamment une base de donnees 
accessible, complète et conviviale; il convient aussi d'assurer la distribution de clones 
de chromosomes artificiels de levure et de cosmides, ce qui requiert un personnel 
important. II sera essentiel de rendre ces rèactifs aisement accessibles a tous les 
scientifiques europeens, par exemple en diffusant largement des "filtres de polytene" 
contenant les chromosomes de levure ordonnès pour tous les chromosomes humains. 
De maniere generate, une gamme plus Vendue de bibliotheques ordonnees sera 
requise pour repondre aux besoins les plus divers de la recherche sur le genome, une 
fois que la premiere carte physique sera ètablie.è 
4. A l'avenir, des collections ordonnees d'ADN c entiers de tous les types de tissus 
corporels seront nècessaires. Les centres d'approvisionnement mettant des 
bibliotheques ordonnees d'ADN c a la disposition de la communaute" scientifique 
doivent avoir une priority èlevèe dans un futur programme "Genome humain". 
5. n convient d'envisager 1'attribution de ressources a des projets de sequencage de 
L'ADN c a tres grande echelle. Le principe du sequencage de l'ADN pour obtenir un 
catalogue complet des genes humains ètait, apres tout, une idee europeenne. 
6. Le sequencage genomique a tres grande echelle, qui n'ètait pas prevu dans le premier 
programme, doit etre envisagè dans un programme futur. II faudra realiser des 
projets pilotes incluant le sequencage d'une tres grande base afin d'evaluer les 
possibility d'aborder le sequencage de chromosomes humains entiers. La possibility 
de sequencer le genome entier gråce a une "approche a 1'aveugle" doit elle aussi ètre 
ètudiee avec attention. II est propose" de creer un groupe ad hoc pour ètudier ce 
probleme. Si la Communautè" europeenne veut participer a un tel projet, elle devra 
augmenter considerablement le budget du programme pour atteindre plus rapidement 
le but final du programme global sur le genome, a savoir realiser la sequence 
complete des nucleotides du gènome humain. 
7. Par ailleurs, EUROGEM aura bientdt termini sa mission avec la realisation de la carte 
gènètique a haute resolution. 
8. La bioinformatique est un domaine qui se developpera sans doute très rapidement dans 
un avenir proche. La conception de logiciels conviviaux destines à l'analyse de 
grandes masses de donnees representera indubitablement un element important d'un 
futur programme "Genome humain". Etant donnè" les norabreuses critiques emises 
contre la BDG, il devient utile d'envisager des solutions de remplacement a cette base 
de donnees, ou du moins un systeme different d'accès a la base: sur ce point, les 
progres de 1'IGD d'Heidelberg ("Integrated Genome Database", base de donnees 
integree sur le genome) semblent prometteurs et le modele de distribution dèfendu par 
ce groupe, qui utilise un systeme ACeDB local aliments par des donnees provenant 
des autres bases de donnees sur le genome est particulierement interessant. 
La communication entre biologistes et informaticiens reste imparfaite: les deux 
groupes appartiennent encore a des cultures tres diffèrentes. Leurs deux domaines ont 
evolue' tres rapidement au cours des dernières annèes, et peu d'individus possedent des 
competences dans les deux secteurs. La seule solution est probablement d'en accroitre 
le nombre, grace a des bourses d' Etudes et a des postes attrayants. 
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En outre, il convient de prendre en consideration et de financer l'amélioration des 
"interfaces" entre le "monde du genome" et la communaute' de la biologie generate, 
qui incluent non seulement la genetique médicale mais aussi, par exemple, des groupes 
réalisant des recherches fonctionnelles sur le systeme de la souris, de maniere a 
rapprocher structure et fonction. 
9. Les projets transnationaux doivent etre poursuivis, bien qu'il faille Ies sélectionner 
soigneusement. En accordant des aides a la recherche et en formulant des suggestions 
sur la repartition des fonds destines a la recherche, il convient de se rappeler que la 
collaboration - indubitablement essentielle - ne peut être planifiee, mais doit s'établir 
spontanément. C'est pourquoi il n'est pas judicieux de prevoir une collaboration entre 
scientifiques venant de certaines regions d'Europe, ou même de subordonner 
1*attribution de fonds a une telle collaboration. Ces idees vont a l'encontre du but 
recherché. II vaudrait mieux lancer un programme special, d'ampleur limitee, pour 
venir en aide a des scientifiques meritants du secteur biomedical dans les pays 
d'Europe qui accusent actuellement un retard en biologie moleculaire mais sont 
capables de le rattraper rapidement. 
10. Le programme de formation paraît, dans l'ensemble, avoir atteint ses objectifs, et sa 
poursuite est recommandee. II faudra cependant peut-être trouver de nouveaux moyens 
de diffuser les informations le concernant, car le nombre des demandes a été beaucoup 
plus faible que prevu. II faut également garder a 1'esprit le fait que des modifications 
du programme pourraient etre tres utiles a de jeunes scientifiques travaillant dans le 
domaine de 1'analyse du genome humain. Tous les pays d'Europe semblent etre 
confrontes au mgme problème, celui d'assurer aide et independance a de jeunes 
chercheurs qui se sont révélés des scientifiques éminents dans leur propre pays ou a 
l'etranger. Une forte attraction est exercee par les laboratoires des Etats-Unis, dont la 
plupart des universites possedent une structure administrative tres souple et, surtout, 
un nombre impressionnant de centres de recherche de haut niveau. II sera de plus en 
plus interessant pour les jeunes Europeens de collaborer avec les laboratoires de ces 
centres pour des periodes plus ou moins tongues, mais generalement pendant leurs 
annees les plus productives pour la recherche originate. De nos jours, les meilleurs 
endroits ou poursuivre des travaux de recherche biomeclicale sont des centres de taille 
critique. II faut reconnaître que l'un des rôles fondamentaux du financement et de 
1'organisation de la science en Europe est de creer un contrepoids a ces tres grands 
centres de recherche biomeclicale fondamentale aux Etats-Unis. Dans ce sens, on peut 
proposer de creer des postes pour de jeunes chercheurs independants dans des 
domaines de recherche biomédicale, qui permettraient a de jeunes scientifiques 
hautement qualifies de poursuivre les recherches de leur choix dans l'une des 
universites europeennes, sans cependant se trouver soumis aux contraintes de leurs 
structures administratives souvent tres "traditionnelles". Des fonds destines aux 
fournitures consommables, aux equipements et au personnel de recherche seraient en 
outre attaches a ces postes. De telles structures contribueraient considerablement a 
attirer ou a faire revenir dans les pays europeens un grand nombre des jeunes 
chercheurs les plus feconds. 
11. Les activites ESLA sont une composante essentielle des programmes sur le genome. 
Le groupe d'experts recommande, bien que sans unanimity, la poursuite de ces 
activites et l'octroi d'une aide a long tenne. II imports que le programme soit public 
le plus largement possible, et que les contractants reçoivent les informations adequates 
concernant les resultats attend us. Fournir aux groupes de participants les moyens de 
cooperer, d'entrer en interaction et d'echanger des idees sera une priority pour les 
futures activites ESLA. 
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Des efforts particuliers devront également être fournis pour inclure dans le programme 
du comity les aspects economiques des changements techniques, la politique de la 
science et les eludes scientifiques. Le desequilibre geographique represente aussi un 
probleme a etudier. 
12. L'aide apportee a 1'organisation de seminaires et de reunions est visiblement un 
element essentiel du programme "Genome humain", et la poursuite de cette action est 
recommandee. Cependant, des changements sont proposes dans 1'administration. II est 
par exemple suggéré d'etablir un comité scientifique consultatif charge d'emettre des 
avis sur la politique du programme et de flltrer les candidatures. II faut s'efforcer 
d'obtenir un meilleur equilibre dans les sujets traites par les seminaires subventionnes. 
L'aide apportee grâce au programme HUGO aux seminaires sur le chromosome 
unique est essentielle et doit etre poursuivie. D'une maniere generate, il convient de 
soutenir par une contribution a leur organisation les seminaires sur les chromosomes 
qui ont lieu en Europe. Le soutien peut egalement prendre la forme de subventions 
couvrant les frais de voyage des Europeans participant a des seminaires organises dans 
des pays non europeens. II semble egalement opportun de soutenir les seminaires qui 
rassemblent des scientifiques travaillant sur des sujets similaires au sein du programme 
"Genome humain" (comme cela a été fait auparavant dans certains cas), par exemple 
les chercheurs qui travaillent au sein d'EUROGEM ou avec des bibliotheques d'ADN 
c. Cela stimulerait bien sur les contacts entre groupes situes dans des pays d'Europe 
differents. 
13. Un autre complement interessant au programme serait la formation de medecins 
exercant dans toute 1'Europe. Pour beaucoup de praticiens, la genetique n'est qu'un 
mauvais souvenir du temps de leurs examens. Les progrès rapides de la genetique 
medicate mettent nos collegues praticiens dans une position difficile vis-a-vis de 
patients qui les pressent de questions. Des programmes de formation specialises 
pourraient apporter une solution au moins partielle a ce probleme. 
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II programma di analisi del genoma umano (PAGU) fa parte del secondo programma quadro delle 
attivita comunitarie di ricerca e sviluppo tecnologico. Questo programma e stato creato sotto la 
voce "Sanita" del settore "Qualità della vita" con il fine di: 
sviluppare e diffondere le nuove biotecnologie riguardanti lo studio del genoma umano allo 
scopo di approfondire la conoscenza del meccanismo delle funzioni genetiche per la 
prevenzione e la lotta contro le malattie dell'uomo; 
elaborare un approccio integrato che tenga conto degli aspetti etici, sociali e giuridici delle 
eventuali applicazioni dei risultati ottenuti. 
Nel dicembre 1992 la Commissione ha designato, in quanto parte integrante di un regolare 
esercizo di valutazione, un gruppo di esperti indipendenti per attuare la valutazione del suddetto 
programma. II gruppo di esperti e previsto dall'articolo 4, paragrafo 3, della decisione del 
Consiglio che addotta il suddetto programma (GU L 196 del 29.6.1990, pag. 8). Lo stesso 
articolo specifica che la valutazione dev'essere effettuata tenendo conto dei progressi scientifici 
e tecnici del programma, la qualita e l'importanza pratica dei suoi risultati, l'efficacia della sua 
gestione, i suoi aspetti etici, sociali e giuridici e il suo impatto e benefici sui programmi di ricerca 
nazionali. 
NeH'effettuare la valutazione, il gruppo ha visitato quattro centri partecipanti nel programma ed 
ha intervistato piu di 30 persone tra cui funzionari della Commissione e funzionari nazionali, 
partecipanti al programma e utilizzatori. 
L'importo totale assegnato a questo programma ammontava a 15,6 Mio di ECU. I fondi erano 
suddivisi come segue: mappe genetiche 21%, mappe fisiche 27,6%, elaborazione di dati e basi 
di dati 15%, tecnologie genetiche avanzate 18%, attivita di formazione 12%, amministrazione 
6,4%. 
Hanno partecipato al programma circa 100 istituti della Comunita europea. 
CONCLUSIONI 
II gruppo di valutazione e del parere che il PAGU stia riscuotendo un gran successo e sia una importante 
forza trainante nel settore della ricerca europea del genoma umano. La ricerca sul genoma, attualmente, 
avanza a velocità rapidissima. Negli ultimi anni il progresso e stato particolarmente evidente in Europa, 
con il successo dei progetti quali la sequenziazione dell'intero cromosoma del lievito, le mappe fisiche 
del genoma completo e sofisticate mappe genetiche. E' chiaro che il PAGU ha rivestito un ruolo 
importante per determinare una relazione piu equilibrata con gli Stati Uniti. Tuttavia, e chiaro che i 
programmi di una certa importanza come quello finanziato dalla AFM in Francia sono stati un 
importante incentivo. II PAGU e stato approvato con un bilancio biennale di 15,6 Mio di ECU. 
L'importo finanziario riservato dalla Comunita europea alia ricerca sul genoma e molto esiguo se 
comparato con i bilanci dei programmi sul genoma negli Stati Uniti e in Giappone. U PAGU ha quindi 
sowenzionato solo programmi a livello nazionale gia in corso e la percentuale dell'aiuto comunitario 
per i programmi individuali dipende in gran parte dal peso dei- programmi nazionali.La Comunita 
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europea ha dato un aiuto assai esiguo a grossi gruppi francesi (meno del 10%) mentre e stato assai 
importante per il Regno Unito, la Germania, l'ltalia ed altri paesi europei. L'aiuto comunitario varia 
dal < 5% al 50% del finanziamento totale di ogni progetto. Per i progetti transnazionali, nella maggior 
parte dei casi, questo aiuto e solo di modesta portata e, per i paesi meno sviluppati, la possibility di 
beneficiare dei programmi transnazionali è limitata. 
L'istituzione di centri di risorse e dei programmi di formazione e di grande aiuto sia per i laboratori 
scientifici organizzati, sia per i gruppi meno progrediti o meno organizzati. Questo aspetto e molto 
importante per il PAGU e in generale per la scienza odierna, visto che l'organizzazione e la disponibilita 
delle risorse sono i problemi di maggiore importanza. A questo riguardo il PAGU e stato di grande 
utilita per la ricerca del genoma nella Comunità europea e si deve tener conto di questo aspetto nella 
progettazione dei futuri programmi. 
II programma del cDNA neU'attuale PAGU non si e sviluppato cosl velocemente come si sperava 
sebbene si siano generate un gran numero di sequenze parziali del cDNA. In futuro saranno necessarie 
sempre piu grandi raccolte di librerie del cDNA di ottima qualita. 
L'obiettivo finale del progetto del genoma umano completo e il sequenziamento dell'intero genoma 
umano. Non sono inclusi nel PAGU, attualmente, programmi di sequenziamento estesi. Si deve 
modificare questa situazione in un PAGU futuro. 
I progetti transnazionali hanno rivestito una certa importanza per la promozione di collaborazioni 
europee. Inoltre, hanno fornito a piccoli laboratori, soprattutto dei paesi meno sviluppati, i mezzi di 
accesso alle tecnologie sofisticate. 
II programma di scambio dei ricercatori e una componente assolutamente essenziale del PAGU e sembra 
che in passato abbia funzionato in modo soddisfacente. 
Si e riconosciuto che le attività intraprese nell'ambito del programma ESLA erano giustificate. Tuttavia, 
il gruppo di valutazione ha discusso per vedere se il programma debba essere finanziato nella stessa 
misura del passato poicheé ci sono risorse 1 imitate e molti problemi incalzanti devono essere analizzati. 
II programma ESLA gia completato pu5 essere considerato come uno studio pilota promettente. II 
gruppo di esperti tiene a sottolineare il fatto che l'Europa offre possibilita uniche al mondo per questo 
tipo di studi, vista la diversita deH'organizzazione sanitaria e dei programmi sociali che operano nei vari 
paesi. 
In passato il finanziamento per il workshop e stato ricavato dal bilancio amministrativo. Sebbene il 
comitate HUG ed il gruppo di lavoro ESLA abbiano dato una partecipazione attiva al programma, 
sembra che in certa misura siano stati amministrati ad hoc. 
RACCOMANDAZIONI 
1. II gruppo di valutazione ritiene che si possa lanciare un terzo PAGU. Sono necessarie, comunque, 
alcune modifiche al piano del progetto, visti gli incredibili progressi realizzati durante l'anno 
passato. Sembra assai probabile che una mappa genetica ad alta risoluzione e inoltre una mappa 
fisica completa basata sullo YAC (cromosoma artificiale del Iievito) del genoma umano verra 
completata nell'arco di un anno. 
2. E' necessario creare un nuovo piano strategico per il PAGU. Tale piano deve prendere in 
considerazione anche la possibilita di attuare il sequenziamento del genoma intero con un 
approccio casuale. Tale procedura richiederebbe un drastico aumento di fondi. 
3. Una caratteristica tipica del PAGU sono i centri informatici ed e importante assicurare la loro 
esistenza ininterrotta. Per quanto riguardal'intera mappa fisica del genoma, sara un'impresa ardua 
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ma necessaria rendere disponibili alla comunità dei ricercatori i risultati gia ottenuti; tale difficile 
compito va affrontato con mezzi informatici comprendendo una base di dati accessibile, completa 
e di facile impiego per l'utente, ma anche a livello della distribuzione di cloni e cosmidi e YAC. 
Un passo essenziale verso l'obiettivo consisterebbe anche nel rendere accessibili questi reagenti 
a tutti gli scienziati europei, per esempio distribuendo su larga scala "filtri politene" che 
contengono YAC ordinati per tutti i cromosomi umani. In generate sono necessarie serie di 
librerie ordinate piu estese che servano agli scopi piu svariati della ricerca sul genoma, una volta 
che la prima mappa fisica sara completata. 
In futuro si richiederanno raccolte ordinate di frammenti di cDNA in tutta la lunghezza 
provenienti da tutti i tessuti del corpo. Data 1'utilita che rivestono per la comunita scientifica i 
centri che forniscono librerie ordinate di cDNA, devono avere l'assoluta priorita in un futuro 
PAGU. 
Si dovrebbe prendere in considerazione l'assegnamento di risorse a progetti di sequenziamento 
del cDNA su larghissima scala. Dopo tutto, il concetto del sequenziamento del cDNA per ottenere 
un catalogo completo dei geni umani, e un'idea europea. 
In un futuro PAGU si deve prendere in considerazione la necessita di creare una sequenziazione 
genomica su larghissima scala, fattore che non e stato preso in considerazione nel PAGU 
originale. Sara necessario realizzare alcuni progetti pilota che comprendano il sequenziamento di 
alcuni milioni di basi per valutare le possibilita future relative ad una politica di sequenziamento 
dei cromosomi umani completi. Inoltre, si deve soppesare attentamente la possibilita relativa al 
sequenziamento dell'intero genoma con un approccio casuale e si suggerisce la creazione di un 
gruppo ad hoc per analizzare questo problema. Se la Comunità europea intende partecipare a tale 
progetto, deve per6 incrementare di molto il bilancio del programma per accelerare l'obiettivo 
del programma globale sul genoma e cioe il sequenziamento completo del nucleotide del genoma 
umano. 
D'altra parte, l'EUROGEM, avra completato presto la sua missione, una volta che la mappa 
genetica ad alta risoluzone sara terminata. 
Probabilmente il settore della bioinformatica si sviluppera molto rapidamente in un prossimo 
futuro. Il progetto di un software di facile utilizzazione per l'analisi di grossi quantitativi di dati 
avrà senz'altro un peso importante in un futuro PAGU. Vista la critica estesa diretta al GDB, 
e utile prevedere basi di dati alternative o perlomeno un diverso sistema di accesso alia base di 
dati: a questo riguardo, il progresso dell'IGD di Heidelberg sembra promettente e altrettanto 
promettente sembra il modello di distribuzione nominato da questo gruppo, che usa un sistema 
locale ACeDB gestito localmente e alimentato con i dati di altre basi di dati del genoma. 
Lascia a desiderare la comunicazione tra i biologi e gli esperti di computer: essi appartengono 
tuttora a due culture totalmente differenti. Entrambi i settori hanno avuto un'evoluzione 
rapidissima negli ultimi anni e sono poche le persone competenti contemporaneamente in entrambi 
i settori. 
Un loro aumento numerico mediante borse di studio e posti attraenti, e probabilmente 1'unico 
modo per ovviare a questa difficolta. 
Inoltre, si deve dedicare una maggiore attenzione e provvedere ad un finanziamento per migliorare 
l'interfaccia tra il "mondo del genoma" e la comunita della biologia generale, comprendendo non 
solo la genetica medica, ma anche, per esempio, gruppi che attuino una ricerca funzionale nel 
sistema del topo cosicche' la struttura e la funzione vengano maggiormente avvicinate. 
I progetti transnazionali devono continuare anche se la loro selezione dev'esser fatta con grande 
cura. Nel sostenere la ricerca e formulare suggerimenti su come distribuire i fondi, e bene 
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ricordare che le collaborazioni, senz'altro assai importanti, non possono essere organizzate da 
chiunque, ma devono svilupparsi e si svilupperanno spontaneamente. A questo riguardo non è 
bene impegnarsi con collaborazioni tra scienziati di certe zone in Europa e neanche fare 
affidamento sui fondi che dipendono da tali collaborazioni. Tali idee sono controproducenti. E 
preferibile, piuttosto, cominciare un programma speciale di un'ampiezza limitata per sostenere 
scienziati promettenti nel settore biomedico che lavorano in quei paesi europei che, per il 
momento, sono ancora deboli per quanto riguarda la biologia molecolare, ma sono in grado di 
recuperare il ritardo rapidamente. 
10. II programma di formazione ha avuto un grande successo e si raccomanda una continuazione dello 
stesso. Pu6 essere necessario, tuttavia, trovare nuovi mezzi per diffondere l'informazione relativa 
al programma, visto che il numero delle candidature era molto più limitato di quanto si 
prospettava. Bisogna anche tenere a mente che alcune modifiche del programma possono essere 
di gran beneficio per giovani scienziati che lavorano nel settore dell'anal isi del genoma umano. 
Sussiste un problema che sembra comune a tutti i paesi europei, vale a dire il sostegno e 
l'indipendenza di giovani ricercatori che si sono rivelati scienziati di alto livello nei loro o in altri 
paesi. C'e un richiamo considerevole dai laboratori degli Stati Uniti con la loro struttura 
amministrativa assai flessibile nella maggior parte delle universita e, soprattutto, con un numero 
impressionante di centri di ricerca all'avanguardia in molte università americane. Per i giovani 
europei è sempre più attraente cercare di associarsi ai laboratori nei suddetti centri per periodi piu 
lunghi o piu corti ma, general mente, negli anni piu produttivi per la ricerca. La ricerca 
biomedica, oggigiorno, pub essere attuata al meglio nei centri che abbiano raggiunto la massa 
critica. E' necessario riconoscere che uno dei compiti principali per il finanziamento e 
l'organizzazione scientifica in Europa sta nel fatto di creare un contrappeso a questi centri cosi 
potenti per la ricerca biomedica di base negli Stati Uniti. A questo riguardo si suggerisce di creare 
posti per giovani ricercatori indipendenti nei settori della ricerca biomedica che permettano ai 
giovani scienziati altamente qualificati di continuare la ricerca che hanno scelto in una delle 
università europee, ma, non dovendo sottostare alle strutture amministrative, molto spesso troppo 
"tradizionali". Oltre ai posti si dovrebbero abbinare fondi per beni di consumo, attrezzature e 
personale di ricerca. In questo modo tali strutture aiuterebbero in modo considerevole ad attrarre 
o a far tornare dall'estero molti dei giovani ricercatori piu dotati nei paesi europei. 
11. I programmi ESLA sono componenti essenziali dei programmi relativi al genoma. II gruppo di 
valutazione raccomanda, anche se non aH'unanimita, che il programma ESLA continui e che si 
fornisca un sostegno a lungo raggio. E' importante che il programma sia esteso il piu possibile 
e che i contraenti ricevano informazioni adeguate relativamente all'obiettivo previsto del 
programma. E' urgente per i futuri programmi ESLA fornire mezzi di cooperazione, azioni 
incrociate e scambi di idee e risultati ai gruppi partecipanti. 
Si devono fare notevoli sforzi per includere gli aspetti economici dei cambiamenti tecnologici, 
della politica scientifica e degli studi scientifici nel programma. La disparita geografica crea un 
altro problema di cui ci si deve occupare. 
12. Si devono finanziare i seminari e le riunioni, componenti essenziali del PAGU e si raccomanda 
una continuazione del programma. Tuttavia, si raccomandano alcuni cambiamenti amministrativi. 
Si suggerisce, per esempio, la creazione di un gruppo scientifico consultivo per dare pareri sulla 
politica del programma e per analizzare le candidature. Vanno fatti sforzi per ottenere un 
maggiore equilibrio tra gli argomenti trattati nei seminari finanziati. II finanziamento tramite 
HUGO per i singoli seminari sui cromosomi e essenziale e deve continuare. In generate, i 
seminari europei sui cromosomi devono ricevere un finanziamento come contributo 
all'organizzazione. Per i seminari al di fuori dell'Europa, si devono accordare agevolazioni ai 
partecipanti europei. Sembra importante anche sostenere i seminari in cui si trovano radunati gli 
scienziati che lavorano aH'interno del PAGU su argomenti simili (come si e fatto in parte in 
passato), per esempio per coloro che hanno collaborato a EUROGEM o alle librerie del cDNA. 
Ovviamente tutto ciò stimolerebbe i contatti tra i gruppi dei vari paesi europei. 
XLIV 
13. La formazione dei medici di tutta Europa va considerata come un elmento positivo da inserire nel 
programma. Per molti medici la genetica e un ricordo traumatico dei loro esami universitari. Con 
il rapido progresso nella genetica medica, i nostri colleghi medici sono gia in una posizione 
difficile di fornte ai loro pazienti che pongono domande incalzanti. Una soluzione almeno parziale 






1. Het Programma Analyse van net Menselijk Genoom (PAMG) is een onderdeel van het 
tweede kaderprogramma van communautaire werkzaamheden op het gebied van 
onderzoek en technologische ontwikkeling. Het programma is in het raam van de actie 
"Kwaliteit van het bestaan", onder het punt "Gezondheid", opgezet met als doel : 
nieuwe biotechnologieen toe te passen en te verfijnen bij de studie van het 
menselijk genoom, met het oog op het verwerven van een beter inzicht in de 
genetische mechanismen enerzijds en de preventie en behandeling van 
menselijke ziekten anderzijds ; 
een geïntegreerde benadering tot stand te brengen van de ethische, sociale en 
juridische aspecten van eventuele toepassingen van de resultaten van dit 
programma. 
2. In het kader van de standaard-evaluatieprocedure heeft de Commissie in december 
1992 een panel van onafhankelijke deskundigen belast met de evaluatie van het PAMG. 
De basis voor de activiteiten van het evaluatiepanel is artikel 4, lid 3, van de 
beschikking van de Raad waarbij dit programma is vastgesteld (PB L 196 van 
29.6.1990, biz. 8). In het bedoelde artikel is bepaald dat bij de evaluatie rekening moet 
worden gehouden met de wetenschappelijke en technische resultaten van het 
programma, de kwaliteit en de praktische toepasbaarheid van die resultaten, de 
doeltreffendheid van het beheer, de ethische, sociale en juridische aspecten en de 
consequenties en voordelen voor de nationale onderzoekprogramma's. 
In het kader van deze evaluatie heeft het panel vier bij het programma betrokken centra 
gevisiteerd en meer dan dertig betrokkenen (ambtenaren van de Commissie en van de 
Lid-Staten, deelnemers aan het PAMG en gebruikers) geïnterviewd. 
3. Voor dit programma is een totaalbedrag van 15,6 miljoen ecu uitgetrokken. Deze 
middelen zijn als volgt verdeeld : genetische kartering 21 %, fysische kartering 27,6 %, 
gegevensverwerking en databanken 15 %, geavanceerde genetische technologieen 18 
%, opleidingsactiviteiten 12 %, administratis 6,4 %. 
Bij het PAMG waren een honderdtal instituten in de EG betrokken. 
CONCLUSIES 
Het panel heeft vastgesteld dat het PAMG grotendeels een succes is geworden en dat het een 
belangrijke impuls heeft gegeven aan het Europese onderzoek van het menselijk genoom. Het 
genoomonderzoek vordert momenteel met reuzenschreden. De jongste jaren is met name in 
Europa grote vooruitgang geboekt en zijn projecten als de sequentiebepaling van volledige 
gistchromosomen, de fysische kartering van het hele genoom en het opstellen van gedetailleerde 
genetische kaarten met succes bekroond. Het laat geen twijfel dat het PAMG een belangrijke rol 
heeft gespeeld bij het herstel van een zeker evenwicht met de Verenigde Staten. Evenzeer is 
echter duidelijk dat ook van grootschalige initiatieven zoals het onderzoekprogramma dat door 
het Franse AFM wordt gesteund, belangrijke impulsen zijn uitgegaan. Bij de vaststelling van het 
PAMG is voor de hele tweejarige looptijd van het programma een budget van 15,6 miljoen ecu 
ter beschikking gesteld. De bedragen die door de EG voor genoomonderzoek worden 
uitgetrokken zijn erg klein in vergelijking met de financiele middelen waarover de 
genoomprogramma's in de VS en Japan beschikken. Het PAMG kon daarom slechts een 
aanvulling zijn van de bestaande inspanningen op nationaal niveau ; het effect van EG-
financiering op individuele programma's hangt in hoge mate af van de sterkte van de nationale 
programma's. Aan de grote Franse onderzoekgroepen heeft de EG bijzonder weinig steun 
verleend (minder dan 10 %) terwijl de steun voor Groot-Brittannie, Duitsland, Italie en andere 
Europese landen zeer belangrijk is geweest. De financiering door de EG varieert van minder dan 5 
% tot 50 % van het totale budget van elk project. Voor transnationale projecten sorteert deze 
vorm van ondersteuning in de meeste gevallen een eerder gering effect. De minder geavanceerde 
landen halen uit deze transnationale programma's ook vrij weinig profijt. 
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Het opzetten van "resource centres" en opleidingsprogramma's betekent zowel voor gevestigde 
als voor minder geavanceerde wetenschappelijke laboratoria en minder gestructureerde groepen 
een belangrijke steun. Dit is een uiterst belangrijk aspect van het PAMG en van de hedendaagse 
wetenschap in het algemeen, aangezien aspecten als organisatie en de beschikbaarheid van 
hulpmiddelen van fundamenteel belang zijn. In dit opzicht heeft het PAMG het Europese 
genoomonderzoek een grote dienst bewezen. Aan dit aspect moet dan ook bij het opzetten van 
toekomstige programma's de nodige aandacht worden besteed. 
Het cDNA-programma van het lopende PAMG is minder expansief gebleken dan verhoopt, 
hoewel heel wat partible cDNA-sequenties zijn bepaald. Het is duidelijk dat er in de toekomst een 
grote behoefte zal bestaan aan omvangrijke cDNA-bibliotheken van zeer goede kwaliteit. 
Het einddoel van het mondiale "Human Genome Project" is de sequentiebepaling van het 
volledige menselijk genoom. Momenteel worden in het kader van het PAMG geen grootschalige 
sequencing-programma's uitgevoerd. Oit dient in een toekomstig PAMG te worden gecorrigeerd. 
De transnational projecten hebben goede diensten bewezen bij de bevordering van de Europese 
samenwerking. Ook hebben zij ervoor gezorgd dat kleinere laboratoria, met name in de minder 
ontwikkelde landen, toegang hebben gekregen tot geavanceerde technologieen. 
Het beurzenprogramma is zeker een essentieel onderdeel van het PAMG. Het laat zich aanzien 
dat dit in het verleden naar behoren heeft gefunctioneerd. 
Het evaluatiepanel erkent dat er goede gronden waren voor het uitvoeren van de in het kader 
van het programma Ethische, Sociale en Juridische Aspecten (ESJA) aangevatte activiteiten. Het 
vraagt zich echter af of dit programma nog in dezelfde mate als voorheen moet worden 
gefinancierd, aangezien de financiele middelen beperkt zijn en vele andere dringende vragen een 
antwoord eisen. 
Het reeds voltooide ESJA-programma kan worden gezien als een veelbelovende verkennende 
studie. Het panel benadrukt dat Europa, in het licht van de grote verschillen tussen de stelsels 
voor gezondheidszorg en sociale zekerheid in de diverse landen, voor dit type onderzoek unieke 
kansen biedt. 
Voor de ondersteuning van workshops is in het verleden de post "huishoudelijke uitgaven" 
aangesproken. De inbreng van CAN-HUG en de ESJA-werkgroep in het programma kan niet 
worden geloochend ; wel schijnt het op een enigszins willekeurige manier te zijn beheerd. 
AANBEVELINGEN 
1 . Het panel is van menig dat er een derde PAMG moet worden opgezet. De aanzienlijke 
vooruitgang die het laatste jaar is geboekt, maakt evenwel bepaalde wijzigingen in de 
opzet van het project noodzakelijk. Het laat zich aanzien dat binnen het jaar een zeer 
gedetailleerde genetische kaart alsmede een volledige, op de YAC-technologie 
gebaseerde fysische kaart van het menselijk genoom zullen zijn voltooid. 
2. Voor het PAMG moet een nieuw strategisch plan worden opgesteld. Daarbij moet 
rekening worden gehouden met de mogelijkheid om bij de sequencing van het volledige 
genoom uit te gaan van een "shotgun"-benadering. Deze optie vereist evenwel een 
drastische verruiming van de financiele middelen. 
3. Een essentieel aspect van het PAMG zijn de "resource centres", waarvan het ' -: 
voortbestaan hoe dan ook moet worden gegarandeerd. De resultaten van de fysische 
kartering van het hele genoom in een gemakkelijk raadpleegbare vorm ter beschikking 
stellen van alle betrokken wetenschappers, is een taak waarvan noch de omvang, noch 
het belang mogen worden onderschat. Om deze tot een goed einde te brengen is niet 
alleen informatisering nodig (met name een vlot toegankelijke, complete en 
gebruiksvriendelijke databank) maar ook een distributiesysteem voor YAC- en 
cosmideclonen. Het opzetten daarvan wordt ongetwijfeld een zeer arbeidsintensieve 
onderneming. Door dit moleculaire alaam ter beschikking te stellen van alle Europese 
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wetenschappers, b.v. via de grootschalige verspreiding van "polytene filters" met 
geordende YAC's voor alle menselijke chromosomen, zou al een essentiele stap zijn 
gerealiseerd. In het algemeen is een breder spectrum van geordende bibliotheken vereist 
met behulp waarvan, na de voltooiing van de eerste fysische kaart, in de meest diverse 
behoeften van het genoomonderzoek kan worden voorzien. 
In de toekomst zal er behoefte bestaan aan geordende collecties integrate cDNA's uit 
de verschillende weefsels van het lichaam. Resource centres die als dienstbetoon aan 
de wetenschappelijke gemeenschap geordende cDNA-bibliotheken ter beschikking 
stellen, dienen in een toekomstig PAMG een hoge prioriteit te krijgen. 
Overwogen moet worden om middelen ter beschikking te stellen voor megaprojecten op 
het gebied van cDNA-sequencing. Oe idee om via sequencing van cDNA's een 
complete catalogus van menselijke genen op te stellen, is ten slotte in Europa geboren I 
Aan sequentiebepaling op megaschaal, die in het oorspronkelijke PAMG niet aan de 
orde was, moet in een toekomstig PAMG de gepaste aandacht worden geschonken. 
Om de kansen inzake sequentiebepaling van volledige menselijke chromosomen voor de 
toekomst in te schatten, zal het nodig zijn enkele proefprojecten uit te voeren waarbij 
megabase-sequenties worden bepaald. Ook moet serieus de mogelijkheid worden 
onderzocht om de basensequentie van het hele genoom via een "shotgun'-benadering 
te achterhalen. Voorgesteld wordt, deze kwestie door een ad hoc werkgroep te laten 
onderzoeken. Indien de EG overweegt in een dergelijk project te participeren, zullen de 
voor het programma uitgetrokken financiele middelen aanzienlijk moeten worden 
uitgebreid om het uiteindelijke doel van het mondiale genoomprogramma - de kennis 
van de complete nucleotidensequentie van het menselijk genoom - sneller te bereiken. 
Daar staat tegenover dat de taak van EUROGEM 
genetische kaart, eerlang zal zijn volbracht. 
het opstellen van een gedetailleerde 
Van de bio-informatica kan in de nabije toekomst een explosieve ontwikkeling worden 
verwacht. De ontwikkeling van gebruiksvriendelijke software voor het analyseren van 
kolossale hoeveelheden gegevens zal ongetwijfeld een belangrijk onderdeel vormen van 
het toekomstige PAMG. Met het oog op de alom geformuleerde bezwaren tegen de 
GDB verdient het aanbeveling het gebruik van andere databanken of ten minste andere 
toegangssystemen niet uit te sluiten : in dit verband is de met de Heidelberger "IGD" 
(Integrated Genome Database) geboekte vooruitgang veelbelovend en lijkt het door de 
betrokken groep bepleite distributiemodel - een lokaal ACeDB-systeem waarin gegevens 
uit de andere genoom-databanken worden ingevoerd - allerlei voordelen te bieden. 
De communicatie tussen biologen en informatici laat nog te wensen over : zij leven nog 
steeds in grotendeels gescheiden werelden. Beide vakgebieden zijn de laatste 
jaren bijzonder snel geevolueerd en maar weinigen beschikken over een 
uitgebreide vakkennis in beide specialismen. 
Waarschijnlijk kan daaraan alleen iets worden gedaan door het creeren van 
aantrekkelijke beurzen en banen die ervoor moeten zorgen dat het aantal van deze 
"bruggenbouwers" toeneemt. 
Bovendien moet werk worden gemaakt (en in enige financiering worden voorzien) van 
een verbeterde communicatie tussen de wereld van de genoomanalyse en de rest van 
de biologische wetenschap - niet alleen de medische genetica maar ook, bij voorbeeld, 
het functioneel onderzoek van het muizegenoom. Dit moet het mogelijk maken 
structuur en functie duidelijker aan elkaar te relateren. 
De transnationale projecten moeten worden voortgezet, al dient bij de selectie daarvan 
de grootste zorg aan de dag te worden gelegd. Bij het steunen van onderzoek en het 
formuleren van suggesties betreffende de verdeling van financiele middelen dient men 
zich voor ogen te houden dat samenwerking, hoe belangrijk ook, niet van buitenaf kan 
worden opgedrongen maar alleen spontaan kan, en moet, tot stand komen. In dit 
verband lijkt het geen verstandige keuze om van de samenwerking tussen 
wetenschappers uit bepaalde regio's in Europa een spijkerharde eis te maken of de 
toekenning van financiele middelen van dit soort samenwerking afhankelijk te maken. 
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Een dergelijke aanpak sorteert alleen een averechts effect. Veeleer verdient het de 
voorkeur een speciaal programma van beperkte omvang op te zetten ter ondersteuning 
van verdienstelijke beoefenaren van de biomedische wetenschappen uit Europese 
landen die momenteel inzake moleculaire biologie een zekere achterstand vertonen maar 
in staat zijn deze snel in te lopen. 
10. Het opleidingsprogramma lijkt goeddeels een succes te zijn geworden en het panel pleit 
voor de voortzetting daarvan. Wei moet misschien worden uitgekeken naar nieuwe 
mogelijkheden om de bekendheid van dit programma te vergroten, aangezien het aantal 
aanvragen veel kleiner is gebleven dan verwacht. Ook dient men zich te realiseren dat 
voor jonge, in de genoomanalyse actieve wetenschappers bepaalde aanpassingen van 
het programma een enorm pluspunt zouden betekenen. Er is namelijk een probleem 
waar álle Europese landen mee te kampen hebben : de ondersteuning van het 
zelfstandig onderzoek van jonge vorsers die zich in hun eigen of in een ander land als 
wetenschappers van topniveau hebben ontpopt. Op deze mensen oefenen de 
laboratoria in de Verenigde Staten een zeer grote aantrekkingskracht uit. De meeste 
universiteiten hebben daar immers een zeer soepele administratieve structuur, en 
bovenal telt het land een indrukwekkend aantal onderzoekcentra van topniveau, 
verspreid over de verschillende universiteiten. Voor jonge Europeanen wordt het steeds 
verleidelijker gedurende kortere of langere tijd in de laboratoria van deze centra te gaan 
; gasteren - meestal gedurende de periode van hun carriere waarin zij de grootste 
G werkkracht en wetenschappelijke creativiteit aan de dag leggen. Biomedisch onderzoek 
kan heden ten dage het best worden gedaan in centra met een bepaalde 
minimumomvang. Men dient zich te realiseren dat één van de belangrijke taken van de 
financiering en de organisatie van het wetenschappelijk onderzoek in Europa erin 
bestaat, een tegengewicht te vormen voor de enorme aantrekkingskracht van deze 
Amerikaanse centra voor fundamenteel biomedisch onderzoek. Daarom wordt hier 
voorgesteld om ten behoeve van jonge zelfstandige biomedische wetenschappers banen 
te scheppen waardoor hooggekwalificeerde jonge wetenschappers onderzoek naar 
eigen keuze zouden kunnen doen aan 66n van de Europese universiteiten, zonder daarbij 
gehinderd te worden door de vaak "traditionele" administratieve structuren van deze 
laatste. Naast deze banen zelf dient ook in (daaraan gekoppelde) financiële middelen 
voor klein materiaal, toestellen en laboratoriumpersoneel te worden voorzien. Dit soort 
voorzieningen kan er in niet geringe mate toe bijdragen een groot aantal produktieve 
jonge wetenschappers uit derde landen naar Europa te lokken c.q. terug te halen. 
1 1 . De ESJA-programma's zijn een essentieel onderdeel van de genoomprogramma's. 
Hoewel ter zake niet unaniem, beveelt het panel aan het bestaande ESJA-programma 
voort te zetten en ervoor te zorgen dat dit ook op langere termijn wordt ondersteund. 
Belangrijk is dat aan het programma de ruimst mogelijke bekendheid wordt gegeven en 
dat de contractanten terdege worden voorgelicht over de resultaten die van het 
programma worden verwacht. In het kader van toekomstige ESJA-programma's dient 
ook absoluut te worden voorzien in middelen die de deelnemende groepen in staat 
moeten stellen samen te werken, op elkaars activiteiten in te spelen en ideeen en 
resultaten uit te wisselen. 
Er moet een extra inspanning worden gedaan om in het programma ook voor de 
economische aspecten van technologische evolutie, voor wetenschapsbeleid en voor 
"wetenschapsonderzoek" de nodige plaats in te ruimen. Ook aan de geografische 
onbalans moet dringend iets worden gedaan. 
12. De ondersteuning van workshops en vergaderingen is duidelijk een essentieel onderdeel 
van het PAMG en de voortzetting van dit programma is zeker gewenst. Wei wordt 
gepleit voor enkele wijzigingen van administratieve aard. Zo lijkt het b.v. wenselijk een 
wetenschappelijke adviesraad op te zetten die de aanvragen screent en de 
verantwoordelijken voor het programma van advies dient inzake beleidskwesties. Er 
moet worden gestreefd naar een beter thematisch evenwicht tussen de ondersteunde 
workshops. De ondersteuning, via HUGO, van workshops over afzonderlijke 
chromosomen is van cruciaal belang en moet worden voortgezet. In het algemeen lijkt 
de ondersteuning van chromosoom-workshops in Europa als bijdrage aan deze 
organisatie een goed idee. Een andere noodzakelijke vorm van steun is het verstrekken 
van reistoelagen aan Europese onderzoekers die aan buiten Europa gehouden 
workshops willen deelnemen. Ten siotte lijkt het verstandig om (zoals in het verleden 
tot op zekere hoogte is gebeurd) "ontmoetingsbijeenkomsten" te ondersteunen voor 
wetenschappers die in het kader van het PAMG op verwante thema's werken - b.v. de 
deelnemers aan EUROGEM of de samenstellers van cDNA-bibliotheken. Dit kan de 
contacten tussen de groepen in de verschillende Europese landen alleen maar ten goede 
komen. 
13. Een laatste welkome aanvulling van het programma is de bijscholing van praktizerende 
artsen in heel Europa. Voor menig praktizerend arts is genetica niet méér dan een nare 
herinnering uit zijn/haar opleidingsperiode aan de universiteit. De snelle vooruitgang van 
de medische genetica heeft ervoor gezorgd dat menig praktizerend medicus zich ten 
aanzien van zijn patienten reeds in een lastig parket voelt gebracht; gespecialiseerde 
opleidingsprogramma's kunnen dit euvel althans gedeeltelijk verhelpen. 
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1. 0 Programa de Analise do Genoma Humano (PAGH) insere-se no segundo 
programa-quadro para acções comunitarias no dominio da investigaçao e 
do desenvolvimento tecnol6gico. Este programa, criado ao abrigo da 
rubrica "Saude" do capitulo "Qualidade de vida", pretende: 
utilizar e melhorar novas biotecnologias no estudo do genoma humano 
para uma melhor compreensao do mecanismo das funcoes geneticas e para a 
prevencao e tratamento de doencas humanas; 
- desenvolver uma abordagem integrada dos aspectos eticos, socials e 
Juridicos das possiveis aplicacoes dos resultados obtidos. 
2. Para o seu exercfcio de avaliacao regular, a Comissao designou, em 
Dezembro de 1992, urn grupo de perltos independentes para procederem a 
avaliacao do PAGH. A competdncia do painel de avaliacao foi 
estabelecida no no. 3 do art!go 4o da decisao do Conselho que adopta 
este programa (JO np_ L 196 de 29.6.1990, p. 8 ) . 0 mesmo artigo 
especifica que a avaliacao deve ser efectuada em relacao aos resultados 
cientlficos e teenicos do programa, a qualidade e importância prat lea 
desses resultados, a eficidncia da sua gestao, aos seus aspectos 
eticos, socials e Juridicos e ao seu impacto e beneflcios para os 
programas de investigacao nacionais. 
Para essa avaliacao, o painel visitou quatro centros associados ao programa 
e entrevistou ma is de trinta pessoas: funcionarios nacionais e da Comissao, 
participantes no PAGH e utiIizadores. 
3. 0 montante total dos fundos atribuidos ao programa foi de 15,6 mi I hoes 
de ecus, com a seguinte distribuicao - mapas geneticos: 21%, mapas 
fisicos: 27,6%, tratamento de dados e bases de dados: 15%, tecnologias 
geneticas avancadas: 18%, actividades de formagao: 12% e administracao: 
6,4%. 
No PAGH participaram cerca de 100 institutos comunitarios. 
CONCLUÕES 
0 painel considera que o PAGH obteve urn dxito consideravel e que constitui 
uma importante forca motriz no dominio da investigacao do genoma humano na 
Europa. Actualmente, a investigaçao sobre o genoma esta a avançar muito 
rapidamente. Nos ultimos anos, o progresso tern sido particularmente not6rio 
na Europa, com o êxito de trabalhos tais como a sequenciacao completa do 
cromossoma de uma levedura, os mapas fisicos de genomas completos e os mapas 
geneticos refinados. 0 PAGH desempenhou claramente urn papel importante no 
estabelecimento de uma relacao mais equilibrada com os EUA, sem esquecer a 
importante forca motriz gerada por programas fortes tais como o apoiado pela 
AFM em Franca. 0 PAGH foi aprovado com urn orcamento de 15,6 mi I hoes de ecus 
para do is anos. 0 montante destinado pela Comunidade a investigacao do 
genoma e muito reduzido, comparado com os orcamentos de programas sobre o 
genoma nos EUA e no Japao. 0 PAGH constitui, assim, apenas urn suplemento dos 
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actuais esforcos empreendidos a nivel nacional e a importancia do 
investimento comunitario em programas especificos depende em grande parte da 
importancia dos programas nacionais. A Comunidade tern dado urn importante 
apoio a Gra-Bretanha, Alemanha, Italia e outros paises europeus, embora urn 
apoio muito reduzido a grandes grupos franceses 
(menos de 10%). 0 apoio comunitario varia entre <5% e 50% do custo total de cada 
projecto. Quanto aos projectos transnacionais, este tipo de apoio tern, na 
maioria dos casos, apenas urn impacto reduzido e a possibiIidade de os paises 
menos avancados beneficiarem dos programas transnacionais e limitada. 
A criacao de centros de recursos e de programas de formacao constitui uma grande 
ajuda tanto para os laboratórios cientificos organizados como para os grupos 
menos avancados ou menos bem estabelecidos. Este e urn aspecto muito importante 
do PAGH e, em geral, da ciência actual, dada a importancia da organização e da 
disponibiIidade de recursos. Neste sentido, o PAGH tern si do de grande utllidade 
para a investigacao do genoma na Europa, urn aspecto que devera ser salientado na 
concepcao dos programas futuros. 
0 programa do ADNc no âmbito do actual PAGH nao se desenvolveu com a rapidez 
esperada, embora tenham si do obtidas uma serie de sequdncias pareiais de ADNc. 
No futuro, havera sem duvida uma grande necessidade de grandes coleccoes de j 
bibliotecas de ADNc de alta qua Iidade. I 
0 objectivo final do projecto global do genoma humano e o de sequenciar o genoma 
humano na sua totalidade. Os grandes programas de sequenciacao nao estao 
actualmente incluldos no PAGH, o que devera ser rectificado no futuro. 
I 
Os projectos transnacionais têm sido importantes para promover a colaboração 
europeia, para a I em de proporcionarem aos pequenos laboratórioss, em especial nos 
paises menos desenvolvidos, o acesso a tecnologias sofisticadas. 
0 programa de bolsas de investigacao constitui uma componente essencial do PAGH 
e tern sido implementado de forma satisfatória no passado. 
0 painel de avaliação, embora reconhecendo que se Justificam as actividades 
empreendidas no âmbito do programa ESLA, debateu a questao de o programa dever 
ou nao ser financiado tal como anteriormente devido a limitação dos recursos e < 
quantidade de questoes urgentes a investigar. 
0 programa ESLA Ja concluido pode ser considerado como urn estudo-piloto 
prometedor. 0 painel salienta que a Europa oferece possibiIidades unicas para 
este tipo de estudos, dada a diversidade dos programas de cuidados de saiide e 
sociais aplicados nos varios paises. 
As despesas do seminário foram, ate agora, costeadas pelo orcamento da 
administração. Embora o CAN-HUG e o grupo de trabalho do ESLA tenham dado a sua 
contribuicao, o programa tern sido, ate certo ponto, administrado de uma forma 
ad-hoc. 
RECOMENDAÇÕES 
1. 0 painel considera que deve ser lancado urn terceiro PAGH, embora seja 
necessario introduzir alteracões no piano de projecto, dados os grandes 
progressos obtidos durante o ultimo ano. E muito provávell que, durante o 
próximo ano, se complete urn mapa genetico de alta resolução e urn mapa 
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flsico integral do genoma humano com base no YAC (Yeast Artificial 
Chromosome). 
E necessario um novo piano estrategico para o PAGH, que devera considerar a 
possibiIidade de uma sequenciacao do genoma inteiro pelo "shot gun 
approach", o que implica um grande aumento do finaneiamento. 
Os centros de recursos sao um factor-chave do PAGH e e essencial garantir a 
sua existência. Pdr a dlsposicao da comunidade os resultados da cartografia 
fis lea integral de um genoma constitui uma tarefa de grande envergadura mas 
necessaria, que deve ser realizada com o apoio de meios informaticos, 
incluindo uma base de dados acessivel, completa e de consulta facil, mas 
tambem atraves da distribuicao de clones de cosmideos e de YAC, o que 
representa um trabalho intensivo. Permitir um acesso facil destes reagentes 
a todos os cientistas europeus, por exemplo atraves de uma vasta 
distribuicao de "filtros de politene" com YAC ordenados para todos os 
cromossomas humanos sera um passo essencial. Em geral, e necessaria uma 
gama mais vasta de bibliotecas ordenadas para responder as mais diversas 
necessidades da investigacao sobre o genoma, uma vez completado o primeiro 
mapa fisico. 
No futuro, serão pedidas, para todos os tecidos do corpo, coleccoes 
ordenadas de ADNc no seu comprimento total. Num PAGH futuro devera ser 
atribuida prioridade aos centros de recursos que fornecem bibliotecas 
ordenadas de ADNc como um servico a comunidade cientifica. 
Deve ser considerada a atribuição de recursos para projectos de 
sequenciacao de ADNc em mega-escala, Ja que o conceito de sequenciacao do 
ADNc para a obtenção de um catalogo completo dos genes humanos e uma ideia 
europeia. 
Num futuro PAGH devera se inciuida a sequenciacao genómica em mega-escala, 
que nao fazia parte do programa original. Sera necessario realizar alguns 
projectos-piloto que integrem a sequenciacao de megabases para avaliar as 
futuras possibiIidades de sequenclar os cromossomas humanos na sua 
totalIdade. A possIbil1dade de sequenciacao do genoma completo atraves do 
"shot gun approach" tambem merece uma consideracao cuidada, sendo sugerido 
que se retina um grupo ad-hoc para analisar este problema. Se a Comunidade 
pretende participar neste projecto, tera de prever um grande aumento do 
orcamento do programa para permitir atingir o objectivo final do programa 
global sobre o genoma, que consiste na sequdncia completa dos nucleótidos 
do genoma humano. 
7. 0 EUROGEM, por outro I ado, tera em breve cumprido a sua missao, uma 
completado o mapa genético de alta resolucao. vez 
A bio-informatica e um dominio que se devera desenvolver muito rapidamente 
num futuro pr6ximo. A concepcao de suporte l6gico de facil utilizacao para 
a analise de grandes quantidades de dados sera, sem dúvida, um aspecto 
importante do futuro PAGH. Dadas as crit leas generalizadas dirigidas ao 
GDB, e conveniente prever bases de dados alternativos ou, pelo menos, um 
si sterna diferente de acesso as bases de dados: a este respeito, o progresso 
registado pelo Heidelber IGD (Integrated Genome Database) parece 
prometedor, em especial o mode Io de distribuição, que este grupo propoe, 
atraves de um sistema ACeDB que funciona a nivel local e e aiimentado com 
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dados de outras bases sobre o genoma. 
A comunicacao entre biólogos e especialistas em informatica continua a ser 
imperfeita: sao ainda duas culturas muito diferentes. Trata-se de dois 
domlnios que evoluiram muito rapidamente nos ultimos anos e poucos 
indivlduos sao competentes em ambos. 
A aumento do seu numero, at raves de bolsas de investigacao e postos de 
trabalho interessantes, e provavelmente a unica forma de ultrapassar esta 
dificuldade. 
AIém disso, deve ser atribulda alguma atencao e a I guns fundos ao 
meIhoramento da interface entre o "mundo do genoma" e a comunidade da 
biologia em geral, incluindo nao s6 a genetica medica mas tambem, por 
exemplo, grupos que se dedicam a estudos funcionais do si sterna do rato, de 
forma a permitir a aproximacao da estrutura e da funcao. 
9. Os projectos transnacionais devem continuar a ser implementados, embora 
sujeitos a uma selecçao cuidadosa. Ao ser dado o apoio a investigacao e ao 
serem apresentadas sugestoes sobre como distribuir os fundos de 
investigacao, e necessario lembrar que as colaboracoes, sem dúvida muito 
importantes, nao podem ser organizadas por alguem mas devem surgir de forma 
espontânea. A este respeito, nao e aconselhavel estipular colaboracoes 
entre cientistas de determinadas regioes da Europa ou mesmo atribuir fundos 
dependentes dessas colaboracoes. Estas ideias sao contraproducentes. Sera 
preferivel lancar urn programa especial de duraçao limitada para apoiar os 
cientistas merecedores no dominio da biomedica nos paises da Europa que sao 
actualmente ma is fracos em biologia molecular mas que sao capazes de 
recuperar rapidamente. 
10. 0 programa de formacao parece, em geral, ter sido bem sucedido, 
recomendando-se a sua continuaçao. Podera, no entanto, ser necessario 
encontrar novos meios de divulgar as informacoes sobre o programa, uma vez 
que o numero de candidaturas foi muito inferior ao previsto. Deve-se ainda 
ter em conta que algumas alteracões do programa podem trazer grandes 
vantagens aos Jovens cientistas que trabalham no dominio da analise do 
genoma humane Urn dos problemas que se verifica em todos os paises europeus 
e o de dar apoio e independdncia aos jovens investigadores que mostraram 
ser cientistas de primeira categoria, no seu ou noutros paises. Nos Estados 
Unidos, os laborat6rios representam uma atraccao consideravel, dada a 
grande flexibiIidade da estrutura administrativa da maioria das 
universidades e, sobretudo, o impressionante numero de centros de 
investigaçao de primeira categoria em muitas delas. Torna-se cada vez ma is 
interessante para jovens europeus procurarem associar-se a laboratórios 
nesses centros por periodos ma is ou menos longos, normalmente durante os 
anos mais produtivos em termos de trabalho original. Hoje em dia, podem 
obter-se os melhores resultados da investigacao em biomedicina em centros 
de pequenas dimensoes. E necessario reconhecer que uma das importantes 
funcoes do financiamento e da organizacao da cidncia na Europa e a de 
contrabalancar os poderosos centros de investigacao de base em biomedicina 
nos EUA. Neste sentido, uma das sugestoes e a de se criarem postos para 
jovens investigadores independentes nas areas de investigacao biomedica que 
permitam aos Jovens cientistas altamente qualificados prosseguir o ramo da 
sua escolha numa universidade europeia sem estarem sujeitos as suas 
estruturas administrativas, muitas vezes demasiado "tradicionais". 
Juntamente com os postos de trabalho devem ser proporcionados fundos para 
material, equipamento e pessoal de investigacao. Estas estruturas deverao 





encontram no est rangeiro se voltem a interessar pela Europa. 
Os programas do ESLA sao componentes essenciais dos programas sobre o 
genoma. 0 painel recomenda, embora nao por unanimidade, que se prossiga com 
o ESLA e que seja dado urn apoio alargado. E importante fazer a maxima 
divulgacao do programa e fornecer aos candidatos as informacoes necessaries 
sobre que resultados se esperam. Uma 
programas ESLA sera a de criar meios 
cooperem, interajam e troquem ideias 
Devem igualmente ser feitos esforcos 
economicos das alteracoes teen leas e 
desequiIibrio geografico e outro dos 
componente urgente dos futuros 
para que os grupos de particlpantes 
e resultados. 
para Incluir no programa os aspectos 
da politica e estudo da ci6ncia. 0 
problemas que carecem de atenção. 
0 apoio a seminar!os e reunioes e, sem duvida, uma das principals 
componentes do PAGH, sendo recomendada a sua continuacao. No entanto, 
recomendam-se algumas alteracoes na sua administrate Sugere-se, por 
exemplo, que seja criado urn comite cientifico consultivo para dar pareceres 
sobre a politica do programa e seleccionar as candidatures. Deve-se 
procurar obter urn melhor equilibrio entre os temas que sao tratados nos 
seminár los apoiados pelo programa. O apoio dado, atraves do HUGO, a 
seminarios sobre urn unico cromossoma e essencial e deve ser mantido. Em 
geral, deve ser dado apoio aos seminarios sobre cromossomas realizados na 
Europa, como uma contribuicao para a organizacao. Deve igualmente ser dado 
apoio, na forma de ajudas de custo, para as viagens de particlpantes 
europeus nos seminarios que se realiam fora da Europa, bem como para os 
seminarios que congregam cientistas que trabalham no âmblto do PAGH sobre 
temas semelhantes (tal como já se fez anterlormente), por exemplo os que 
trabalham no EUROGEM ou com bancos de ADNc, o que Ira obviamente incentivar 
os contactos entre grupos de varios paises europeus. 
Outra vertente desejável do programa seria a formacao dos medicos a nivel 
de toda a Europa. Multos deles guardam da genetica uma lembranca traumatica 
do tempo em que estudaram nas faculdades. Com o rapido avanco da genetica 
medica, os nossos colegas encontram-se Ja numa posicao dlficil em relacão 
aos sous pacientes, que Ihes fazem perguntas diftcels. Os programas de 







The idea of mapping and sequencing the human genome was widely discuss in the mid 1980s. 
These discussions culminated in proposals for human genome programmes in a number of 
European countries as well as in USA and Japan. The aims of most were identical: to produce 
detailed maps of all 23 chromosome pairs, in order to make it easier to find, sequence, and 
study the genes. There was a further commitment to support technology development, in order 
to address the long-term aim of sequencing the whole genome. It was also generally agreed 
that the Human Genome Project, as it is often called, should be a global collaborative effort. 
2. HISTORY 
In 1987 the Council of the European Communities decided 'that, within the second Framework 
Programme for community activities in the field of research and technological development, 
there should be initiated, under the heading "Health in the "Quality of Life" section, new 
activities relating to the development of knowledge of human genome. 
In July 1988 the Commission presented a "Proposal for a Council Decision on a specific 
research programme in the field of health protective medicine; Human genome Analysis2. This 
proposal was given its first reading in the European Parliament in February 1989. Thirty eight 
amendments were adopted by the Eruopean Parliament most of which dealt with the 
justification in the proposal and, to a great extent, with possible misuses of the long term 
results. In relation to the public concern expressed mainly in Germany but also by the 
European Parliament, Vice President Pandolfi, Commissioner responsible for research & 
Technology, introduced a delay at this stage. In November 1989 a modified proposal, 
incorporating 16 of the Parliament's amendments and accommodating to some extent another 
10, was submitted by the Commission to the Parliament. With very minor modification, this 
text became the basis of the Council common position adopted in December 1989. Following 
the second reading in Parliament in May (at which a further 6 amendments were proposed), 
the programme was finally adopted by the Council on June 29, 1990s. 
The most notable change was in the title, "predictive medicine" being omitted. 
The 2 years which had elapsed since the programme was first mooted had been put to good 
use by an ad hoc Working Party on Human Genome Analysis first chaired by Professor P 
Pearson (NL) and later by Professor M Ferguson-Smith (UK) (Appendix I) This Working 
Party set up 6 Study Groups (Appendix II). 
'Council Decision 87/516, Euratom, EEC of 28/09/1987 
OJ N° C27. 2.2.1989, p. 6 and OJ N° C302, 12, 1989, p. 18 
'Council Decision 90/395/EEC of 29/06/1990 
i) Genetic mapping 
Chairperson: Professor M Ferguson-Smith 
iO Physical mapping (ordered clone libraries^ 
Chairperson: Professor J-L Mandel 
iii) Data handling and databases 
Chairperson: Dr C Frontali 
'Council Decision 90/395/EEC of 29/06/1990 
iv) Advanced genetic technologies 
Chairperson: Professor L Bolund 
v) Training 
Chairperson: Professor P Pinho de Costa 
vi) Ethical, social and legal aspects 
Chairperson: Professor E-L Winnacker (D) followed by Professor M Niermeijer (NL) 
Based on the reports of the first five of these groups, the Working Party produced a work 
plan. Budget subdivisions were also suggested; a plea was made for a specific allocation to 
data-handling and data bases, which was taken up by the Commission and endorsed in the 
Council decision. A "final" report was submitted to the CG C in June 1989. It was expected 
that the programme was about to be adopted. However, the work then continued into the first 
half of 1990. During the latter phase, the Working Party conducted a survey of "resources" 
in Member States, in preparation of the setting up of the Resource centers and networks of 
laboratories foreseen in their report, with the following results: 
-EUROGEM52 laboratories contacted 
28 expressed interest 
-YAC libraries 4 libraries offered 
5 offered to screen libraries 
-cosmid libraries 2 replies 
-cDNA libraries3 groups expressed interest 
-data resource 2 laboratories expressed interest 
The 2 year programme came into being on June 29, 1990, with a budget allocation of 15 
MECU, 3 of which for 1990. Under the system of annual budgets imposed by Parliament, this 
3 MECU had to be allocated by December 1990 or would be lost from the programme. Given 
the difficulties encountered in the administration process, it would have been unwise to 
attempt to launch a call for proposals before the programme Advisory Committe (CAN-HUG) 
had met; this could not be arranged before September. The CAN and the Commission faced 
a dilemma; there was clearly insufficient time for an open call, peer review, contract 
negotiations etc. However, unless contracts could be concluded by December 3 MECU, 
amounting to more than 25% of the total sum available for the research contracts, would be 
irrevocably lost The CAN and the Commission agreed that a limited call, restricted to the 
provision of resource centres and participation in the EUROGEM network, should be directed 
to those laboratories which had responded to the ad hoc Working Party's enquiries. This was 
done and, in the light of advice from experts and the CAN, contracts were signed for 8 
Resource Centres and the participation of 23 laboratories in the EUROGEM network. The 
CAN agreed, in all cases, to err on the side of inclusion rather that exclusion. 
The first task of the Advisory Committe (CAN/HUG) was to advise the Commission on the 
open call for proposals, which was launched in October 1990 (deadline for applications was 
January 10,1991). Forty-eight proposals for transnational research projects were received and 
after peer review, and comprehensive discussion with CAN-HUG, 14 of these projects were 
funded. An indicative distribution of funds between the various areas of the programme was 
included in the Council decision. However, this was altered on the strong advice of CAN-
HUG, recommending that none of the proposals for transnational research projects on data 
handling and databases should be supported, although they advised that the Data Resource 
should be supported and that the remaining funds should be transferred to physical mapping, 
where there had been a large number of good proposals. A reserve list was also established 
in the event a further 0.6 MECU was made available by the Parliament which would allow 
3 more proposals to be funded. The final distribution of funds was as follows: 
Genetic map3.3 
Physical map4.3 
Data handling and databases2.3 
Advanced genetic technologies!. 8 
Training activitiesl.9 
Ethical, social, legal aspectsl.O 
Administration 1.0 
TOTAL15.6 
A separate, open Call for Proposals for studies on the ethical, social and legal aspects was 
launched on August 14, 1991 (deadline November 4, 1991). Forty-eight proposals were 
received and after peer review and discussions with CAN-HUG 18 were funded. 
3. THE REQUIREMENT FOR EVALUATION 
The requirement for evaluation is laid down in Article 4 of Council Decision 90/395/EEC of 
29 June 1990 adopting a specific research and technological development programme in the 
field of health: human genome analysis (1990 to 1991) The same Article specifies that the 
evaluation shall be carried out by independent experts and published in the form of a 
communication to the European Parliament and the Council. Further it indicates that this 
communication shall be established having regard to the objectives and evaluation criteria set 
out in Annex II of this Decision (Appendix HI) and in accordance with Article 2 (2) of 
Decision 87/516/Euratom, EEC (Appendix IV) 
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5. SOURCES OF INFORMATION 
The panel received a number of documents from the Commission which covered the nature 
of the programme itself and the evaluation criteria. The list of all the documents submitted 
to the list the Panel is given in Appendix V. Giving the timing of evaluation, very few 
progress reports were available. The Panel then decided that in addition to the written 
information they would interview some of the contractors of the different projects as well as 
visit some centres involved in the programme. A list of the contractors interviewed and of the 
centres visited is given in Appendix VI. 
Most of the leaders of the ESLA projects were interviewed by Dr Latour over the telephone. 
Dr Bertrand Jordan participated in some of the panel meetings and provided very valuable 
information about the worldwide ongoing genome efforts. The panel is grateful to Dr Jordan 
for useful discussions and for providing a very valuable report which was used in preparing 
this document. 
6. HUMAN GENOME RESEARCH IN A WORLDWIDE PERSPECTIVE* 
Below is a description of the present state of the four major components of genome 
programmes: genetic mapping, physical mapping, sequencing and informatics. 
6.1 Genetic mapping 
The concept of a general genetic map of the human genome based on DNA polymorphisms 
is only a little over ten years old, but the * construction of such a map has made tremendous 
progress since it was first proposed. Optimism was high in the mid to late eighties, with the 
publication in 1987 of the first comprehensive genetic map having an average spacing of 10 
to 20 centimorgans. Prediction of, and planning for, a 2 centimorgan map by 1991 or 1992 
was incorporated, for example, in the US genome programme. Progress turned to be slower 
than anticipated, both because of the amount of work required and because of the rather 
uninspiring nature of the day to day effort involved and of a certain lack of interest by 
funding agencies. It was also felt, in some circles, that large-scale physical maps based on 
pulsed field gel experiments and using "linking clones" were around the corner, and that they 
would make much of genetic mapping obsolete. 
However, it was soon realized that physical maps would have to be based on contigs of 
cloned DNA segments to be really useful - and that this was not going to be easy. It also 
became apparent that in any case a complete and detailed genetic map with high quality 
* extracted from the report "An assessment of progress in human genome programmes worldwide", written by 
Dr B. Jordan; see pp. 51-71 of this report 
landmarks was, and would remain, essential to the positional cloning ("reverse genetics") 
approaches. More polymorphic markers were found, first minisatellites or VNTRs, later the 
microsatellites - so that by the time Southern blotting was more or less automated RFLPs 
were no longer the main genetic mapping tool. Generation of large numbers of microsatellites 
is going ahead in a number of laboratories, and the first whole-chromosome, and even whole-
genome, genetic maps based solely on microsatellites have already been published. Data 
capture and analysis using this system remain too cumbersome, and ways are being found to 
efficiently multiplex the assay of microsatellitepolymorphisms and to call the results more or 
less automatically. Throughout this stage, as well as the preceding one, the general availability 
of the CEPH panel of families as DNA samples has played an important and very positive 
role. 
Two general maps have been published late in 1992, the one produced by collaborating groups 
using the CEPH panel (NEH/CEPH collaborative mapping group, 1992) and a "pure" 
microsatellite map obtained by Jean Weissenbach's laboratory at Genethon. Although less 
detailed (814 markers instead of 1416), the Genethon map is both more reliable (being 
constructed by a single group rather than assembled from many different sets of data) and 
more useful since it is exclusively based on highly polymorphic markers. 
The software available to perform genetic analysis has made good progress (aided of course 
by the very large increase in computing power per dollar) and is now able to tackle difficult 
problems including the search for genetic components in multifactorial diseases such as 
diabetes or hypertension. Input of data, however, remains a largely manual and error-prone 
procedure which should be automated if at all possible or at least made much more user-
friendly. 
It now appears quite feasible to generate a density of highly polymorphic markers equivalent 
to one per centimorgan. This does not mean that it will be easy to order all of them with 
respect to each other, since at such small recombination fractions the search for individuals 
with recombinations in the interval becomes the bottle neck. It may however not be necessary 
to do this by genetic means, since efficient cytogenetic methods (interphase mapping, or even 
in situ hybridization to highly decondensed chromosomes) may be able to do this much more 
quickly. A recent variant of "sperm mapping", in which the whole DNA of a single sperm is 
first amplified with random primers thus making it possible in later stages to assay many 
markers on the same haploid DNA complement, may also become very significant. Thus it 
seems very likely that a high-resolution genetic map of the human genome will be available 
in the near future 
6.2 Physical mapping 
At the beginning of genome programmes the concept of whole chromosome physical maps 
based on pulsed field gel analysis of Not I cut genomic DNA complemented by a complete 
set of the corresponding linking clones (segments of DNA containing the rare Not I sites and 
a few kilobases of DNA on either side) was entertained by several groups. It soon became 
clear that this approach suffered from serious technical difficulties and shortcomings, and that 
a really reliable and useful map of a whole human chromosome had to based on a complete 
set of overlapping cloned DNA segments. 
Contig building across human chromosomes was initiated, in particular for chromosomes 16 
and 19 at Los Alamos and Lawrence Livermore. This rather heroic undertaking (it takes 5,000 
to 10,000 cosmids to cover a chromosome) was pursued until coverage reached 60 to 70%, 
and benefited from the arrival of YACs which made closure possible, as has been the case for 
the nematode genome. The extensive investment in cosmids was not a complete loss since, 
in practice, it turns out to be very useful to have a "cosmid layer" underlying a YAC contig 
map; cosmids provide DNA in a form which is very amenable to further experiments such as 
looking for genes and sequencing. 
Chromosome-specific YAC libraries are in principle an important resource for the construction 
of a physical map: alignment of the few hundred large YACs needed to cover an average-
sized chromosome should be almost trivial compared to the equivalent endeavour with many 
thousands of cosmids. They can be obtained the hard way, by making a library from a suitable 
human-hamster hybrid cell line and subsequently screening for the few per cent of human-
specific clones, as done in Saint-Louis for the Xq24 to Xq28 library. Attempts to make such 
libraries from sorted chromosomes have given some promising results but have so far failed 
to provide complete libraries. The alternative route of "extracting" chromosome-specific 
components from a whole-genome YAC library is much more appealing, and recently two 
groups have reported success in doing this using as a mixed probe sequences derived from 
a chromosome-specific cosmid library or from a somatic hybrid. 
It is now generally accepted that the primary whole-chromosome physical maps will be based 
on YACs, in spite of the problems with chimeric clones, at least until some better vector 
comes along. Physical mapping of chromosomes 7 and X has been pursued in Saint-Louis, 
using "STS content mapping" and the whole genome YAC library. This approach relies on 
defining about one thousand STS per chromosome and then assaying YACs with the 
corresponding oligonucleotides. Positive YACs usually contain two or three such STS and can 
be overlapped with their neighbours by looking for the common STS. This very robust 
approach is work-intensive but reliable. Daniel Cohen's group at Genethon has used a 
somewhat similar STS content method to construct the complete chromosome 21 map, and 
a more adventurous fingerprinting technique to build contigs simultaneously over the whole 
genome. The latter project, which uses the high-capacity blotting machines installed at 
Genethon, appears well on the way to produce a nearly continuous contig map of the whole 
genome. 
Thus YAC-based physical maps of many whole chromosomes will soon be obtained. These 
maps can be tremendously useful to the whole community, particularly if they together with 
the underlying reagents, are made available in a convenient format. In this respect, the 
example set by the nematode community is worth considering. The LMB laboratory provides 
so-called "polytene filters" which contain a complete set of YACs ordered as they occur along 
the six nematode chromosomes. A similar scheme could be used to make available maps and 
reagents for each of the human chromosomes. 
6.3 Sequencing 
When genome programs were first discussed in the mid-eighties, it was generally expected 
that sequencing technology would progress rapidly and that megabase sequencing at prices 
well below one dollar per base was just around the corner. Such progress has not occurred; 
instead several megabase sequencing projects initiated in the late eighties and aiming at 
obtaining one or several megabases of sequence have failed to deliver the expected results. 
The traditional sequencing method has been automated in part or (in Japan) in toto. but 
throughput in the latter case cannot yet be assessed; multiplex sequencing, a very rational 
approach, has run into serious difficulties with handling of the huge amounts of data 
produced. Exotic methods based on microscopy have generated much initial excitement but 
have not yet demonstrated feasibility; the same is true for very fast techniques based on single 
molecule degradation and extremely sensitive analysis of single bases. Sequencing by 
hybridization is closer to a real-life feasibility demonstration; it certainly holds a lot of 
promise for detection of mutations in known genes and may well develop into the 
megasequencing method of the late nineties. Efforts must be continued, since only radically 
new technologies are capable of bringing speed up, and cost down, by the one or two orders 
of magnitude necessary to make sequencing of whole genomes a realistic task. 
Current results show that it is indeed feasible with present technology to sequence a few 
hundred kilobases, up to at least one megabase, at a cost in the order of one dollar per base. 
In this respect the model for near-future megabase sequencing appears to be the Nematode 
operation rather than the EEC yeast effort which has been useful and worthwhile but very 
expensive (i.e. close to ten dollars per base): sequencing will in the future have to be divided 
in larger chunks between a smaller number of centres. Sequencing at this cost is certainly 
worthwhile for model organisms with small genomes such as E. coli, Bacillus subtilis or even 
yeast. As genomes get larger and less densely populated with genes, the answer becomes less 
obvious. In the human system megabase-sequencing can only at this point be considered as 
a model experiment: sequencing a few 1-2 megabases long, particularly "interesting" regions, 
to find out how such sequencing produces results in a genome very rich in repetitive 
sequences, how efficient present algorithms are at finding genes in such DNA and whether 
anything unexpected comes out of such massive experiments. It will then be easier to decide 
whether, and how, to proceed. 
Massive and partial cDNA sequencing was proposed several years ago, in particular by 
Sydney Brenner, but the most publicized implementation of this strategy occurred in USA. 
The approach has turned out to be quite effective at finding "new" genes, and provides partial 
sequence data on several thousands of hitherto unknown genes. It is practiced in a number of 
laboratories outside the USA, including the HGMP resource centre in Harrow, the Genethon, 
the Osaka Institute of Molecular and Cellular Biology and others. Some scientific questions 
remain open: how effective is the approach at finding all, or even a significant fraction, of the 
existing genes? For example, one may wonder how many of the 182 chromosome TH genes 
in yeast would have escaped detection by this approach. Another issue is the localization of 
the "new" genes revealed by this approach: even simple chromosome assignment is, at this 
time, very cumbersome and new methods are badly needed. As these exercises continue, the 
question of real time data availability becomes more and more important, to avoid duplication 
of effort. This has two aspects: data must be comparable, i.e. laboratories should agree to 
sequence the same region of cDNAs (5' or 3'), and it should be deposited and made accessible 
very quickly. Finally, of course, the vexing problem generated by attempts to patent these 
partial sequences should be resolved, ideally by a general decision not to indulge into such 
exercises. The recent negative ruling by the US patent office is a big step in the right 
direction although the issue is far from closed yet. 
A problem with the cDNA approach is that it may be difficult to convince anyone to produce 
the complete sequence after the first "glamerous" discovery has been made. 
Discussion on the relative merits of these two approaches are heavily dependent on the 
organism considered and on the cost of large-scale sequencing. Under present conditions (one 
to two dollars per base) sequencing of genomic DNA definitely makes sense for small 
genomes, up to a few megabases: a S megabase (E coli) or even 15 megabase (yeast) 
sequence is clearly feasible, and the wealth of information provided (as shown by the recent 
nematode and yeast results) justifies the relatively high price of the exercise. The high gene 
density found in these organisms reduces the saving which could be achieved by going the 
cDNA way. 
For larger genomes with intron-containing genes (such as the 100 megabase nematode 
genome) the question becomes more debatable. For the human genome, if one takes the 
presently accepted upper limit for the number of genes of 100,000, and allows l.S Kilobases 
of coding sequence per gene, one ends up with an exon content of 5% - a figure which does 
make cDNA approaches attractive. So far large human DNA sequences do not appear to 
contradict current estimates of gene density - but the sample is too small to be representative. 
In any case, if cost can be brought down to below 0.1 dollars a base by new techniques or 
by very efficient implementation of present methods, a whole chromosome could be 
sequenced for a sum of the order of 10 million dollars, i.e. roughly the amount previously 
budgeted for the physical map of such an entity in the US genome programme: large-scale 
sequencing would become irresistible. 
Informatics has been recognized from the start as a very important component of genome 
programmes, and has been funded accordingly, in particular in the USA. Significant progress 
has been made, but the situation is still far from satisfactory because of the exponential 
growth in the amount of data and the bewildering variety of tasks which need to be addressed. 
6.4 Databases 
Several genome databases have been established to cater to the growing needs of genome 
mappers. In addition to the familiar DNA sequence databases (EMBL and Genbank), there 
are systems storing all kinds of human mapping data (GDB), information on the mouse 
genome (GBASE), clinical description with mapping results (OMIM, GENATLAS) to name 
but a few. In principle these systems only store "public" data, either already published or 
adequately verified by expert inspection and released for general distribution. Thus the data 
is in most cases quite reliable, but often lags behind recent work. It would probably be very 
useful to display provisional data (flagged as such), since such non-verified results often 
provide very useful hints to others. 
Databases have been developed over the years using a variety of database structures: IRX for 
OMIM, SYBASE for GDB and GENATLAS, INGRESS for GBASE... Each of these systems 
has its own query structure and its particular quirks; their only standard feature is their lack 
of user friendliness, which makes it relatively difficult for the average biologist to use them. 
A rising star in this world of databases is the Nematode system, ACeDB ("A Cenorhabditis 
elegans Data Base) which is winning over scientists from other fields thanks to its 
performance and ease of use: the system is now used for the Arabidopsis programme 
(AAtDB), by some Drosophila groups, and it constitutes the front end of the Integrated 
Genome Database (IGD) being developed at the DKFZ in Heidelberg. 
Because of the complex nature, of the variety of data stored and of the many ways in which 
links can be established between different kinds of information, these databases are normally 
used on-line. Accessing them requires not only a local computer (which is easy), but also a 
high-speed link to the database itself or to one of its secondary nodes, and sufficient local 
network expertise to actually establish the connection in a reliable way. While the high-speed 
link situation is relatively satisfactory in most of the US, it is definitely not so in the rest of 
the world. Using a database such as GDB with transmission speeds below 9600 baud is 
essentially hopeless. 
The growing power and dropping price of microcomputers and Unix workstations, in 
conjunction with these transmission problems, is causing a shift towards systems in which a 
local, periodically updated version of the database is used. 
Computerized laboratory notebook systems are often discussed, but few groups actually 
implement and use them. Yet the need is obvious: even partial automation leads to a large 
increase in the number of objects handled in the laboratory, thus rigourous and efficient data 
organization and storage become absolutely essential to avoid a disaster. But the development 
of such a system for the average group is not easy, as it makes great demands on flexibility 
and user friendliness, not to mention raw computing power and storage space. Only fairly 
large groups organized around a common task seem to succeed in this endeavour, for example 
the Lawrence Livermore group which has set up a sophisticated and relatively easy to use 
system to record and follow progress on its cosmid fingerprinting and contig building work, 
or the Genethon team for their whole-genome contig building task. Such large groups end up 
building local databases which must then be able to communicate with the "general" 
databases. 
Comparing a sequence to all known sequences is a task whose complexity increases 
exponentially with the number of known sequences. In spite of the very rapid growth of 
computing power per dollar over the past decade, it is not certain that computers will keep 
up with the increasing flow of data. New algorithms are being perfected, and massively 
parallel machines, using dedicated hardware chips, may be the answer. Finding exons in a 
large genomic DNA sequence is still a vexing problem, as shown by the difficulties 
encountered in interpreting a recent 106 Kilobase genomic sequence from chromosome 19; 
the algorithm used found less than half of the exons subsequently detected by other methods. 
More work is clearly needed in this area. 
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Communication between biologists and computer scientists remains imperfect: they still 
belong, by and large, to two quite different cultures. Both fields have been evolving very 
quickly in recent years, and few individuals have real dual competence. 
6.5 Instrumentation 
Newcomers to recombinant DNA laboratories, and even to genome centres, are often appalled 
by the predominance of manual work. Most procedures are performed by hand, machines 
being used only for a few specific steps. Even DNA "sequencers" only automate a small -
albeit vital - part of the sequencing procedure. In fact, even in most specialized genome 
centres, manual work still predominates. Few laboratories, for example, have completely 
automated cosmid preparations; construction of YAC libraries still involves lengthy and 
tedious hand picking of clones into microtiter plates; and apart from a few pipeting robots (in 
most cases the Beckman Biomek machine, originally developed for Elisa assays) there are 
very few commercially available robots around. Exceptions exist, the foremost being Hans 
Lehrach's operation at the ICRF, the "Genethon" centre set up near Paris. Another case, 
however not yet functional - is the HUGA "sequencing factory" in Tsukuba. But on the 
whole the penetration of instrumentation and robotics has been disappointingly slow in 
laboratories implementing human genome programmes. 
This unfortunate state of affairs reflects some very real problems. Recombinant DNA 
technology is still in a state of flux: thus a manufacturer's decision to develop an instrument 
automating a certain procedure entails a very serious risk: the probability is high that by the 
time the instrument is ready to be marketed the procedure will have become obsolete. The 
"Labimap" Southern blotting machine has just been marketed, more than four years after the 
programme started, and by now PCR has replaced Southern blotting in most of its 
applications; likewise the HUGA set-up is based in part on obsolescent sequencing 
technology. In addition genome research, even today, is a relatively small sector: the market 
for a hypothetical high-throughput sequencing machine capable of reading 500,000 bases per 
working day is likely to be quite small - unless the resulting sequence is very affordable. 
Other, more "cultural" reasons hinder progress: most biologists are not very instrument-literate, 
and the race to a publishable result does not lend itself to careful investment in new 
technology; and communication between robotics specialists and biologists suffers some 
problems - as with informatics. 
There are, however, some signs of progress. ABI has sold more than 1 000 sequencers world-
wide, even though they are not all in actual use; semi-automated procedures based on the 96-
well microtiter plate are becoming more common; and instrument literacy, as well as 
computer knowledge, is increasing among biologists. Genome programmes have had a positive 
effect, by providing both the incentive and the funds for at least partial automation; and the 
demonstrated success of some groups in performing some routines by machine is now 
tempting smaller, more conventional laboratories to do the same. Concurrent increases in 
computing power per dollar for small computers make it easier to automate complex 
procedures: mechanical precision can be substituted by software sophistication - an 
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increasingly available commodity. Numerous opportunities exist in this field, both for research 
groups to operate more effectively and for astute companies to generate profits. 
7. EUROPEAN INVOLVEMENT IN HUMAN GENOME RESEARCH 
It is difficult to draw conclusions in such a study at a time when events are moving so 
rapidly. Clearly the balance has shifted in recent time towards Europe, with the success of 
enterprises such as yeast whole-chromosome sequencing, whole genome physical maps and 
refined genetic maps. Agencies in the US have, as usual, been quick to assess the new 
situation and to launch new centers incorporating some of the features of Genethon and in 
attracting the CEPH MegaYAC library to the other side of the Atlantic. It is clear that HGAP 
has played an important role in capitalizing on this - possibly temporary - success to establish 
a more balanced relationship with the USA. It is, however, also clear that strong programs 
such as the one supported by AFM in France have been an important driving force. 
The European engagement in various activities is summarized below: 




Microsatellite-based genetic mapping 
Making genome data bases more user-
friendly 
moderate to significant 
low, although significant 




8. EVALUATION OF EUROGEM AND THE RESOURCE CENTRES 
The resource centres were established to improve the infrastructure of the HGAP in Europe, 
by delivering specialised services. The program included the following activities: 
a) One resource centre included the CEPH in Paris and the ICRF unit in South Mimms, 
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UK. These comprise centralised facilities supplying 22 network laboratories with the 
resources for linkage studies (DNA, filters, probes and primers). The resource centres 
and the network laboratories are expected to produce new genetic markers and a high 
density linkage map of the human genome. 
b) Resource centres were established to produce and distribute chromosome specific 
cosmid libraries and ordered YAC libraries to research groups interested in screening 
such libraries as well as to organise databases which will integrate information about 
the probes and clones obtained from these libraries. One resource centre for cosmid 
libraries and 5 for the screening and distribution of YAC clones have been established. 
c) Resource centres for cDNA libraries were also established; a consortium of four 
laboratories was formed to provide normalised cDNA libraries and services. 
d) A central facility for computing services was established in Heidelberg 
e) A Danish family bank, comprising cells and information about 1000 families was 
established as an instrument for genetic analysis of normal traits. 
The EUROGEM Network and Resource Centres seem to be fulfilling their commitment of 
positioning about 1000 genetic markers on human chromosomes in the 24 months the program 
has run. From the scientific report of the Probe Resource Centre it is not possible to establish 
how the remaining part of the program has run. A genetic map is not yet available but all the 
markers could be mapped within the remaining time of the program. The main drawback of 
the EUROGEM program seems to have been the decision to use RPLPs and filter 
hybridisation, failing to foresee that genetic maps can be constructed more quickly and 
efficiently using microsatellites. The project has thus been surpassed by other projects, 
microsatellite-based, mainly the Genethon project. The Resource Centres and the Network 
laboratories have now switched to use the microsatellites developed at Genethon and already 
mapped at Genethon using 8 CEPH families only. This seems a wise decision and will 
produce an informative and precise genetic map. Since many more (2-4000) microsatellites 
have been produced by Genethon and are being mapped on the CEPH families it may be 
useful to continue this collaboration to complete the human genetic map within the next one 
to two years. Once the first map will be completed, the remaining regions, where fewer 
markers have been localised by the random approach of Genethon, will have to be completed: 
this could be accomplished by ad hoc programs and this may be pursued in a future HGAP 
with open calls for proposals. 
At the time of this report, cosmid, YAC and cDNA resource centres have all been working 
for some time. Cosmid libraries for chromosomes X and 21 were intially available for 
screening by filter hybridisation at the ICRF but have since been expanded to include other 
chromosomes. YAC libraries can be screened by PCR or by filter hybridisation at the 
screening centres. Not all the centres have all the available libraries: the StXouis library has 
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not been aquired by the Pavia Centre, and the ICRF library is not available to other Centres. 
All Centres have the ICI library and all have now acquired the CEPH MegaYAC library 
which has been distributed recently. 
A final decision on a common database has not been taken: at the ICRF, a data base already 
exists for cosmids and YACs screened in house and could also store data from other centres. 
An important role for the screening centres has been the technical support to laboratories 
without large experience in the specific field which in addition to the screening may obtain 
help in related techniques for yeast cultivation and analysis of clones. The YAC- and cosmid-
library resource centers that have been sponsored by the current HGAP have been of 
immense value to European scientists, interested in gene mapping. 
Less information has arrived to the panel on the cDNA resource centres: normalised libraries 
have been prepared for a number of tissues and a large numbr of cDNAs have been sequenced 
by some of the groups. The Genethon group seems to have sequenced the largest number of 
cDNAs from commercially avaialble libraries which unfortunately have been found to be 
contaminated with sequences from other organisms. However, EC funding has been a small 
percentage (less than 10%) of the support received by the group. Difficulties for the 
consortium may also have derived from the cDNA patenting issue. The services offered by 
the cDNA resource center may have been exploited less than other resources, but they are 
likely to become very relevant in the future, when many YACs and cosmids will be ordered 
in contigs. The experience obtained in the first HGAP may therefore be used profitably. 
The data resource for human genome research in Heidelberg has operated as support for 
research as well as to develop new software for genome mapping. The EDR provides on-line 
access to major analysis tools and packages. This includes the HUSAR package, for sequence 
analysis, the LINKAGE package for genetic mapping, the ICRF package for physical 
mapping and others. An open software system was developed, IGD, to handle human 
genome data. As for other resource centres, among the activities was the organisation of 
training and workshops. The centre might have been more used if computer connection with 
Germany had been of better quality. This problem has probably discouraged potential users. 
It seems, however, that the computer connections with Germany are likely to improve in the 
near future. 
The resource centres seem in general to be a very important and useful support for the 
HGAP. 
9. EVALUATION OF TRANSNATIONAL RESEARCH PROJECTS 
The program included 6 projects on physical mapping of regions from chromosomes X, Y, 
21 and 22. The other 11 projects concerned the improvement of methods and basis for the 
study of the human genome. 
The small number of transnational projects funded reflects to a large extent the human genome 
projects going on in Europe at the time of the call for proposals. The scientific qualifications 
of the groups which have received support are in general quite high and the results obtained 
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are therefore of good quality. It is, however, difficult to make an evaluation of individual 
projects due to the lack of progress reports. Some information could, however, be extracted 
through interviews with a limited number of the project leaders and from some reports that 
were avialble. Many of the projects are known from publications. 
In addition to the scientific results several important goals have been obtained as a result of 
HGAP: 
1) An important goal of the transnational project was to stimulate new collaborations 
among European laboratories. This seems to have happened in many cases. In addition, 
the availability of funds for a common goal may have strengthened already existing 
collaborations. It appears that collaborations based on previous scientific contacts were 
much more successful than those based on newly established links. 
2) A second goal was the development of new technologies for genome research. Projects 
included mapping, sequencing, cDNA normalisation, in situ hybridisation etc.. Some 
interesting projects were included in this part of the HGAP and in many instances 
significant improvements of the existing technologies have been accomplished (e.g. 
sequencing, new mapping techniques based on chromosome deletions etc.) 
10. EVALUATION OF THE TRAINING PROGRAM 
Fellowship grants and specialised courses were regarded as an important instrument for the 
distribution and the utilisation of knowledge and technological applications stemming from 
human genome research training, i.e. fellowships and courses. A budget of 1.9 
MECU was earmarked for this task. 
The Commission services and the Advisory Committee (CAN-HUG) agreed that a prerequisite 
for a fair and equal selection of trainees was widely available information to young scientists. 
Therefore, prior to the first selection round opportunities for training were advertised in 
Nature. 
There were three rounds for the selection of trainees: 
Selection round 1 (July 1991): 15 applications 
Accepted for support: 9 candidates (origin 2 D; 2 E; 2 F; 2 I; 1 NL) 
Location of host laboratories: 2 B; 1 D; 2 F; 4 UK 
Selection round 2 (October 1991): 18 applications 
Accepted for support: 10 candidates (origin: 4 D; IE; 2 F; 1 GR; 2 I) 
Location of the host laboratories: ID; 4 I; 5 UK 
Selection round 3 (May 1992): 16 applications 
Accepted for support: 8 candidates (origin: 1 D;3 E;l F; 
1 GR; 1 I;l P) 
Location of host laboratories: ID; 1 F; 6 UK 
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It was the opinion of the selection committee (Professors: Gannon (IRL), Hanoune (F; he did 
not participate in the last meeting), Maniatis (GR) and Dr. Rodriguez de Cordoba (E) that 
sufficient funds were available to give support in all cases where the candidates met the 
required high scientific standards and a good work programme relevant to the scope of the 
HGAP was presented. Indeed they were disappointed that more candidates had not applied, 
particularly from areas where the relevant techniques are less developed. 
Selected candidates received a bursary for a maximum of two years to learn new techniques 
with a view to continue a scientific career. A bench fee was given to the host laboratory to 
provide for materials but could also be used for travelling in order to enable the trainees to 
participate in international scientific conferences. 
A more targeted support, exclusive to candidates from countries in the Mediterranean 
(inclusive of Portugal) was provided through support for summer courses. Candidates were 
selected with the help of the same selection committee. However, only the Advanced Course 
on Molecular Genetics, (Leiden May 31 to June 5 1992) was considered for support. Travel 
expenditures and accomodation for 4 participants (two from Greece, one from Italy and one 
from Portugal) were reimbursed by the Commission. (Additional support to other courses was 
made available through Commission resources outside the programme). 
In addition to the implementation of procedures as foreseen in the Council Decision two 
important modifications were discussed by CAN-HUG: 
-The specific requirement to spread more sophisticated methods of 
human genome analysis throughout Member States would justify a deviation from the general 
principle of awarding bursaries only to scientists. It was suggested that support also could 
be given for the training of technical staff. 
-Well trained scientists would contribute significantly to the establishment of new technologies 
in their home countries. Therefore it was recommended that a bursary should be continued for 
up to 12 months after the two years spent abroad. 
It is the opinion of the evaluation panel that the training program is an important aspect of 
the HGAP and that it has been implemented successfully. Given the general need for post-
doctoral support it is surprising that the number of applicants was so small. In the future all 
possible efforts ought to be made to spread information about the fellowship program well in 
advance of the application deadline. 
The idea of providing support to the fellows after returning to their home countries seems 
worthwile and is encouraged (see also below) and the panel likes the idea proposed by CAN-
HUG that technical staff also could be included in the program. 
11. EVALUATION OF THE WORKSHOP ACTIVITIES SPONSORED WITHIN THE 
HGAP 
In the budget of the HGAP, 1 MECU were allocated for administration. Parts of this 
allocation have been utilised for the support of workshops. Altogether 29 workshops were 
supported between 1990 and 1992. Of particular importance is the support that is awarded to 
HUGO for the the single chromosome workshops. A particularly urgent part of the support 
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is given to European scientists as travel support ascertaining strong European participation in 
distant workshops. 
The panel was surprised that a very large fraction of the workshops dealt with ethical, social 
and legal aspects of HGAP. It also seems that the number of workshops that received support 
was very large and that the support given in each case usually was small (10 000 ECU or 
less) It may in the future be appropriate to be more selective and support the most urgent 
workshops to a greater extent Lastly the panel was surprised to learn that decisions about 
workshop funding in some of the cases were made by the administrator of the program. It is 
recommended for the future that a peer review committe is established which makes decisions 
about policies regarding the future workshop program and which also screens the applications 
for support Such a committe has, for instance, been established by EMBO which has a 
workshop program, similar to that of the HGAP. 
12. EVALUATION OF THE PROGRAM ON ETHICAL. SOCIAL AND LEGAL 
ASPECTS 
The ESLA program is a significant component of HGAP. It was unfortunate that the grants 
were only awarded for a period of one year. It is the opinion of the evaluation panel that the 
EC got a lot for its limited amount of money; the reports, even if they are somewhat unequal 
in quality represent a useful first attempt at the immense array of problems that the human 
genome initiative raises. By social science standards, the reports represent an impressive 
collection of information and research trails. Those first studies support the view that 
producing a genetic map of the genome is only one part of the initiative and that the biggest 
problems will be in transforming those technical possibilities into full scale medical practice. 
If the scientists involved in genome research believe they will be through once the technical 
problems have been solved they have to brace themselves from deep disappointments. 
It is striking from the reports that there is no basic opposition to most of the aspects of the 
genome initiative from the general public; in other words, there is no major confrontation 
between technology on the one hand and ethics on the other; on the contrary the public seems 
sometimes to be more daring than the medical practitioners. This does not mean that the 
transformation from technical possibilities to medical practice will be easy. 
The panel was surprised by the uneven geographical distribution of the ESLA projects. 
Particularly the almost complete absence of France from the program was unexpected. This 
might be due to lack of interest rather than poor advertising of the program. Another 
unexpected finding was the absence of projects dealing with economical issues. 
The complete absence of questions related to science policy was another astonishing 
observation. This is unfortunate since science policy is one domain that should closely link 
the social and the natural sciences. Lastly the absence of the "science studies" which could 
provide us with first hand detailed empirical results on the practice of natural scientists and 
medical practitioners and on their way of handling the social, ethical, economical and 
philosophical aspects of their own technical work. Instead too much of the reports include 
bibliographic searches or purely philosophical surveys that lack empirical assesment of how 
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the scientists and physicians apply the knowledge generated within the human genome project. 
13. INDUSTRY'S VIEW OF THE HUMAN GENOME ANALYSIS PROGRAMME 
This section was solicited from Mr Pascal Brandys, President and Chief Executive Officer, 
Genset, Paris and is presented in Appendix VII 
14. ADMINISTRATIVE ASPECTS 
The HGAP has been managed by a small staff with limited resources. It was the impression 
of the panel that the program administrators had done their very best to implement the 
program and to establish good contacts with applicants and later with the contractors. There 
was nevertheless many complaints regarding the bureacracy associated with the program. It 
was the opinion of several of the scientists participating in the present program that the 
amount of paper work required to apply for and to maintain funding in the present program 
was very considerable and outright disturbing. There were also severe delays in distributing 
the money after decision had been made about the grants. Although, it is clear that the 
problems sometimes arose at the national level, for instance when signing subcontracts, it is 
clear to the panel that there is substance in the criticism. It would, therefore, be important to 
seriously consider that the administrative process be simplified and that adequate time is 
allowed between the announcement of a program and the deadline for applications. It would 
be a much appreciated service to the scientific community, if one were to rectify 
administrative matters at the EC. 
Another administrative aspect that disturbed the panel was that the system of open 
applications and peer review was not always strictly practised. For instance, when funds were 
awaraded to the resource centers and the EUROGEM network a limited call for proposals was 
made. It is recognized that the time limit for the grant made it difficult to make an open call 
for proposals followed by evaluation by peer review. Nevertheless it was unfortunate that 
applications could not be selected in an open competition. It is to some extent understandable 
that such a selection procedure had to be employed, because the program was new, shackled 
somewhat by a tight and inflexible administrative structure and had suddenly to be launched 
within a very limited span of time. However, this procedure should not be repeated or serve 
as the model for future programs or planning. The panel must insist that, in the future, 
programs be generally announced in time and made available for application to the entire 
scientific community in the respective fields of research. 
Similarly, both for the selection and the evaluation procedures, the proven system of critical 
peer review must be strictly adhered to. 
An efficient peer review system, both during the screening of applications and in the 
evaluation of research accomplished, would safeguard against unjustified or exaggerated forms 
of critizism by fellow-scientists. 
Lastly the panel was surprised to find that progress reports from many of the programs were 
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lacking when the evaluation started. From the interviews it became apparent that many of the 
investigators were unaware of the fact that the deadline for submitting the reports was since 
long passed. It is urgent that the program administration in the future enforces strict deadlines 
for reports in order to facilitate the evaluation of the program. 
15. CONCLUSIONS 
The panel finds that the HGAP has largely become a success and is an important driving force 
in the field of European human genome research. Genome research is for the moment 
advancing with an extremely rapid pace. In recent years the progress has been particularly 
striking in Europe, with the success of enterprises such as yeast whole-chromosome 
sequencing, whole genome physical maps and refined genetic maps. It is clear that HGAP has 
played an important role to establish a more balanced relationship with the US. It is, however, 
also clear that strong programs such as the one supported by AFM in France have been an 
important driving force. The HGAP was approved with a two year budget of 15 MECU. The 
amount of money devoted to genome research by the EC is very small compared to the 
budgets of the genome programs in the US and Japan. The HGAP has therefore only 
supplemented ongoing national efforts and the weight of EC funding on individual programs 
greatly depends on the strength of the national programs. The EC has given a very minor 
support to large French groups (less than 10%), while it has been quite important for British, 
German, Italian and other European countries. The EC support would range from <5% to 50% 
of the total funding of each project. For the transnational projects, this kind of support can in 
most cases only have a modest impact and the potential for less well advanced countries to 
benefit from the transnational programs is limited. 
On the other hand, the establishment of the resource centres, and training programs is of great 
help to organised scientific laboratories as well as less advanced ones or less established 
groups. This is a very important aspect of the HGAP and in general in today's science since 
organisation and availability of resources are major issues. In this respect the HGAP has been 
very useful to the European genome research community, and this aspect should be stressed 
in the design of the future programs. 
The cDNA program in the current HGAP has not developed as fast as was hoped although 
quite a number of partial cDNA sequences have been generated. There will clearly be a great 
need for large collections of high quality cDNA libraries in the future. 
The ultimate goal of the global human genome project is the sequencing of the whole human 
genome. Large sequencing programs are presently not included in the HGAP. This situation 
should be rectified in a future HGAP. 
The transnational projects have been of importance for promotion of European collaborations. 
They have also provided means for small laboratories, particularly in less developed countries 
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to gain access to sophisticated technologies. 
The fellowship program is a very essential component of the HGAP. It appears to have been 
implemented in a satisfactory way in the past. 
It was recognized that the activities undertaken within the ESLA program had justification. 
However, the evaluation panel debated whether the program should be financed to the same 
extent as done in the past simply because there are limited resources and many pressing 
questions to be investigated. 
The already completed ESLA program can be regarded as a promising pilot study. The panel 
would like to emphasize that Europe offers unique possibilities for these kinds of studies due 
to the diversity in the health care and social programs that operate in the different countries. 
The workshop support has in the past been taken from the administration budget. Although 
CAN-HUG and the ESLA working group provided input into the program it seems to some 
extent to have been administrated in an ad hoc manner. 
16. RECOMMENDATIONS 
(1) It is the opinion of the panel that a third HGAP should be launched. Modifications in 
the project plan are, however, necessary due to the remarkable progress that has been 
made during the last year. It seems very likely that a high resolution genetic map and 
also a complete YAC-based physical map of the human genome will be completed 
within another year. 
(2) It is necessary to make a new strategic plan for the HGAP. This strategic plan should 
also consider the possibility of approaching sequencing of the entire genome by a 
"shot gun approach". Such an effect would require a drastic increase in funding. 
(3) A key feature of HGAP are the resource centers and it is essential to ascertain their 
continued existence. Making the results of whole genome physical mapping readily 
available to the community will be an extensive but necessary task; it must be tackled 
by informatic means including an accessible, complete and user-friendly database, but 
also at the level of the distribution of YAC- and cosmid clones, a very labour-intensive 
task. Making these reagents readily accessible to all European scientists, for instance 
by wide distribution of "polytene filters" containing ordered YACs for all human 
chromosomes would be an essential step. In general a wider range of ordered libraries 
is required, to serve the most diverse needs of genome research, once the first physical 
map will be completed. 
(4) In the future ordered collections of full length cDNAs will be required from all 
different tissues of the body. Resource centers providing ordered cDNA libraries as a 
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service to the scientific community should be given high priority in a future HGAP. 
(5) Allocation of resources to megascale cDNA sequencing projects should be considered. 
The concept of cDNA sequencing to obtain a complete catalogue of the human genes 
was after all a European idea. 
(6) Mega-scale genomic sequencing which was not a component of the original HGAP 
needs to be considered in a future HGAP. It will be necessary to carry out som pilot 
projects involving megabase-sequencing to assess the future possibilities to approch 
sequencing of whole human chromosomes. Also, the possibility of sequencing the 
entire genome by a "shot gun approach" needs careful consideration. It is suggested 
that an ad hoc group is assembled to look into this problem. If the EC intends to 
participate in such a project it will have to greatly expand the program budget to faster 
reach the ultimate goal of the global genome program, the complete nucleotide 
sequence of the human genome. 
(7) EUROGEM, on the other hand, will soon have completed its mission once the high 
resolution genetic map has been finished. 
(8) Bioinformatics is a field that is likely to develop very rapidly in the near future. The 
design of user-friendly software for analysis of massive amounts of data will 
undoubtedly be an important aspect of a future HGAP. In view of the very widespread 
criticism directed to GDB, it becomes useful to envision alternative databases or at 
least different database access systems: in this respect, the progress of the Heidelberg 
IGD (Integrated Genome Database) appears promising and the distribution model 
advocated by this group, using a locally running ACeDB system fed with data from 
the other genome databases, appears particularly promising. 
Communication between biologists and computer scientists remains imperfect: they 
still belong largely to two quite different cultures. Both fields have been evolving very 
quickly in recent years, and few individuals possess competence in both fields. An 
increase in their numbers, through attractive fellowships and positions, is probably the 
only way of easing this difficulty. 
Moreover attention, and some funding, should be devoted to improving interfaces 
between the "genome world" and the general biology community, including not only 
medical genetics but also, for example, groups performing functional research in the 
mouse system so that structure and function are brought closer together. 
(9) The transnational projects should be continued although they must be selected with 
great care. In supporting research and formulating suggestions on how to distribute 
research funds, it will be cogent to remember that collaborations, which are 
undoubtedly very important, cannot be organized by anyone, but must and will 
develop spontaneously. In that respect, it cannot be wise to stipulate collaborations 
between scientists from certain areas in Europe or even make the assignment of funds 
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dependent on such collaborations. Such ideas are counterproductive. It would be 
preferable to rather start a special program of a limited extent for the support of 
deserving scientists in the bio-medical field working in those countries of Europe 
which are presently still weaker in molecular biology but are capable of catching up 
rapidly. 
(10) The training program appears largely to have been a success and a continuation of the 
program is recommended. It may, however, be necessary to find new means to spread 
information about the program since the number of applications was much smaller than 
anticipated. It should also be kept in mind that some modifications of the program 
might be very beneficial for young scientist working in the field of human genome 
analysis. There is one problem, which all European countries seem to share, i.e., the 
support and independence of young investigators who have proven themselves in their 
own or in other countries as first rate scientists. There is a very considerable lure by 
laboratories in the United States with its very flexible administrative structure at most 
universities and, above all, with an impressive number of top research centers at many 
U.S. universities. It will be increasingly attractive for young Europeans to seek to 
associate themselves with laboratories at such centers for longer or shorter periods of 
time, but usually during their years most productive for original research. Biomedical 
research, nowadays, can best be performed at centers of a critical size. It is necessary 
to recognize that it is one of the important tasks for science funding and organization 
in Europe to create a counterbalance to these very powerful centers for basic 
biomedical research in the U.S. A suggestion along these lines is to create positions 
for young independent researchers in the biomedical research areas which would allow 
highly qualified young scientists to pursue research of their own choice at one of the 
European universities, but uninhibited by their often very "traditional" administrative 
structures. In addition to positions, funds for consumable supplies, equipment and 
research personel should be attached to these positions. It is proposed that such 
structures would help very considerably in attracting or re-attracting many of the most 
productive young researchers from abroad to European countries. 
(11) ESLA pograms are essential components of genome programs. The panel recommends, 
although not unanimously, that the ESLA program is continued and that long range 
support is provided. It is important that the program is announced as extensively as 
possible and that the contractors receive the proper information about the expectd 
output of the program. An urgent component in future ESLA programs will be to 
provide means for the participating groups to cooperate, interact and exchange ideas 
and results. 
Special efforts should also be made to include economics of technical change, science 
policy and science studies in the program. The geographical inbalance is another 
problem that needs attention. 
(12) Support to workshops and meetings is clearly an essential component of HGAP and 
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continuation of the program is recommended. However, some administrative changes 
are recommended. It is, for instance suggested that a scientific advisory board is 
established to advice on the policy of the program and to screen applications. Efforts 
should be made to obtain a better balance with regard to topics among the workshops 
that are supported. The support via HUGO to single chromosme workshops is essential 
and should be continued. In general, support should be given to chromosome 
workshops taking place in Europe as a contribution to the organization. Support 
should also be given as travel grants to European participants in workshops taking 
place outside of Europe. It seems also worthwile to support workshops which bring 
together scientists working within the HGAP on similar topics (as has been done to 
same extent in the past), for instance those working in EUROGEM or with cDNA 
libraries. This would obviously stimulate contacts between groups in different 
European countries. 
(13) Another welcome addition to the program would be education of practising physicians 
all over Europe. With the rapid progress in Medical Genetics our practising colleagues 
are already in a difficult position vis-a-vis their patients who will ask pressing 
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COUNCIL DECISION 
of 29 June 1990 
adopting a specific research and technological development programme in the field of health: 
human genome analysis (1990 to 1991) 
(90/395/EEC) 
THE COUNCIL OF THE EUROPEAN COMMUNITIES, 
Having regard to the Treaty establishing the European 
Economic Community, and in particular Article 130q (2) 
thereof, 
Having regard to the proposal from the Commission (*), 
In cooperation with the European Parliament (z), 
Having regard to the opinion of the Economic and Social 
Committee (*), 
Whereas Article 130k of the Treaty provides that the 
framework programme is to be implemented through specific 
programmes developed within each activity; 
Whereas, by its Decision 87/516/Euratom, EEC (4), as 
amended by Decision 88/193/EEC, Euratom(J), the 
Council adopted a framework programme for Community 
activities in the field of research and technological 
development (1987 to 1991), which defined activities to be 
undertaken in the field of health; 
Whereas that Decision provides that Community action is 
justified where research contributes, inter alia, to the 
strengthening of the economic and social cohesion of the 
Community and to the promotion of its overall harmonious 
development, while being consistent with the pursuit of 
scientific and technical excellence; 
Whereas two successive pluriannual programmes of research 
and training of the European Economic Community in the 
field of biotechnologies ('), the second of which is still in 
progress, have shown the possibility and usefulness of 
Community action promoting the utilization of modern 
biology for scientific, medical and industrial purposes; 
Whereas the framework programme provides, under the 
heading "Health' in the 'Quality of Life* section, for the 
(') OJ No C 27, 2. 2.1989, p. 6 and OJ No C 303, 2. 12. 1989, 
p. 18. 
(l) OJ No C 69, 20. 3. 1989, p. 85 and OJ No C 149, 18. 6. 
1990. 
(J) OJ No C 56, 6. 3. 1989, p. 7. 
[*) OJ No L 302, 24. 10. 1987, p. 1. 
[') OJ No L 89, 6. 4. 1988, p. 35. 
(') OJ No L 375,30.12.1981, p. 1 and OJ No L 83,25. 3.1985, 
p . l . 
initiation of new activities relating to the development of 
knowledge of the human genome; 
Whereas, following the adoption of a third Community 
Framework Programme for activities in the field of research 
and technological development (1990 to 1994), it is ' 
necessary to continue the implementation of the second 
Framework Programme (1987 to 1991) by means of specific 
programmes for which the latter makes provision; 
Whereas a specific programme to study the human genome is 
therefore necessary and, in particular, it is necessary to: 
— develop and disseminate the basic technologies 
, concerning the study of the human genome, with the 
intention of improving knowledge of matters of medical 
importance, 
— increase the resolution of the human genetic map and 
improve the physical map by the creation of ordered 
clone libraries, as a basis for locating genes of medical 
importance on chromosomes and for a better general 
understanding of gene function, and 
— organize networks and coordination, on a European and 
international scale, of researchers from all disciplines 
working in this field; 
Whereas achievement of the abovementioned goals requires 
the undertaking at Community level of action aimed at: 
— filling some existing gaps in scientific and technological 
knowledge, and 
— encouraging cooperation between European research 
establishments with a view to furthering the development 
of existing technologies, while promoting all research 
sectors capable of generating new lines of research; 
Whereas, simultaneously, measures must be taken to 
promote cooperation between the Community programme 
and similar ones developed in third countries or by 
international organizations; 
Whereas the right to a genetic identity forms part of the 
integrity and the dignity of an individual and this principle is 
recognized in the constitutions and laws of Member States 
and in the Community legal system as forming part of the 
fundamental rights for which respect is ensured; 
Whereas the results which can be achieved from human 
genome research require the development of an integrated 
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approach, taking into account the medical, ethical, social 
and legal aspects of the possible applications of such results 
and the need to avoid any improper use thereof; 
Whereas the development of an integrated approach was 
proposed by the European Parliament in its resolution of 16 
March 1989 (»); 
Whereas there are good grounds for guaranteeing the right of 
an individual to have an informed choice as to whether or not 
he should receive information concerning his genetic 
characteristics; 
Whereas, in the absence of clear standards and provisions 
concerning possible developments in the field of genome 
analysis, there may be a risk, on the one hand, that attempts 
will be made to intervene in the human genome in order to 
make the modifications so obtained hereditary and, on the 
other, that genetic analyses will be carried out for monitoring 
purposes, which may have a profound effect on social life; 
whereas mere are, accordingly, good grounds for taking die 
necessary steps to preclude unacceptable developments, 
particularly in terms of predictive medicine; 
Whereas, furthermore, it is necessary to examine in detail, 
during the course of the programme, the prenormative 
aspects arising from human genome analysis by establishing 
a reliable scientific data set which could provide a basis for 
political authorities to establish sound, clear and responsible 
rules; 
Whereas die Scientific and Technical Research Committee 
(Crest) has been consulted, 
HAS ADOPTED THIS DECISION: 
Article 3 
Detailed rules for the implementation of the programme and 
die rates of the Community's financial participation are set 
out in Annex II. 
Article 4 
1. The Commission shall send the European Parliament 
and the Council an annual report on the progress of the 
programme. 
2. In the second year of implementation of the 
programme, the Commission shall review it and send the 
results of its review to the European Parliament and the 
Council; the report shall be accompanied, where necessary, 
by proposals for amendment or extension of the 
programme. 
3. An evaluation of the results achieved shall be carried 
out by independent experts and published in the form of a 
communication to the European Parliament and the 
Council. 
4. The abovementioned reports shall be established 
having regard to the objectives and evaluation criteria set out 
in Annex II and in accordance with Article 2 (2) of Decision 
87/516/Euratom, EEC. 
Article S 
The Commission shall be responsible for the execution of the 
programme. It shall be assisted by a committee of an advisory 
nature, hereinafter referred to as "the Committee', composed 
of the representatives of the Member States and chaired by 
the representative of the Commission. 
Article 6 
Article 1 
A specific research and technological development 
programme for the European Economic Community in the 
field of human genome analysis, as defined in Annex II, is 
hereby adopted for a period of two years commencing on 29 
June 1990. 
Article 2 
1. The funds estimated as necessary for the execution of 
the programme amount to ECU 14 million, including 
expenditure on a staff of two. 
2. An indicative allocation of funds is set out in 
Annex I. 
(•) OJ No C 96, 17. 5. 1989, p. 165. 
1. The representative of the Commission shall submit to 
the committee a draft of the measures to be taken. The 
committee shall deliver its opinion within a time limit which 
the chairman may lay down according to the urgency of the 
matter, if necessary by taking a vote. 
2. The opinion shall be recorded in the minutes; in 
addition, each Member State shall have the right to ask to 
have its position recorded in the minutes. 
3. The Commission shall take the utmost account of the 
opinion delivered by the committee. It shall inform the 
committee of the manner in which its opinion has been taken 
into account. 
Article 7 
The procedure laid down in Article 6 shall apply in particular 
to: 
— the contents of the calls for proposals, 
38 
N o L 196/10 Official Journal of the European Communities 26. 7. 90 
the assessment of the proposed projects and the estimated 
amount of the Community's contribution to them, 
departures from the general rules governing Community 
participation set out in Annex II, 
the participation in any project by third-country 
organizations and enterprises referred to in Article 
8 (2) , 
any adjustment to the indicative allocation of resources 
set out in Annex I, 
the measures to be undertaken to evaluate the 
programme, 
the arrangements for the dissemination, protection and 
exploitation of the results of research carried out under 
the programme. 
scientific and technical cooperation with the Community, 
with a view to associating them with the programme. 
2. Where framework agreements for scientific and 
technical cooperation between third countries and the 
European Communities have been concluded, organizations 
and enterprises established in those countries may, on the 
basis of the criterion of mutual benefit, become partners in a 
project undertaken within this programme. 
3. No contracting party based outside the Community 
and participating as a partner in a project undertaken under 
the programme may benefit from Community financing for 
this programme. Such contracting party shall contribute to 
the general administrative costs. 
Article 9 
This Decision is addressed to the Member States. 
Article 8 
1. The Commission is authorized, in accordance with 
Article 130n of the Treaty, to negotiate agreements with 
third countries and international organizations, particularly 
with third countries participating in European Cooperation 
in the field of Scientific and Technical Research (COST) and 
with States which have concluded framework agreements for 
Done at Luxembourg, 29 June 1990. 
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ANNEX II 
SPECIFIC RESEARCH PROGRAMME IN THE FIELD OF HEALTH: HUMAN GENOME ANALYSIS 
1. OBJECTIVES 
Use and improvement of new biotechnologies in the study of the human genome for a better understanding of 
the mechanisms of genetic functions, as well as the prevention and treatment of human diseases. In the pursuit 
of these objectives, optimal cooperation will be sought with the programmes of third States and international 
organizations. 
At the same time, measures will be taken to draw up an integrated approach to the medical, ethical, social and 
legal aspects of possible applications of results obtained through the programme to ensure that they are not 
misused and also, with prenormative aspects in mind, to establish a set of bioethical principles to be followed in 
the developments to come. 
Alteration of germ cells or any stage of embryo development with the aim of modifying human genetic 
characteristics in a hereditary manner is excluded from the programme objectives. 
2. TECHNICAL CONTENT 
Precompetitive Community research, setting up and reinforcement of networks of European laboratories, and 
training, intended to allow the use of modern technologies for the study and setting up of the human genetic 
map as well as possible medical applications of the knowledge gained. 
The research described below will require the use of data-processing facilities for the handling of data and the 
setting up of integrated databases to serve European networks, in close cooperation with other Community 
research programmes. 
2.1. Improvement of the human genetic map 
Setting up a European network, extending worldwide, for the collection and mapping of the DNA of 
large families, in order to provide research scientists with well-characterized genetic material and sets of 
probes to determine the location of the relative positions of genes on the chromosomes. 
2.2. Setting up of ordered clone libraries of human DNA 
Setting up of a European network of laboratories working on establishing overlapping clone libraries and 
support for limited sequencing of cDNA. 
2.3. Improvement of the methods and basis for the study of the human genome 
New biochemical reagents (restriction enzymes, etc.). Improvement of methods for the detection and 
localization of genetic markers (techniques for labelling DNA probes, amplification of genes, etc.). 
Development of new vectors for the cloning of large DNA fragments and of procedures for the 
transfection of chromosomes. 
Development of model systems for the reproducible and stable expression of medically important genes 
both in vivo and in vitro, aimed at the wellbeing of patients. Development of new computer software for 
the storage and manipulation of data from genome sequencing and mapping. 
2.4. Training 
Setting up of a training programme to assist with the technology transfer of molecular genetics methods, 
in particular to Member States in which these techniques are currently underdeveloped. 
3. IMPLEMENTATION 
3.1. The programme shall be implemented through entering into cost-shared or marginal cost contracts, 
support to-centralized facilities and new or existing networks, entering into training contracts, issue of 
training, grants, organization of courses, consultations with national experts, organization of 
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study-group meetings, participation in seminars and symposia, publications, studies, dissemination of 
results to all interested groups and organization of public presentations. 
For shared-cost contracts, the Community participation will be up to 5 0 % of the total expenditure. 
However, in the case of universities and research institutes carrying out projects under this programme, 
the Community may bear up to 100% of the additional expenditure involved. In other cases, Community 
participation could reach 100%. 
Participants may be research establishments, universities, private enterprises or combinations thereof 
located in Member States or in the third countries referred to in Article 8, or competent organizations in a 
position to make a significant contribution. 
Projects must be carried out by participants from more than one country, and include at least two 
independent partners from two Member States. 
Fellows coining from third countries will be accepted in the training programme, provided that they meet 
the required conditions and that their costs are covered from other sources, such as other Community 
programmes or actions which support fellows coming from developing countries. 
The contracts concluded by the Commission will govern the rights and the obligations of each party, in 
particular the means of distribution, protection and exploitation of the results of the research. 
3.2. The drawing up of research contracts can only take place if the contracting parries undertake to abstain in 
this programme from all research modifying, or seeking to modify, the genetic constitution of human 
beings by alteration of germ cells or of any stage of embryo development which may make these 
alterations hereditary. 
The contracts shall regulate the granting of licences arising out of research projects and, in particular, 
there shall be no right to exploit on an exclusive basis any property rights in respect of human DNA. In 
addition, the Commission shall reserve the right to publish the results of the research performed within 
the scope of the contracts. 
The contracts will guarantee, that the members of the families participating in the studies referred to in 
paragraph 2.1 will be fully informed of, and have consented to the use and study of, their DNA. The 
contracts will also guarantee complete protection of the confidentiality and anonymity of the personal 
data obtained in the programme. 
3.3. The Commission will ensure that during the execution of the programme there will be wide-ranging and 
in-depth discussion of the ethical, social and legal aspects of human genome analysis and that possible 
misuses will be identified regarding applications of the results obtained or of future developments of that 
research. It will ensure that the far-reaching consequences of the research will be evaluated in a 
responsible manner and will submit to the European Parliament, the Council and the Economic and 
Social Committee an annual report, possibly with legislative recommendations arising as much from the 
research policy angle as from the legal one. To this end, the Commission will obtain advice from experts 
in different fields of science, law, philosophy and ethics, together with representatives of patient's 
associations. 
4. EVALUATION CRITERIA 
The communication from the Commission to the Council on a Community action plan relating to the 
evaluation of Community research and development programmes (') states that the objectives and milestones 
for each research programme have to be set out in verifiable and, where possible, quantitative form. These 
reference marks are listed below: ■ 
4.1. The long-term objective of this programme is to contribute to a better understanding of the mechanisms 
of genetic function as well as to the fight against human diseases arising from genetic variation (including 
genetic diseases sensu stricto and many common diseases with a genetic component, such as heart disease 
and cancer), through early diagnosis, prevention, and improvement of prognosis and therapy. The 
Commission proposes to achieve this objective by: 
— the organization of networks of laboratories around European facilities for (a) the improvement of 
the human genetic map, and (b) the setting up of ordered clone libraries of human DNA, either of the 
complete genome or of selected chromosomes, together with cDNA sequencing, 
(•) OJ No C 14, 20. 1. 1987, p. 5. 
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— the launching of a programme of prenormative research aiming at improvement of the methods and 
basis of the study of the human genome, 
— the setting up of a programme of training to increase the distribution of modern genetic technologies 
in Europe and to improve technological know-how in European laboratories, 
— the promotion of cooperation with third countries.and international organizations. 
4.2. The primary short-term objective is that the programme should succeed in establishing the 
abovementioned European networks of laboratories in the fields of: 
— the human genetic map, 
— ordered clone libraries of human DNA and cDNA sequencing, 
— improvement of the methods and basis for the study of the human genome, 
by using data-processing facilities for data-handling and by setting up integrated databases. 
These objectives should be verifiable in 1991. 
4.3. Particular objectives to be attained within two years of the programme's implementation are as 
follows: 
1. Concerning the human genetic map: 
— the present total of 40 well-studied large families which form the basis for the genetic map should 
be increased to 60 families, 
— genetic material from these families, and DNA probes, should be made available to the European 
laboratories concerned, while respecting the individual rights of those families, 
— a central facility should be identified to pool the results and establish an improved genetic map at 
the one to five centunorgan level, and an integrated databank should be set up. 
2. The strategies for setting up ordered clone libraries of human DNA should be compared and a better 
approach defined; facilities for maintaining the stocks of cloned DNA fragments should be 
established and the available clones dispatched to interested European laboratories. 
3. Substantial improvements should be obtained in the following research fields to improve the methods 
and the basis for the study of the human genome: 
— new reagents, such as restriction enzymes, 
— methodology for cloning large DNA fragments and for the transfection of chromosomes, 
— gene vectors adapted to human somatic celles in vitro, 
— methodology for the detection of a particular gene in a cell, 
— localization, cloning and sequencing of new genes, especially those which are disease-related, 
— new computer software for processing of DNA sequence data. 
4.4. In addition, the programme should ensure that the following general criteria are met: 
1. That throughout the execution of the programme, the ethical, social and legal aspects of human 
genome analysis should be the subject of wide-ranging and in-depth discussions, and possible abuses 
of the results or later developments of the work should be identified; principles for their utilization 
and control should be proposed. 
2. That the drawing up of research contracts should presuppose that the contracting parties undertake 
to abstain in this programme from all research modifying or seeking t o modify the genetic 
constitution of human beings by alteration of germ cells or of any stage of embryo development which 
may make these alterations hereditary. 
3. That the members of the families taking part in the studies mentioned in point 2.1 must have been 
informed and must have given their consent, and the confidentiality and anonymity of personal data 
must be ensured. 
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4. That the development and the application of somatic gene therapy are not provided for within the 
framework of the present programme. 
5. That only somatic actual or potential medical applications should be facilitated. 
6. That potential opportunities for industrial development should be explored. 
7. That the overall scientific standard of the participating European laboratories must have been 
improved. 
8. That, taking account of the results of Community, national or commercial research activities in 
human genetics, the evaluation panel should consider whether the human genome analysis has 
contributed to the transfer of knowledge and the development of the results of the said activities in 
regions of the Community other than those in which the research was conducted. The evaluation 
panel should also ascertain whether cooperation with third countries and international organizations 




REQUIREMENTS FROM THE 2ND FRAMEWORK PROGRAMME 
1 Article 2 of the Framework Programme Decision (87/516/EURATOM,EEC) states 
that each specific programme shall: 
state its precise objectives and provide for an evaluation of results achieved 
in relation to these objectives; 
be evaluated in the light of all selection criteria set out in Annex III, which 
include that of contributing to the strengthening of the economic and social 
cohesion of the Community. 
2 The selection criteria set out in Annex III to the Framework Programme decision state 
that: 
"In general, Community R&TD actions should be selected on the basis of 
scientific and technical objectives, their scientific and technical quality and 
their contribution to the definition or implementation of Community policies. 
A particular aim of Community R&TD shall be to strengthen the scientific and 
technological basis of European industry - including that of SMEs - especially 
in strategic areas of high technology, and to encourage it to become more 
competitive at the international level. 
Community action can be justified where it presents advantages (added value) 
in the short, medium or long term from the point of view of efficiency and 
financing or from the scientific and technical point of view as compared with 
national and other international activities (public or private). 
The following criteria in particular justify Community action: 
research which contributes to the strengthening of the economic and social 
cohesion of the Community and the promotion of its overall harmonious 
development, consistent with the pursuit of scientific and technical quality, 
research on a very large scale for which the individual Member States could 
not, or could only with difficulty, provide the necessary finance and 
personnel, 
research, the joint execution of which would offer obvious financial benefits, 




research which, because of the complementary nature of work being done 
nationally in part of a given field, enables significant results to be obtained in 
the Community as a whole for the case of problems whose solution requires 
research on a large scale, particularly geographical, 
research which contributes to the achievement of the common market and to 
the unification of the European scientific and technical area, and research 
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An Evaluation of the Human Genome Analysis Programme of 
the Commission of the European Communities from an 
industrial perspective 
By : Pascal Brandys 
President and Chief Executive Officer 
Genset 
1, passage Etienne Delaunay 
75011 Paris 
The Human Genome Analysis Programme adopted by the Commission of the European 
Communities in 29 June 1990 is now completed. During this period of three years, there has 
been a dramatic evolution in the field which can be chraracterized by four main aspects : 
fast progress of genetic mapping, and to a lesser extent of physical mapping, with now 
evidence of the probable completion of the total mapping of the Human Genome 
before the end of the millenium; 
limited progress in basic technologies involved: YAC libraries, sequence tagged sites, 
cDNA libraries and Sanger sequencing still constitute the main tools currently used 
in laboratories; 
fast development of an industry serving genome research with instruments and 
reagents; 
involvement of private companies in human genome research and patenting of the 
results of this research, particularly in the U.S.A. 
Human Genome Research is now a field of extremely active global competition with the 
support of massive private funding. Accordingly, it will be driven in the coming years by 
its potential applications in human diagnotics, prognostics and therapeutics. 
In order to take advantage of the comparatively good level of human genome science in the 
European Community, the Commission should now focus on the following organizational 
issues: V 
definition of activities between public and private laboratories; 
optimal use of the E.C. industry resources for the genome research; 
support of the E.C. industry seeking to exploit the results of human genome 
programmes. 
With these goals in mind, the following comments can be made on the results of the current 
Human Genome Analysis Programme : / 
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1) Resource centres are necessary to organize and distribute libraries, not to provide 
reagents or perform routine experiments. 
The success of the CEPPH YAC libraries is a clear indication of the added-value of a well-
organized resource centre. On the other hand, the use of academic laboratories for routine 
or production operations has proved to be a waste of resources. 
First, the use of talented scientists for routine DNA sequencing, DNA synthesis or cloning 
operations slows down the progress of fundamental research which is the primary vocation 
of these laboratories. 
Second, the academic laboratories are not organized to handle these activities efficiently. For 
instance, the dramatic economies of scale in DNA sequencing and synthesis can only be 
achieved in industrial organizations that focus on automation, engineering development, 
purchasing know-how, and industrial organization. 
2) Routine activities should be contracted to the industry with qualified bidding 
procedures and a preference for E. C. companies. 
The current E.C. industry counts a number of efficient companies ready to provide human 
genome research with quality products and services at competitive world prices. Contracts 
should be awarded to the lowest bidders among qualified E.C. companies. This contracting 
approach would allow substantial savings in global research budgets and put the E.C. industry 
on a par with its American counterpart with benefits from similar procedures. 
This contracting approach would also favor the development of projects to exploit results of 
the programmes with the development of new products for research, human diagnostics or 
therapeutics. 
3) Academic biochemistry laboratories are not efficient to develop new instruments. 
All instrumentation currently used in human genome research laboratories has been 
developped by the industry. The only exceptions are found in the laboratories of biochemical 
instrumentation that tend to use their own equipment to perform their experiments. It is clear 
that the results of current instrumentation programmes are very disappointing, as the 
developped systems never reached the market. 
The activity of instrument development bound on established technologies should be left to 
the industry. The investigations on new technologies for genome research can also be 
conducted with existing instruments. For example, it is possible to study DNA sequencing 
by mass spectometry on tunnel microscopy with existing commercial equipment. 
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4) A network using UNIX workstations should be established between all European 
Community Human Genome laboratories. 
The handling of data and exchange of information between genome research laboratories will 
probably be the major challenge of the coming years. UNIX workstations are fast becoming 
the standard for software applications requiring large computing power and storage capacity. 
They also have the immense advantage to allow interactive communication on the Internet 
network. The Commission should support the establishment of a workstation network which 
will allow fast and efficient distribution of databases, communications between research 
laboratories and resource centers, and communication between research laboratories and 
industrial contractors for the supply of services and products. This network will be also a 
firm foundation for the launch of new databases which could complete effectively with the 
overwhelmingly dominant U.S. databases. 
5) Results of Human Genome Programmes supported by the European Commission should 
be patented. 
The current position of providing free access to the European results of Human Genome 
research is no longer tenable when the U.S. public institutions and private industries are 
engaged in a massive effort of patenting cDNAs, expressed tagged sites, genetic markers and 
complete genes. This evolution may lead to a huge dificit of intellectual property within the 
European Community, which in turn could essentially eliminate the E.C. industry from the 
applications in human diagnostics and therapeutics. The consequences could be estremely 
severe during the next millenium. The Commission should make compulsory the patenting 
of the key results of the programmes it supports by the contractors. In order to facilitate the 
transfer of property rights, an office should be established to organize licensing for the 
benefits of instrumentation, reagents, diagnostic and pharmaceutical companies. Exclusivity 
and preference rights should be established on the basis of the qualification and the origin of 
licensees. 
It is suggested that the above comments could help in the definition of a new Framework 
Programme which could organize four main types of activities : i) resource centres dedicated 
to distributing libraries; ii) industrial contractors dedicated to providing services and reagents; 
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